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Abstract 
Advanced therapy medicinal products (ATMPs), which include cell and gene therapies, have 
the potential to revolutionise the healthcare industry through curing conditions which have 
previously been manageable at best. ATMP developers face challenges due to the complexity 
of their products since cells dynamically change, and are changed by, their environment 
through complex interactions. Defining the relationships between cells and their environment 
will allow developers to better characterise and control their processes, leading to more 
consistent and lower risk processes, which in turn would reduce COGs. 
Here, it was hypothesised that modelling approaches could be used to define complex cell-
environment interactions and produce meaningful process improvements for cell-based 
therapy manufacture. To test this hypothesis, two modelling approaches were applied to a  
clinically relevant, cell type that would face the same generic challenges a commercial, 
allogenic cell-based therapy (system productivity and maintaining or producing the required 
cell quality) – forward programmed platelet precursor cells (megakaryocytes) FOPMKs. 
The first modelling approach selected was Quality by Design (QbD) due to its acceptance and 
promotion by regulatory bodies for the manufacture of small molecules. A Quality Target 
Product Profile (QTPP) was compiled for an in vitro platelet product and Critical Quality 
Attributes (CQAs) – extracellular marker positive expression of CD41a, CD42a and CD42b and 
negative expression of CD235a - were identified.  
In order to reproducibly measure CQAs, substantial analytical development was undertaken 
to develop a novel flow cytometry assay that measured extracellular marker expression and 
characterise the differentiation of FOPMKs including on-target and off-target expression. 
ii 
Following assay development statistical Design of Experiments (DOE), was used to link control 
variables to CQAs. This work showed that concentrations of medium consumables 
doxycycline (Dox) and thrombopoietin (TPO) correlated with increased yield and CD41a 
expression. Whereas seeding density and removal of Dox from culture correlated with lower 
cell yields and lower CD41a expression. 
The second modelling approach applied was a novel, dynamic, mechanistic modelling 
approach which showed that cell growth was inhibited, and viable cells were converted non-
viable cells as a function of cell.time mediated medium exhaustion. Firstly, the system 
productivity was found to be approximately 1.48 ± 0.28 × 106 viable cells.mL-1 and the system 
limitation was a product of the number of cells present and time. Dynamic modelling 
confirmed this hypothesis and indicated that growth inhibition as a function of medium 
exhaustion was also present. 
Dynamic models were also applied to pluripotent cell culture where growth inhibition was 
shown to be a function of cell density, and the density threshold at which the cells became 
growth inhibited could be increased through the addition of Rhok Inhibitor in the first 24 
hours of culture. 
Future work for FOPMKs should focus on identifying the root cause of the medium limitation 
(initial screening showed it was unlikely to be glucose, lactate or ammonium concentrations). 
Modelling frameworks for phenotypically unstable populations require the ability to handle 
higher numbers of parameters, or more efficient methods to screen and reduce the number 
parameters required. 
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1.1. Introduction 
1.1.1 Research area and motivation 
So far only 13 Advanced Therapy Medicinal Products (ATMPs) have been approved by the 
European Medicines Agency (EMA), and four of those have been withdrawn. Concurrent with 
the development of this research the regenerative medicine industry has undergone a sea-
change, with the first genetically modified T-cell therapies (known as CAR-T therapies) 
KYMRIAH and YESCARTA receiving market approval in 2017. As this industry begins to move 
into the commercialisation phase, new challenges are emerging. 
Both approved CAR-T therapies command reimbursement prices of over $100,000. The high 
cost of goods (COGs) are driven by the availability of vectors used in genetic modification and 
the expansion of the cells [1]. There are many uncertainties in the processes which drive cell 
expansion and genetic modification since cells are complex structures, which change 
dynamically in response to their environment. An additional complexity for cell therapy 
developers has been the lack of understanding of the mechanism of action (MOA) by which 
treatments are effective, and therefore critical quality attributes (CQAs) are challenging to 
identify [2]. The lack of CQAs is challenging for cell therapy developers since the impact of 
process changes on product efficacy cannot be easily measured. 
Annually there are over 4.5 million platelet transfusions worldwide, currently all of which are 
sourced from volunteer donors. Receiving a platelet transfusion is not a risk-free process, as 
10% of new HIV diagnoses in developing countries are a result of contaminated blood 
transfusions in the early 2000s [3] and the Serious Hazards of Transfusion (SHOT) scheme 
(which was established following the contaminated blood scandals of the 1980s and 90s) 
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showed that there were 49 infections from contaminated blood products in the decade after 
enhanced monitoring was introduced [4]. 
To overcome the reliance on volunteer donors, an approach for developing genetically 
modified platelet-precursor cells (forward programmed megakaryocytes) from pluripotent 
stem cells was developed [5]. To develop a process that produces functional platelets at a 
clinically relevant quantity, and a price which is cost effective for healthcare providers, 
process development work must be undertaken to first define and then improve expansion 
of these cells whilst retaining the desired cell quality. 
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1.2 Overview of the Field 
1.2.1 Regenerative Medicine 
Regenerative medicine is defined as the replacement, or regeneration of cells, tissues or 
organs to restore or establish normal function [6]. It has the potential to revolutionise 
healthcare worldwide, as it offers cures for ailments which until now have been treated using 
pain management and symptom control. The therapeutic application of cells, known as cell 
therapies or cell-based therapies, is a crucial platform technology which bridges regenerative 
medicine and other treatment approaches [7]. In relevant literature, the terms “Regenerative 
Medicine” and “Cell Therapy” are often intertwined, however in this review the terms are 
used as defined above. 
1.2.2 Cell Therapy 
The last five years have been a water-shed moment for cell therapies with the regulatory 
approval of three products; firstly Strimvelis in 2016, an orphan drug for ADA-SCID, followed 
by KYMRIAH and YESCARTA in 2017, both for oncology applications. By the first quarter of 
2019, there were over 640 active clinical trials involving cell therapies [8]. Cell therapies can 
be broadly categorised into two fields, autologous and allogeneic. The cells from autologous 
treatments are derived from the patient, expanded or modified in some form and infused or 
transplanted into the same patient. Allogeneic, or “off-the-shelf” therapies are generally not 
patient specific, cells are harvested from donors and expanded to make a product which is 
then infused into multiple patients [9]. Some cell therapies exist which use allogeneic cells for 
a single patient’s treatment, such as specific T-cells or human leukocyte antigen (HLA) type 
matched bone marrow grafts but these are not scalable approaches to meet the demands of 
large patient populations without significant investment in infrastructure, as has been 
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achieved in cord blood transplantation [10]. In contrast Allogeneic, one to many, cell 
therapies are more aligned to traditional bioprocessing, including centralised manufacturing 
and employing economies of scale; process development challenges will focus on “scale-up”. 
Autologous treatments are likely to follow more bespoke manufacturing routes, including 
distributed manufacturing and process development will focus on “scale-out” [11]. 
Despite these very different challenges, commercialisation of both autologous and allogeneic 
cell therapies will require solutions to common problems as all regulatory-approved cell 
therapies must be safe, efficacious and consistent. COGs must also be low enough to enable 
widespread market adoption and return on investment for developers. To achieve this, 
process and product variability must be minimised. This challenge will be partly met by the 
implementation of automation, to minimise operator error and contamination risks, and by 
moving towards xeno-free media components, reducing inherent lot-to-lot variations [12]. 
However, the greatest challenge for many cell therapies is defining Critical Quality Attributes 
(CQA) that measure desired functional outputs and link to simple, convenient or online 
monitoring assays. These are used to optimise manufacturing processes [2] and ensure 
product purity, potency, stability safety and efficacy. In many cases the Mechanism of Action 
(MoA) is not fully defined, which makes developing CQA more challenging since the defining 
features for clinical efficacy are not  known and therefore cannot be linked to assays for use 
in process control [13]. 
1.2.2.1 Hematopoietic Cell Therapies 
The hematopoietic linage is relatively well characterised [14], and therefore CQAs for CT using 
hematopoietic cells may be easier to define. HSCs are readily available as there are multiple 
sources of hematopoietic cells including bone marrow [15], umbilical cord [16], peripheral 
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blood [17]; pluripotent sources can also be differentiated or genetically programmed to 
specific cell types [5]. Perhaps this contributes to hematopoietic cells being the most common 
cell type used in active CT clinical trials and their use in a wide range of clinical fields; such as 
oncology, immunology and cardiology [18]. However it should be noted there is a great deal 
of variation in the current clinical processes which utilise HSCs [19]. 
From a bioprocessing perspective, hematopoietic cells are suspension cells so their culture 
and harvest is less complex compared to adherent clinical cell types, for example 
mesenchymal stromal cell (MSC) culture requires optimisation of microcarrier attachment 
surface [20], cell to microcarrier ratio [21] and cell detachment from microcarriers [22]. More 
parameters are intrinsic to processes with greater complexity, the impact of which must be 
assessed to define appropriate levels of control to reduce the resulting process variability. 
The suspension nature of hematopoietic cells allows them to be grown in traditional 
biotechnology equipment, such as stirred tank reactors, without the need for additional 
components, such as microcarriers, which are required for adherent cell culture. This in turn 
permits the reuse of decades of scale-up knowledge developed. Technology transfer in this 
way will allow the CT industry to take advantage of systems that have been well characterised 
over the past century [23]. 
1.3 Manufacture of Platelets 
1.3.1 Uses of Platelets 
1.3.1.1 Clinical Need 
Platelets are enucleate cells produced by fragmentation of megakaryocytes (MKs) in vivo [24] 
(see section 1.3.2 for further discussion). Platelets circulate in peripheral blood at a 
concentration of 100-450 × 109 L-1 [25] and play key roles in haemostasis, inflammation, 
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wound healing and innate immunity [26]. Thrombocytopenia (platelet deficiencies) may occur 
as a result of bone marrow failure, caused by inherited conditions or from certain cancer 
treatments, or following an event that requires a massive transfusion, such as a motoring 
accident [27]. Regardless of cause, the most effective method to treat thrombocytopenia in 
the short term is platelet transfusion and demand for platelet transfusions is increasing due 
to ageing populations [28]. Indeed from 2006-2008 platelet transfusions increased by 16.8% 
in the USA; the average unit price of apheresis platelets was  US$535.17, and approximately 
2.2 million units are transfused annually [29]. In the UK nearly 300,000 platelet units were 
transfused in 2012, representing a 30% increase from 2000 [30], at a cost of £192.42 per 
standard unit in 2015/16.  
Currently platelets are sourced from volunteer donors; these units must be ABO and Rhesus-
D matched, and in some circumstances patients require specifically matched donations [31]. 
Collected platelet samples for transfusion (with concentrations of approximately 3-4 × 1011 
platelets per unit [32]) have a short life span of 3-7 days and must be stored at room 
temperature [28], which increases contamination risks from bacteria. Although rare, 
occurring in 1:3000 platelet units, transfusion of contaminated products often leads to death 
in patients who are immunosuppressed or undergoing cancer therapies. Platelet units which 
exceed this storage time are discarded leading to significant waste; approximately a third of 
platelet units are disposed of in this way [29]. In military operations, the short-shelf life can 
lead to platelet units being exhausted quickly resulting in transfusions of whole blood. Military 
personnel who received platelet transfusions had a 20% lower mortality risk compared to 
those receiving whole blood [33]. 
1-8 
Despite their widespread use, platelet transfusions are not risk-free. Platelet transfusions can 
transmit blood-borne pathogens such as HIV, hepatitis C and CMV. Blood donors are screened 
for conditions, and those at risk are prevented from donating. Through screening, 
transmission of these pathogens has greatly decreased, but it is impossible to eliminate this 
risk whilst relying on donors. Immunological reactions can occur in patients such as Graft vs. 
Host Disease (GvHD), alloimmunisation and transfusion-related acute lung injury (TRALI). 
These are prevented by donor screening for antibodies, irradiation and leucocyte reduction 
[34].  
The in vitro manufacture of platelets for transfusions has the potential to alleviate the current 
reliance on blood donors, and therefore overcome supply and logistical challenges currently 
associated with platelet sourcing. Furthermore, the risk of pathogen transmission from donor 
to patient will be eliminated along with donor-to-donor variability, leading to a more 
consistent platelet transfusion product. Since platelets are enucleate, the final platelet 
product can be irradiated prior to transfusion, which gives a significant safety advantage as 
potentially oncogenic cell fractions arising in the production process will be eliminated [35]. 
1.3.1.2 Human Platelet Lysate  
Fetal Bovine Serum (FBS) is commonly used in the production of CTs as a source of growth 
and attachment factors, proteins and nutrients to support proliferation of cells. Despite the 
regulators consent for its use in the manufacture of regulated CTs [36], FBS is a source of 
process variability [37]. It is at risk of contamination by prions or other known and unknown 
adventitious pathogens and may illicit immune reaction from patients [38]. Furthermore as 
the CT industry comes to fruition the supply of FBS will become more constricted, indeed 
currently only three countries produce over 90% of the FBS demand [38]. This limited supply 
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will cause costs to escalate. Human platelet lysate (hPL) has been proposed as a xenofree 
alternative to FBS supplementation. It has been shown to reduce variability and promote 
higher proliferation in MSC cultures [39].  
Fully defined, serum-free media has advantages over both HPL and FBS. This includes minimal 
lot-to-lot variations, lower risk of contamination from pathogens and potentially fewer supply 
chain issues [38]. However, serum is a complex milieu of beneficial components. PDGF-BB, 
TGF- β1 and bFGF are growth factors found in hPL which were shown to have the largest 
impact on MSC proliferation when removed. A cocktail of these growth factors, at equal 
concentrations as found in hPL, were used to supplement basal media and did not promote 
MSC proliferation [40]. 
To manufacture platelet lysate currently, whole blood is collected from donors, and is 
screened according to regulatory procedures for pathogens. Plasma and red blood cells are 
separated from platelets using multiple centrifugation steps. Using approximately 450 mL of 
whole blood, a standard platelet unit is produced of approximately 50 mL with a 
concentration of 1.2 × 106 μL-1 platelets [41]. This solution then undergoes freeze-thaw cycles 
in order to lyse the platelet solution. MSC cultures are supplemented with approximately 10% 
(v/v) hPL [42]. 50 mL of clinical grade hPL can be brought for approximately £92.50. In vitro 
platelets can produce anywhere between 5 and 2,000 platelets per MK [43].Assuming in vitro 
megakaryocytes produced 100 platelets per cell , then 600 million MKs are required for one 
50ml unit of hPL, to supplement 500 mL of basal media. In vitro culture of platelets for the 
production of hPL has the potential to overcome supply and biohazard burdens associated 
with the harvest of platelets from donors, whilst retaining the culture benefits of hPL.  
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1.3.2 Platelet and Megakaryocyte Biology  
As discussed in section 1.2.2, defining CQAs that link to in vivo function is essential to 
manufacturing CT products as this enables control strategies to be implemented to optimise 
final products. This section reviews platelet and megakaryocyte biology which will be crucial 
to informing product specifications.  
The hematopoietic linage is relatively well defined, as mentioned in Section 1.2.2.1, although 
the exact hierarchy of the linage is still debated [44]. The process of megakaryocyte 
differentiation from hematopoietic stem cells, megakaryopoiesis, and platelet biogenesis is 
shown in Figure 1-1. The development can be divided in four main stages [45], [46]. Firstly, 
HSCs proliferate within the bone marrow, maintaining their multipotency. The second stage 
is megakaryocyte differentiation, where the cells become committed to first the 
Megakaryocyte–erythroid lineage and then megakaryocytes only. Cells in this stage have the 
highest nucleus to cytoplasm ratio and contain elevated levels of RNA and α-granules [47].  
In the third stage endomitosis occurs, which is the duplication of the cell’s nucleus, without 
the cell splitting. The extent to which this occurs in a single cell is known as its ploidy, and is 
transcribed as copies of the chromosomes, for example 2N is two copies of the chromosomes 
and is therefore the equivalent to one complete nucleus. Mature MKs are polyploidy and are 
up to 128N. During this stage cytoplasm also matures and expands and cells can reach 50-100 
μm in diameter. 
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Figure 1-1: Summary of megakaryopoeisis and platelet production in vivo. 
The final stage of maturity is platelet biogenesis where MKs undergo cytoskeletal 
reorganisation [48] extend and protrude blood vessels, and pro-platelets are sheared off. 
There is evidence to suggest that this is not the final stage of platelet maturity, as they 
continue to mature as they circulate in peripheral blood [49] and platelets can also be formed 
from a more global fragmentation of the cytoplasm [50]. 
1.3.3 Potential Cell Sources 
MKs are the least represented cell type in the bone marrow, making a proportion of less than 
0.01% of total nucleated cells. Due to their lack of availability,  studies have been conducted 
which successfully produced MKs from CD34+ HSCs. These were sourced from umbilical cord 
blood (CB) [43], mobilised peripheral blood (mPB) [51], and bone marrow [45]. Although high 
platelet yields were achieved from each MK, the yield of MKs per HSC was often low or 
variable, producing anywhere between 0.04 MKs per input cell to 1,580. Usually either FBS or 
human serum was required (as discussed in Section 1.3.1.2 the use of serum should be 
avoided where possible), and/or a complex mixture of growth factors was required. GMP 
grade growth factors are costly which will weigh heavily on future COGs. Each extra 
component added must be validated and increases process complexity [52], therefore the 
number of different growth factors should be minimised where possible. Furthermore, all 
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sources listed must be routinely collected from donors which has implications on supply and 
biosafety hazards. 
Some studies have identified embryonic stem cells (ESCs) and induced pluripotent stem cells 
(iPSCs) as a way of overcoming supply issues faced by using HSCs [53]. Gaur et al. (2006) 
differentiated ESCs to produce functional and platelet producing MKs, but again the culture 
yielded only 0.1 MK per input ESC. Other groups have increased the yield of MKs [54], but 
these culture systems required co-culturing with feeder cells, which is not desirable for 
commercial manufacture. A more recent approach reported utilising iPSCs, does not use 
feeder cells, and is cultured in serum-free medium, however in this case only 12 mature MKs 
are produced per input iPSC [55].  
To overcome the culture limitations, a novel process has been devised which can produce 
large numbers of MKs from iPSCs. Using a process known as “forward programming” (FOP) 
where exogenous transcription factors GATA1, FLI1 and TAL1 are introduced to iPSCs using a 
lentiviral vector. This method produces over 200,000 MKs per iPSC cell input over 90 days. 
Furthermore cells are cultured in serum-free conditions using only recombinant Stem Cell 
Factor (SCF) and Thrombopoietin (TPO) [5]. 
1.3.4 Manufacturing Challenges - Platelets Production for Transfusion 
A process flow diagram for the production of platelet transfusions from FOPMKs is shown in 
Figure 1-2, and the challenges at each stage are briefly considered in order to assess where 
improvements should be investigated. 
Either embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) can be used as 
the source material in FOPMK production. Both cell types are pluripotent, i.e. they have the 
potential to differentiate into cells from all three germlines and cells are able to theoretically 
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Figure 1-2: Process flow diagram depicting the stages required for platelet production from iPSCs using a 
forward programming process. 
 
produce an unlimited number of cells. However, since iPSCs are somatic cells genetically 
reprogrammed using a small number of genes to resemble ESCs [56], they pose fewer ethical 
issues as ESC production requires the destruction of human embryos [57]. 
The pluripotent cell of choice is then forward programmed using lentiviral vectors with 
transcription factors GATA1, FLI1 and TAL1 as noted in Section 1.3.3. This process was 
developed across 2 generations. The first process utilised a cocktail of lentiviral vectors to 
produce a polyclonal population. The transduction process had an efficiency of approximately 
60%, and by day 15 >95% of the cells expressed CD41a. The first generation FOPMKs could 
then be expanded for around 90 days. Indeed, some cultures expanded until day 132 [5]. 
However, since one iPSC was reported to generate 200,000 FOPMKs over 90 days, this is 
equivalent to a doubling time of approximately 5 days. The equivalent proliferation rate was 
low compared to many human cells, for example the doubling time of MSCs is approximately 
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24-48 hours [39], and is as low as 12 hours for HSC [58]. In the second generation of the 
FOPMK production process, a TET-ON promoter was incorporated in a genetic cassette 
containing the three transcription factors, followed by colony selection, produced a mono-
clonal population. The inclusion of the TET-ON promoter allowed the modified iPSCs to be 
cultured (theoretically) indefinitely as pluripotent cells, with forward programming 
triggerable by the addition of a chemical trigger, doxycycline. The promoter therefore 
reduced the reliance on viral vectors. 
During the expansion of FOPMKs, proplatelet particles can be constantly seen forming in 
culture, but to produce larger numbers of platelets the MKs must be differentiated using co-
culture with feeder cells. Some groups have investigated platelet production using silk 
bioreactors [59], which is preferable for clinical platelet production as feeder cultures pose 
contamination risks. Platelet Biogenesis, a spin-out company from Harvard University, also 
claims to have developed a platform to produce a high number of functional platelets from 
megakaryocytes [60], but their technology is confidential currently. 
Since stages 1-3 (will be common for all products using FOPMKs (for example platelet 
transfusion units and HPL production); these are examined in further detail below. 
1.3.4.1 iPSC Generation 
There are many ways in which variation can occur within iPSC cultures, the effect of which on 
the FOPMK culture and subsequent platelet production is not yet known. A study of genetic 
integrity of 66 iPSC lines showed that approximately 20% of lines displayed genetic 
abnormalities which may affect their differentiation potential [61]. The variation between 
iPSC cell source and donor variability has also been investigated, and it was concluded that 
the variation between donors outweighed the variation between initial somatic cell type. 
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Here the authors cite “DNA-methylation, gene-expression, miRNA, and splicing differences” 
which may all lead to ultimately different iPSC characteristics [62], but again the ultimate 
effect on iPSC function or characteristics is yet to be verified. It should be noted that genetic 
abnormalities may be indicative of tumorgenicity in vivo [63]. If these abnormalities are in 
clinically relevant cells differentiated cells, this may pose a risk to patient safety. Since 
platelets for transfusion are enucleate, transfusion units can be irradiated, as mentioned in 
section 1.3.2, and therefore tumorgenicity arising from iPSC genetic variations is less 
concerning for platelet production. 
It has been shown that automating iPSC generation, can reduce genetic abnormalities and 
produce more consistent lines [64]. However, the CQAs used to characterise and select iPSC 
lines are still being debated, and therefore if the wrong criteria of selection are used this could 
still lead to producing inferior quality iPSC lines, albeit lines which are more consistent.  
1.3.4.2 Forward Programming 
Production of FOPMKs using somatic cells as the initial cell type requires two rounds of 
transduction. Firstly, to produce iPSCs and secondly to transform pluripotent cells to MKs. 
Throughout the past three decades there has been significant research into gene therapy, 
where gene therapy is the introduction of genetic material into cells to correct and treat 
disease [65]. This research has led to great advances in genetic programming which ultimately 
led to advances which make forward programming possible since the goal of gene therapy is 
to produce stable and safe genetic expression in the target tissue [66]. The first generation of 
adenovirus and retroviral vectors produced promising preclinical results. However the phase 
one clinical trials for ornithine transcarbmaylase (OTC) deficiency led to the death of 18 year 
old Jessie Gelsinger [67], and the use of retroviral vectors to treat X-linked severe combined 
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immunodeficiency (SCID) led to leukaemia [68]. These tragic incidents sparked research into 
safer transduction methods such as the lentiviral vectors, used in FOPMK production, and 
gamma retroviral vectors [69], [70]. The development of these safer vectors has also enabled 
revolutionary cancer treatments using genetically modified T-cells [71]. 
As discussed in Section 1.3.4.1, donor to donor variation transduction processes can lead to 
variation between iPSC lines, although it is not clear what effect these variations have on 
overall iPSC function. Since the forward programming process for FOPMK production is similar 
to iPSC generation the same principles could also be applied to both and therefore could be 
assumed that automation will enable more consistent FOPMK production. Viral transduction 
leads to the generation of polyclonal populations [72] with a distribution of integration of the 
factors into the genome. Coupled with heterogeneous pluripotent cell populations, this 
random transduction led to a transduction efficiency of 60% of iPSCs as reported in Section 
1.3.3. 
1.3.4.3 Expansion of FOPMKs 
Despite the challenges, the current protocols have so far produced FOPMKs and functional 
platelets which have been effective in mouse models; yet the expansion of FOPMKs in culture 
is not yet well characterised. The effect of variation in iPSC generation and forward 
programming is not easily measurable until the expansion of FOPMKs is more fully 
understood. Furthermore, once the efficiency of the MK expansion is known, this will 
determine the required production rate of platelets from FOPMKs; and in large-scale 
allogeneic treatments such as platelet transfusions, where more than 100,000 doses per year 
will be required, it is estimated that the medium will make up to 58% of the COGs [73].  
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Current process inconsistencies could in part be due to a lack of understanding of what the 
cells require. Cell cultures grow and develop in response to the complex composition of the 
cell culture media. However, the environment is not constant but is changed dynamically by 
the cells. Some of these changes are qualitatively generic across different cell types, such as 
utilisation of a carbon source for energy. However others, such as release of cell specific 
cytokine profiles, and sensitivity in feedback, will be highly specific to individual phenotypes. 
FOPMK expansion, and indeed CT manufacture in general, requires a detailed understanding 
of such media modification and feedback loops both to control quality of product and 
maximise economic product yield. Appropriate models of these dynamic characteristics will 
allow optimisation and risk reduction. Section 1.4 reviews methods for modelling cell culture 
processes. 
Commercial platelet manufacture will also require process transfer to scalable technologies. 
Currently expansion of FOPMKs takes place in static culture, i.e. in T-flask or plates. At small 
scale, these culture platforms do not offer online monitoring of key process parameters, such 
as dissolved oxygen (DO) concentration and pH. Despite being suspension cells, FOPMKs 
settle to the bottom of the flask if left unmixed. When the volume of medium in the culture 
flask is less than 4mm it can be assumed that the DO concentration at the bottom of the flask 
is equal to the concentration at the gas interface which is approximately atmospheric or 20% 
[74]. However, this assumption does not hold at larger volumes or flask stacks, where mass 
transfer may become limiting and will lead to heterogeneous cultures. Heterogeneity will lead 
to inefficient use of media by limiting the maximum number of cells supported and producing 
variations in cell populations [12].  
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Conventional stirred tank systems are widely used in the culture of CHO cells for biologics 
production. These systems incorporate on-line monitoring and control which promotes 
homogenous culture environments. To meet the required lot sizes for platelet production 
stirred tank reactors will be required.  
1.4 Quantifying cell culture productivity limits and population dynamics 
Cells are complex, dynamic structures which exhibit variation from each other. When 
considering methods to quantify population dynamics it is essential to consider the required 
model output since the closer a model becomes to reality, the more complex it becomes. A 
more complex model requires more a detailed background understanding of the observed 
cell culture system for model construction, more computational power for model execution 
and more analytical insight, which require more resources. 
There are many ways in which models of cell cultures have been defined. However, these 
definitions are not standardised within the literature. In order to provide a common level of 
understanding for analysis common definitions are outlined in Table 1-1, along with examples 
of where they have been applied to cell culture. Furthermore these definitions are not always 
straight-forward to apply and models can combine elements from apparently contradictory 
stances; for example a pseudo-stochastic and deterministic model was developed by Nielsen 
et al. to describe in vitro haematopoiesis [75].  
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Table 1-1: Different modelling approaches and examples of their application to cell based therapy or cell growth. 
Approach Definition Examples Also known 
as 
Empirical Relationships derived from observations of the system. This approach 
produces correlative equations which do not necessarily reflect underlying 
mechanisms. Different statistical methods can be used to develop empirical 
models such as factorial design of experiments (DOE) and response surface 
methodology (RSM) for linear relationships and artificial neural networks 
(ANN) for non-linear relationships. 
Design of Experiments (DOE) 
[13] 
Response surface 
methodologies (RSM) [76] 
Neural networks [77], [78] 
 
Mechanistic Model structure attempts to explicitly quantify behaviour by understanding 
underlying phenomena. 
[79]–[82]  
Deterministic Randomness does not influence the outcome of a system. [81], [82]  
Stochastic Outcome which is based on a probability distribution and cannot be 
predicted absolutely. 
  
Segregated The segregation of a culture into individual units.  Agent based models (ABM) 
or individual based models 
(IBM) (cultures segregated 
into individual cells). 
Corpuscular 
[83] 
 
Non-segregated Approach assumes that the culture is “lumped” together as a single 
population with identical behaviour. 
  
Structured Approach assumes cells are composed of different chemical, biochemical or 
physical components which can vary from each other and/or overtime. 
Metabolic flux analysis [84]  
Unstructured Assumes constant cell composition of individual or populations of cells. [80] Macroscopic 
[85] 
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Top-down Using observations at a whole system level to develop understanding of 
fundamental molecular networks. 
[86]  
Bottom-up Developing an understanding of fundamental molecular component 
interactions (e.g. genome) from independent experimental data to inform 
system characteristics. 
[87]  
Population 
Balance Model 
(PBM) 
PBMs characterises cells as they change dynamically relative to a state 
variable which is a continuum [88]. 
[89]  
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When developing quantitative models, the simplest model that delivers the required level of 
insight should be chosen. This fundamental principle of developing parsimonious models is 
known as “Occam’s Razor” [90]. For a cell therapy production system, a model closest to 
reality would incorporate mechanistic, deterministic, stochastic, segregated and structured 
elements. However, this complexity would be challenging to practically achieve. A simpler 
model may deliver the level of understanding required and under Occam’s Razor would be 
preferred.  
Two modelling approaches have been selected to test their applicability and utility in defining 
cell population dynamics. The first, statistical DOE is empirical and stochastic. The second is a 
novel, dynamic, mechanistic modelling platform which treats cells as whole homogenous 
populations (or can split cells into distinct populations). The two approaches are outlined in 
more detail below in Sections 1.4.1 and 1.4.2. A model platform which split cells into further 
sub-components was not selected since this would have required significantly more resource. 
Rather than attempt to fully characterise cell populations, these two approaches were chosen 
as they readily accessible for proof of concept studies to determine the utility of quantifying 
cell population dynamics to develop more robust manufacturing processes for cell therapies.  
1.1.1. Quality by Design 
Quality by Design (QbD) is a risk-based approach to product and process development, 
endorsed by regulatory bodies for the development of pharmaceutical products. Its 
objectives include the development of meaningful product quality specifications that are 
linked to clinical mechanism of action, reduce product variability and enhance post regulatory 
approval change management [91].  
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The QbD process is outlined in Error! Reference source not found.; initially the Target Product P
rofile (TPP – also referred to as Quality Target Profile) defines the attributes of the product 
that are required to achieve the desired clinical outcomes. From the QTPP, measurable Critical 
Quality Attributes (CQAs) can be identified which are “a physical, chemical, biological, or 
microbiological property or characteristic that should be within an appropriate limit, range, 
or distribution to ensure the desired product quality” [92]. A systematic risk assessment which 
links control variables to CQAs is undertaken using available qualitative and quantitative 
knowledge. Variables are ranked based on criticality, occurrence and detectability [93] which 
is important to reduce variables to a manageable number for onwards experimentation. 
Appropriate experimentation is then used to link prioritised control variables to CQAs to 
Figure 1-3: Schematic diagram of the QbD process. The focus of QbD is to design quality into a product 
through understanding how variation in input and processes impact final product outcome. QbD can be 
iterative process, as more knowledge is built it can be used to redefine earlier parts of the process. 
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define the process design space. Once this has been validated a manufacturing process can 
be implemented. The information gained can be recycled back into the start of the QbD 
process to inform process refinement. 
1.4.1 Design of Experiments 
Factorial design of experiments (DOE) is a structured methodology facilitating the 
investigation of multiple conditions on process outcomes. DOE has been used to characterise 
elements of CT processes, including determining effect of metabolites on net growth rate 
during the exponential growth rate [58], and understanding effects such as time since 
previous passage and freeze rate on the quality of hESC during cryopreservation [13]. It is an 
efficient methodology as it allows multiple process variables to be analysed in a single 
experimental set-up which can be easily analysed in a range of commercial software packages. 
When properly designed to include randomisation and replication these stochastic models 
allow an estimate of the variation in a system and empirical, correlative equations can be 
obtained which link all tested process variables to process outcome [94]. 
Factors chosen for investigation should be selected based on a mechanistic rationale of effect 
on process outcome, but the complex nature of cell therapy production could lead to the 
empirically defined relationships failing across the longer time courses required for cell 
therapy manufacture as that the control variables lead to an evolving environment over time. 
Although these  multiple arising subsidiary variables will be a function of the selected control 
variables at any given time, they are likely to generate a complexity of relationship between 
the initial control variables and the response variables that will not be well represented by 
the linear or simple curvilinear equations to which DOE is most suited.  
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1.4.2 Mechanistic modelling 
The simplest type of mechanistic modelling is unstructured, unsegregated and deterministic. 
These types of models have been applied to bacterial and mammalian cultures to enhance 
control and productivity of such systems [76], [79], [80], [95]. Models have been as simple as 
developing a Monod type approach which characterised the response of HSCs to growth 
factors [96]. Such modelling techniques have also been applied to PSC cultures. Yeo et al [82]. 
developed ODE kinetic models by dividing a culture into two homogeneous subpopulations - 
pluripotent or differentiated - in stirred suspension reactors. The conversion rate of 
pluripotent into differentiated cells was modelled as driven by the accumulation of inhibitory 
molecules. ODE models have also been used to describe the transition of cells across four 
differentiation states based on gene expression where gene expression was dependent of the 
use of different differentiation protocols [97]. A further example is the application of ODE 
models to describe the nutrient and oxygen depletion of PSC fed-batch cultures and following 
development of perfusion cultures[98]. ODE models have also been applied to HSC cultures 
and used to successfully predict growth limitations [99]. 
The above approaches show the applicability of ODE, mechanistic modelling and its potential 
utility. However, there is a high barrier to entry in terms of the mathematic and programming 
knowledge required for the development and implementation of these types of models. Our 
group has developed a flexible platform [100] which allows users to describe cell populations 
behaviours using a series of Di-graphs, and can test these hypothesises through fitting 
ordinary differential equation based models to experimental data using a least squares 
method. Proof of concept studies have shown that this mechanistic modelling methodology 
can be applied to describe growth inhibition in euthyroid lineage cells [81]. This work aims to 
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test the broader applicability of the modelling paradigm to more complex cell / environment 
interactions. 
1.5 Conclusion 
This introduction outlines the relevant background information, including current state and 
major challenges, for the regenerative medicine and cell therapy industries. The production 
of platelets for transfusion from pluripotent stem cells exemplify the challenges of cell 
expansion for cell therapies including high cell yields required, high COGs and undefined 
system productivity limits. Different methods for quantitative models are described and two 
methods are presented for further investigation as potential methods for defining cell and 
environment interactions in order to first define and then improve system productivity. The 
first is established statistical modelling through DOE and the second a novel mechanistic 
modelling paradigm. Both were tested in detail throughout Sections 4, 5 and 6. Finally, 
detailed background for the analytic technique flow cytometry was presented, which was the 
analytical technology selected for cell characterisation. Flow cytometry allows single cell 
measurements to be taken from a heterogenous population of cells, but assay development 
must be meticulous and an in-depth understanding is required of cell attributes to be 
measured, flow cytometry equipment used and fluorochrome selection to develop robust and 
reliable assays. Selection of measured cell attributes and subsequent flow cytometry analysis 
is presented in Section 3. 
1.5.1 Aims and objectives 
This research aims to address some of the issues discussed above by using forward 
programmed megakaryocytes as a manufacturing case study. Specifically, the work will 
focus on defining bioprocesses for upstream manufacture of FOPMKs, whilst simultaneously 
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evaluating the methodologies applied for deficiencies and potential improvements 
considering the characteristics of the system. The focus will further be on the productivity of 
the culture system with respect to use of upstream input resource, mainly cell culture 
medium and processing time, and quality of output cells  
for the useful application of modelling tools to characterise cell expansion systems to define 
and improve system productivity. 
The objectives of the project were to: 
• Identify candidate CQAs for Megakaryocytes, and develop robust assays to monitor 
CQAs, to provide a sound basis for quality assessment in process development. 
• Identify process characteristics that inform the selection of a process development 
methodology; provide a narrative analysis of the transfer of the exemplar process 
between laboratories and the insights that can be used for planning detailed process 
design. 
• Apply both the industry standard and relatively generic Design of Experiments 
approach, and an ODE based mechanistic framework, to characterise FOPMK 
production. Compare and review the advantages and disadvantages of the 
approaches and where methodological opportunities exist for improvement to 
characterise megakaryocyte expansion and linkage of process variables to CQAs. 
• Given the applied methodologies discuss the current state of potential FOPMK and 
platelet manufacture, process improvement opportunities identified in this work, and 
where future focus is required to make manufactured platelets a reality. 
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2. Materials 
and Methods 
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2.1. Introduction 
‘The research aims of this work are to investigate, identify and define the behavioural 
characteristics of FOPMKs in culture to the level required to achieve the overarching goal: 
definition of a manufacturing strategy aligned with market demands. The aim of this section 
is to outline the materials and methods used throughout the work. However, because this 
work process development focused, individual experiments will require different 
methodologies to test the impact of processing on product outcomes. In these instances, a 
basal protocol is specified, and deviations from the protocol detailed in the relevant chapters. 
2.2. Non-inducible FOPMK Culture 
2.2.1. Derivation 
FOPMKs were provided by Cedric Gheavart, Hematology department, University of 
Cambridge. Cells were derived by our collaborators as described by Moreau et al. [5]. Briefly, 
iPSC lines are transduced with three different batches of lentiviral vectors containing 
transcription factors GATA1, FIL1 and TAL1 to produce self-replicating FOPMKs which can be 
sustained for approximately 90 days in culture.  
Three independently derived iPSC lines were used: BOB (formal line name A1ATD1) and BOBc 
were derived from the same donor [101], with the BOBc line being corrected for the A1AT 
gene [102]. FFDK originated from a different donor [103].  
2.2.2. Culture 
For static culture FOPMKs were cultured in ultra-low attachment tissue plastic ware (Corning, 
UK). Unless otherwise stated the culture medium used was Cellgenix SCGM (Cellgenix, 
Germany) which was supplemented with 20 ng.mL-1 TPO and 50 ng.mL-1 SCF (both R&D 
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Systems, UK). Initially cells were seeded at 5 × 105 cells.mL-1 and medium supply was defined 
by regular time intervals where every 3 days the culture volume was doubled by the addition 
of fresh medium with double concentrated growth factors. When viable cell seeding densities 
exceeded 1.5 × 106 cells.mL-1, cultures were reseeded at 5 × 105 cells.mL-1.  Every 10 days a 
complete medium exchange was performed. Cells were placed into an incubator at 37°C, 100% 
humidity and 5% CO2. 
For stirred suspension culture spinner flasks were used. For spinner flask cultures the glass 
surfaces of two Integra Cellspin 100 mL spinner flasks (diam. T = 70mm, SLS, UK) with a 
magnetic, vertical stirrer bar (diam. D = 20mm) were siliconised with Sigmacoat (Sigma-
Aldrich, UK) according to manufacturer instructions. Following inoculation the culture was 
agitated constantly at a low at a rate of 20 revolutions per minute (RPM). Medical grade 
tubing was used to assemble a syringe pump (PHD/Ultra, Havard Apparatus, UK) for drip 
feeding medium into the spinner flasks. The spinner flasks were also modified to allow a 
sample point and gas air filter to be assembled. The system was placed into the incubator at 
37°C, 100% humidity and 5% CO2. Each spinner flask was positioned on one magnetic stirrer 
(Bellennium Compact Five Position Magnetic Stirrers, BellCo, USA).  
2.3. Inducible FOPMK culture 
2.3.1. Derivation 
Inducible FOPMKs were provided by Cedric Gheavart, Hematology department, University of 
Cambridge. Briefly, the iPSC line BOBc were targeted with a TET-ON system, which 
incorporated a tetracycline-responsive promoter, GFP, GATA1, TAL1 and FLI1. Post 
transduction, cells which are stable homozygous clones, were cultured as PSCs. When 
required, the genetic cassette was activated by adding doxycycline hyclate (Dox – a 
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tetracycline derivative) to the culture medium, which induced forward programming. The 
derivation of this inducible system is not currently published.  
2.3.2. Culture 
2.3.2.1. PSC culture 
Based on information from our collaborators the following culture methods were employed: 
Prior to induction iPSC were cultured in medium called AE6 which contained DMEM/F12 
(Gibco, UK) supplemented with 0.05% w/v Sodium Bicarbonate (Gibco, UK), 64.1 mg.L-1 L-
Ascorbic acid 2-phosphate sesquimagnesium salt hydrate (LAA) (Sigma-Aldrich, UK), Insulin-
Transferrin-Selenium (Gibco, UK) and sterile filtered. On the day of use medium was 
supplemented with 15 ng.mL-1 FGF2 and 15 ng.mL-1 Activin-A (Biotechne, UK) and was 
exchanged daily. Upon passaging, cell cultures were washed with PBS and were then treated 
with 0.5 mM EDTA incubated for 7 minutes in a humidified incubator at 37˚C. Cells were 
seeded at 10,000 cells.cm-2 (5 × 104 cells.mL-1) in medium containing 10 μM ROCK inhibitor 
Y27632 (Miltenyi biotech, Germany). Tissue culture plastic was coated with 5 µg.mL-1 
Vitronectin for a least one hour prior to use, according to the manufacturer’s instructions. 
2.3.2.2. Forward Programming 
Prior to forward programming, iPSCs were passaged using TryPLE (Gibco, UK) and were 
incubated for 7 mins in a humidified incubator at 37˚C. TrypLE was quenched using sterile AE6 
medium. Unless otherwise stated, cells were seeded at 12,500 cells.cm-2 in 0.2 mL.cm-2 PSC 
supplemented medium with ROCK inhibitor. Twenty-four hours later (referred to as Day 0) 
PSC medium was aspirated and replaced with 0.2 mL.cm-2 of mesoderm medium – which 
contained, unless otherwise stated, AE6 supplemented with 20 ng.mL-1 FGF2 and 10 ng.mL-1 
BMP4 (Biotechne, UK) and 1 µg.mL-1 Dox (Sigma-Aldrich, UK). At two days post Dox addition 
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(day 2) mesoderm medium was aspirated and replaced with MK programming medium which 
contained, unless otherwise stated, Cellgenix SCGM (Cellgenix, Germany) supplemented with 
1 µg.mL-1 Dox, 100 ng.mL-1 TPO and 25 ng.mL-1 SCF.  
At four days after Dox addition (Day 4) the culture volume was doubled through addition of 
fresh MK programming medium with double concentrated growth factors (2 µg.mL-1 Dox, 200 
ng.mL-1 TPO and 50 ng.mL-1 SCF) so the total volume of medium was 0.4 mL.cm-2. At Day 6 
and Day 8 50% of the culture volume was removed and cells were collected by centrifugation 
at 120g for 8 mins, slow acceleration and slow brake. Spent medium was aspirated and 
replaced with fresh MK programming medium with double concentrated growth factors. At 
Day 10 cultures were passaged. Medium supernatant containing suspended cells were 
collected and cells were washed with PBS, and incubated with for 7 mins in a humidified 
incubator at 37˚C. TrypLE was quenched using sterile Celgenix medium and passaged cells 
were mixed with spent medium containing suspended cells and were centrifuged at 120g, for 
8 mins, slow brake and slow acceleration. Supernatant was aspirated and cells were 
suspended in MK expansion medium – Cellgenix SCGM supplemented with 20 ng.mL-1 TPO 
and 25 ng.mL-1 SCF - at 5 × 105 cells.mL-1 in ULA tissue culture plastic. 
2.3.2.3. MK culture 
From Day 13 onwards medium supply was defined by regular time intervals where every 3 
days the culture volume was doubled by the addition of fresh medium with double 
concentrated growth factors. When viable cell seeding densities exceeded 1 × 106 cells.mL-1, 
cultures were reseeded at 5 × 105 cells.mL-1.  Every 10 days a complete medium exchange was 
performed. 
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2.4. Other cell culture processes 
2.4.1. Cryopreservation 
Cells were cryopreserved at 1-10 million cells.mL-1 using sterile filtered medium containing 
RPMI 1640 (Life Technologies, UK) 10% Anhydrous DMSO (Sigma Aldrich, UK) and 4% human 
serum albumin (Irvine Scientific, USA). Cells were frozen using a CoolCell™ FTS30 Freezing 
container (Biocision, USA) placed at -80°C for 24 hours and transferred to vapour phase of 
liquid nitrogen for long term storage. 
2.4.2. Thaw 
Two centrifuge tubes containing medium were prepared for thaw, one containing 50 ng.mL-1 
SCF and 20 ng.mL-1 TPO and the second containing no growth factors. These were warmed in 
a water bath for 15 min. The required vial was removed from the vapour phase of a cryostore 
and thawed for 2 min in a water bath whilst gently agitating the vial. Using a 1000 μL pipette 
tip cells and cyro-medium solution were removed from the vial and gently added to a tube 
labelled “SCGM no added growth factor”. 
Using the same 1000 μL pipette tip, 1 mL of medium containing no added growth factors was 
added to a vial to wash. The medium was gently mixed twice in the vial and added to 
remaining cell/medium solution containing no growth factors. The tube was centrifuged for 
8 min, 120g, slow acceleration and slow brake.  
Supernatant was aspirated and the tube was gently tapped to suspend the cell pellet. The 
target seeding density post-thaw was 7.5 × 105 cells.mL-1 and the volume of the medium 
containing growth factors was added accordingly. This was mixed twice prior to adding to 
tissue culture vessel. The vessel was gently tilted to ensure base was covered. 
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2.5. Cell counting methods 
Since FOPMKs are suspension cells, samples were taken by mixing vessels (either tissue 
culture plate, T-flasks or spinner flasks) thoroughly, aspirating and releasing a least half the 
culture medium three times with sterile pipette tips or stripettes. 
Viable cell counts were assessed in several ways discussed below. The specific expansion rate 
of cells was calculated as follows: 
𝜇 =
𝑙𝑛(𝜌
𝑣𝑖𝑎𝑏𝑙𝑒 𝑡2
𝜌
𝑣𝑖𝑎𝑏𝑙𝑒 𝑡1
⁄ )
∆𝑡
 ( 2-1 ) 
Where 𝜇  is the specific expansion rate (h-1), and 𝜌𝑣𝑖𝑎𝑏𝑙𝑒 𝑡1  and 𝜌𝑣𝑖𝑎𝑏𝑙𝑒 𝑡2  are the viable cell 
densities (cells.mL-1) at the end and beginning of a culture period respectively, and ∆𝑡 is the 
culture period (h). The specific expansion rate can be used to calculate the doubling time (𝑡𝑑):  
𝑡𝑑 =
ln (2)
𝜇
 ( 2-2 ) 
The number of population doublings (PDs) over a given time period (∆𝑡) was calculated as 
follows: 
𝑃𝐷𝑠 =
𝑙𝑛(𝜌
𝑣𝑖𝑎𝑏𝑙𝑒 𝑡2
𝜌
𝑣𝑖𝑎𝑏𝑙𝑒 𝑡1
⁄ )
𝑙𝑛(2)
 ( 2-3 ) 
2.5.1. NucleoCounter® 3000 
When using a NucleoCounter® NC-3000™ (Chemometec, Allerod, Denmark) 76 μL of cell and 
medium solution was taken from a well-mixed vessel. Four μL of solution containing 30 μg.mL-
1 acridine orange (Sigma-Aldrich, Dorset, UK) and 100 μg.mL-1 DAPI (Thermo Fisher Scientific, 
Loughborough, UK) dissolved in distilled water was added to cell and medium solution. 32 μL 
of cell/medium/stain mix was added to a single chamber in an A2 slide for analysis or 11 μL 
added to a single chamber in an A8 slide. 
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2.5.2. Flow cytometry 
The BD FACS CANTO II (BD Biosciences, San Jose, USA) was used for cell counts obtained 
through flow cytometry (see Section 2.6.2 for equipment details). 75 μL of cell and medium 
solution was taken from a well-mixed vessel and 150 μL flow buffer (see Section 2.6.1) was 
added to a 96 well plate for analysis. Data was acquired using the high throughput system 
(HTS) using the following settings in Table 2-1 and the PMT voltage settings shown in Table 2-2. 
Table 2-1: HTS settings for cell counting acquisition 
Parameter Value 
Sample volume flow rate 1.5 μL.s-1 
Sample volume 150 μL 
Mixing volume  100 μL 
Mixing speed 100 μL.s-1 
Number of mixes 5 
Wash volume 200 μL 
  
Table 2-2: Parameters and PMT voltages used for cell count protocols 
Marker/ 
attribute 
Fluorochrome Laser PMT - filter Voltage 
Viability DAPI (Invitrogen, UK) Violet B – 450/40 165 
Cell size FFS Blue N/A 125 
Granularity SSC Blue F 350 
 
Cell densities were calculated using the following equations: 
𝜌𝑡𝑜𝑡𝑎𝑙 =
1000 ×
𝑣𝑐 + 𝑣𝑑
𝑣𝑐
𝑣𝑠
× (𝐸𝑠𝑖𝑛𝑔𝑙𝑒𝑡𝑠 + 2𝐸𝑑𝑜𝑢𝑏𝑙𝑒𝑡𝑠) ( 2-4 ) 
𝜌𝑣𝑖𝑎𝑏𝑙𝑒 =
1000 ×
𝑣𝑐 + 𝑣𝑑
𝑣𝑐
𝑣𝑠𝑎𝑚𝑝𝑙𝑒
× [(𝐸𝑠𝑖𝑛𝑔𝑙𝑒𝑡𝑠 × 𝑃𝑠𝑁𝐷𝑃) + (2𝐸𝑑𝑜𝑢𝑏𝑙𝑒𝑡𝑠 × 𝑃𝑑𝑁𝐷𝑃)] ( 2-5 ) 
 
Where: 
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• 𝜌𝑡𝑜𝑡𝑎𝑙  is the total cell density (cells.mL
-1),  
• 𝑣𝑐  is the volume of cell and medium sample, in this case 75 μL, 
• 𝑣𝑑 is the volume of diluent flow buffer and DAPI solution, in this case 150 μL, 
• 𝑣𝑠 is the volume of sample analysed, in this case 150 μL, 
• 𝐸𝑠𝑖𝑛𝑔𝑙𝑒𝑡𝑠 is the number of events which are single cells as defined by the forward and 
side scatter profiles, 
• 𝐸𝑑𝑜𝑢𝑏𝑙𝑒𝑡𝑠 is the number of events which are doublet cells as defined by the forward 
and side scatter profiles, 
• 𝑃𝑠𝑁𝐷𝑃  and 𝑃𝑑𝑁𝐷𝑃  are the proportion of cells which are non DAPI permeable in the 
singlet and doublet cell populations respectively 
After acquisition FACS files were exported to FACS Analysis software FlowJo® for analysis. The 
gating strategy to define the events required for the inputs required for equations ( 2-4 ) and 
( 2-5 ) is shown in Figure 2-1 as an example of two samples with high and low viability. First, 
debris was excluded using FSC-SSC plots, followed by selection of singlet and doublet cell 
populations using a histogram of forward scatter width. Figure 2-1 far right shows the 
resulting gated populations. 
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Debris were excluded and the remaining events were categorised as “MKs”. Cells were then 
gated based on a histogram of forward scatter width and back gated to the position of the 
cells on SS/FS plots. The exclusion of DAPI was the criterion for cell viability. It should be noted 
that there are many methods to determine viability, and the choice of membrane integrity is 
based on wide acceptance, literature citation and good correlation with FS/SS [104](see 
Section 3.4  for discussion of cell counting methods development).  
 
  
Figure 2-1: Gating stragey for cell counts. Debris was excluded first and from the remaining sample 
doublets and singlets were separated. DAPI positivity was determined based on unstained controls. 
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2.6. Flow cytometry 
2.6.1. Sample preparation 
The target cells of interest for this work, FOPMKs, are suspension cells and therefore sample 
preparation does not require enzymatic or mechanical treatment to achieve a cell suspension. 
When analysing tissue samples or adherent cell populations it is critical that any pre-
treatment steps do not impact the attributes being measured, or at least the impact is 
understood and managed, as this could lead to false conclusions. Cell clumping was minimised 
as these larger clumps could cause blockages within the cytometer, cause interference with 
fluorochrome binding and distort output data (for example showing a large single event with 
higher marker expression, when the event is two adjoined cells). 
Necrosis induced through sample preparation causes excessive debris and the release of 
components that could interact with the cells and/or fluorochromes, which could also skew 
data outputs. This is especially important when cell counting assays are required. To preserve 
cells in the required state and minimise clumping, a flow cytometry buffer was employed that 
contained dissociation reagents and protein in a salt solution with the correct osmolality. In 
this case the flow cytometry buffer used contained 1% Bovine Serum Albumin, 1 mM EDTA 
and 2 mM HEPES dissolved in PBS (all Sigma-Aldrich, UK), stored at 4⁰C and added to a 
collection tube or 96-well plates. Non-viable cells often have increased non-specific binding 
which could lead to falsely high expression levels in target cell populations. Methods for 
identifying non-viable cell populations are discussed in Section 3.4, and where possible 
viability probes (DAPI or fixable viability stain – FVS) have been included in flow cytometry 
experiments. 
2-38 
In order to measure cell ploidy level cells were fixed using a 4% formaldehyde solution and 
incubated for 10 minutes at room temperature and washed prior to staining. After staining 
(see Section 2.6.3 for details), cells were permeabilised using Perm Wash Solution (BD 
Biosciences, Oxford, UK). 
2.6.2. Flow cytometry equipment 
During acquisition samples were collected either from collection tubes attached to the sample 
injection tube (SIT) or from the 96 well plates using the high through-put system (HTS) which 
connects to the SIT. Target particles suspended in buffer solutions were forced through the 
flow cell, where the laser interacted with the sample, at a flow rate designated by the user. 
The flow cytometer used for this work was the BD FACS Canto II (BD Biosciences, USA) with 
the 4-2-2 configuration, meaning it was possible to run assays with up to eight fluorochromes. 
Three lasers emitted light: Coherent Sapphire solid state blue laser (488 nm), JDS Uniphase 
HeNe air cooled red laser (633 nm) and Point Source™ iFLEX™2000-P-1-405-0.65-30-NP violet 
laser (405 nm) [105]. The filters and mirrors are summarised in Table 2-3. 
The photomultiplier tubes (PMTs) collected the side scattered light and fluorescence from the 
articles measured in the flow cell. The forward scatter was collected by a photodiode, and the 
light was directed to the collection optics. The 4-2-2 configuration used for this work contains 
three collection arrays. Light from the blue laser is collected in the octagon array containing 
five PMTs and the light from the violet and red lasers are collected in trigon arrays.  
Once the light arrived at an array a longpass (LP) mirror (filter) transmitted the highest 
wavelengths through into the first PMT, and reflect lower wave lengths to the next PMT. The 
filter in front of the next PMT which transmited the next highest wavelengths, and reflected 
the lower wavelength further round the array etc.. The PMTs produced a signal proportional 
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to the amount of light detected which was then converted to electronic signals. The 
magnitude of these signals was determined by the PMT voltage set. 
Table 2-3: Details of the lasers and collection arrays in the BD FACS Canto II used for this work adapted 
from the BD FACS Canto Reference Manual [105] 
Laser PMT LP 
Mirror/Filter 
BP Mirror or LP 
Mirror 
Common fluorochromes 
Blue A 735 780/60 PE-Cy7 
 B 655 670 PerCP-Cy5.5, PerCP, PE-Cy5 
 C 610 -  
 D 556 585/42 PE 
 E 502 530/30 FITC, AlexaFlur 488 
 F - 488/10  SSC 
 G - -  
 H - -  
Red A 735 780/60 APC-Cy7 
 B 685 - - 
 C - 660/20 APC, Alexa Fluor 647 
Violet A 502 510/50 AmCyan, BV510, BV500 
 B - 450/40 DAPI, Pacific Blue, BV421 
 C - -  
 
2.6.3. Staining and sample acquisition protocol 
When using FOPMKs, cell counts were performed (see Section 2.5) and then at least 1×105 - 
1×106 cells were used for phenotype analysis where practically possible suspended in 100 or 
150 μL of flow cytometry buffer (see Section 2.6.1) or cell culture medium. The appropriate 
volume of antibody volume was added to the cell / buffer suspension (volumes were 
determined by either manufacturers recommendation or using antibody titrations - see 
Section 3.3.2) and were protected from light and incubated at RT for 30 minutes in 2 mL 
Eppendorf tubes (Fisher Scientific, Loughborough, UK).  
After 30 minutes 1.5 mL of flow cytometry buffer was added to Eppendorf tubes containing 
stained cells. Tubes were centrifuged for eight minutes at 120g, with low acceleration and 
low brake. Supernatant was aspirated and cells were suspended either in 300 μL or 500 μL of 
2-40 
flow cytometry buffer containing 1 μg.mL-1 DAPI solution and transferred to either non-tissue 
culture treated 96 well plates for use with the high throughput system (HTS) or collection 
tubes for use with the sample injection tube (SIT). When using the HTS the following 
parameters were used for collection:  
Table 2-4: Parameter used for sample acquisition with the HTS system 
Parameter Value 
Sample volume flow rate 2.0 μL.s-1 
Sample volume 200 μL 
Mixing volume  100 μL 
Mixing speed 100 μL.s-1 
Number of mixes 5 
Wash volume 200 μL 
 
When using the SIT the sample flow rate selected was “medium” and in both cases the 
number of events set to record was a minimum of 30,000 of the target population, where 
possible, or the maximum number of events. 
2.6.4. Optic capture settings 
Optic capture settings and corresponded PMT voltages are described in Section 3.3. 
2.6.5. Calculating compensation 
Either cells or compensation beads were used to calculate appropriate compensation values, 
depending on which particle gave the highest signal. Particles were stained for 30 mins then 
washed with flow cytometry buffer and centrifuged at 120g for 8 minutes when using cells or 
500g, 5 mins when using beads. Particles were resuspended in 300 µLof flow buffer for sample 
acquisition. Assay development and comparison of compensation methods is discussed 
further in Section 3.3.  
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2.6.6. Gating strategy 
Where possible, biological controls were used to set gates; for example where there were 
large and obvious separations between populations. This method was used in conjunction 
with isotype controls to check for non-specific binding, “fluorescence minus one”(FMO) 
controls to check for errors caused by incorrect compensation and unstained cells to check 
for auto-fluorescence issues. 
2.6.7. Antibody reagents 
The antibodies used throughout this thesis are listed below in Table 2-5. 
Table 2-5: List of antibody reagents 
Marker Flurochrome Supplier Cat number  Lot number Isotype control 
            
CD235a PE BD Biosciences 555570 4283906 mouse IgG2b 
CD235a PE-Cy7 BD Biosciences 563666, 563667 7319640 mouse IgG2b 
CD34 PerCP-Vio700 Miltenyi 130-097-951 5161107547 mouse IgG2aκ 
CD41a APC BD Biosciences 559777 7215863 mouse IgG1 
CD41a BV510 BD Biosciences 563250 7164967 mouse IgG1 
CD41a FITC BD Biosciences 555466 6112532 mouse IgG1 
CD41a PE BD Biosciences 555467 3162697 mouse IgG1 
CD42a FITC BD Biosciences 558818 5323668 mouse IgG1 
CD42a PE BD Biosciences 558819 5204818 mouse IgG1 
CD42a BV421 BD Biosciences 565444 7145668 mouse IgG1 
CD42b BB700 BD Biosciences 742219 7212833 mouse IgG1 
CD42b PE BD Biosciences 555473 6012555 mouse IgG1 
CD49b 
Alexa Fluor 
647 
BD Biosciences 564314 5295626 mouse IgG2a 
CD49b PE BD Biosciences 555669 715950 mouse IgG2a 
CXCR4 APC BD Biosciences 555976 7151568 mouse IgG2b 
Ki-67 PE BD Biosciences 51-36525X 77187 mouse IgG1 
NANOG PE BD Biosciences 560483 8087675 mouse IgG1 
Oct3/4 PerCP-Cy5.5 BD Biosciences 560794 8100700 mouse IgG1 
TRA-1-
81 
Alexa Fluor 
647 
BD Biosciences 560793 7283709 mouse IgGM 
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2.7. Nutrient and metabolite analysis 
To assess the metabolic activity of cell during culture, 0.6 mL of culture volume was removed 
from cultures. Samples were taken from each culture vessel (static tissue plastic or spinner 
flask), and centrifuged at 500g for 5 mins. Medium supernatant was collected and stored 
initially at -18°C and then transferred to -80°C for long term storage. Multiple medium 
samples were thawed, randomised and analysed for glucose, lactate, ammonia and lactate 
dehydrogenase (LDH) using the Cedex Bio-HT metabolite analyser (Roche, Germany). 
2.7.1. Cedex Bio-HT 
The Cedex is an automated, high-throughput analyser. Its technology is based on enzymatic 
assays with photometric and potentiometric analysis, principles of which have remained 
unchanged since mid-20th century [106]. The system requires minimal manipulation by users 
which contributes to the low CV data presented in its brochures.  
2.7.1.1. Glucose 
In the presence of hexokinase (HK) Glucose was phosphorylated by ATP to glucose-6-
phosphate (G-6-P). Glucose-6-phosphate was oxidized by NADH in presence of glucose-6-
phosphat dehydrogenase (G-6-PDH). The rate of NADPH formation was measured UV-
photometrically and was directly proportional to the glucose concentration. 
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 + 𝐴𝑇𝑃
𝐻𝐾
→ 𝐺 − 6 − 𝑃 + 𝐴𝐷𝑃 
𝐺 − 6 − 𝑃 + 𝑁𝐴𝐷𝑃+
𝐺−6−𝑃𝐷𝐻
→       𝐺𝑙𝑢𝑐𝑜𝑛𝑎𝑡𝑒 − 6 − 𝑃 + 𝑁𝐴𝐷𝑃𝐻 + 𝐻+ 
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2.7.1.2. Lactate 
In the presence of lactate oxidase (LOD), lactate was oxidised to pyruvate and peroxide. In 
the presence of peroxidase (POD), a coloured dye was produced and the photometrically 
measured absorbance was proportional to the L-lactate concentration. 
𝐿 − 𝑙𝑎𝑐𝑡𝑎𝑡𝑒 + 𝑂2
𝐿𝑂𝐷
→  𝑃𝑦𝑟𝑢𝑣𝑎𝑡𝑒 + 𝐻2 𝑂2 
𝐻2𝑂2 + 𝐻 𝑑𝑜𝑛𝑜𝑟 + 4 − 𝐴𝐴𝑃
𝑃𝑂𝐷
→  𝐻2𝑂 + 𝐶ℎ𝑟𝑜𝑚𝑜𝑔𝑒𝑛 
2.7.1.3. Ammonium 
In the presence of glutamate dehydrogenase (GLDH), ammonium reacted with 2-oxoglutarate 
and NADPH in a reductive amination to form L-glutamate and NADP+. The decrease of NADPH 
was directly proportional to the ammonia concentration and is measured photometrically at 
340 nm. 
𝑁𝐻4
+ + 2 − 𝑜𝑥𝑜𝑔𝑙𝑢𝑡𝑎𝑟𝑎𝑡𝑒 + 𝑁𝐴𝐷𝑃𝐻
𝐺𝐿𝐷𝐻
→   𝐿 − 𝑔𝑙𝑢𝑡𝑎𝑚𝑎𝑡𝑒 +𝑁𝐴𝐷𝑃+ + 𝐻2𝑂  
2.7.1.4. LDH 
The oxidation of L-lactate to pyruvate by NAD was catalysed by Lactate dehydrogenase (LDH). 
The initial rate of NADH formation was directly proportional to the catalytic LDH activity and 
was measured photometrically. 
𝐿 − 𝑙𝑎𝑐𝑡𝑎𝑡𝑒 + 𝑁𝐴𝐷+
𝐿𝐷𝐻
→  𝑃𝑦𝑟𝑢𝑣𝑎𝑡𝑒 + 𝑁𝐴𝐷𝐻 + 𝐻+ 
2.8. Statistical Analysis 
2.8.1. Design of experiments 
All DOE experiments conducted were 2-level factorial designs analysed with backwards 
stepwise elimination analysis (α = 0.1 for removal), which retained hierarchy using statistical 
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analysis software Minitab version 17. The factors used, their respective levels and whether a 
mid-point was included is specified in relevant sections. 
2.8.2. ANOVA 
To determine statistically significant differences, one-way ANOVA was applied using statistical 
analysis software, Minitab (α = 0.05). 
 
2.9. Mechanistic modelling framework 
The modelling paradigm used to construct mechanistic models is described in detail by Stacey 
et al. [100]. Briefly, a parsimonious framework was built using a set of ordinary differential 
equation modelling building blocks that represented common cell culture dynamics and was 
designed to avoid mathematical pathologies. Cell culture behaviour hypothesises were 
developed using a set of di-graphs and the framework fitted model parameters using a least 
square method based on user-inputted model parameter estimates and ranges. 
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3. QTPP and assay 
development for a 
Quality by Design 
approach to in vitro 
platelet manufacture 
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3.1. Introduction 
This section focuses on the identification of CQAs that indicate the potential for FOPMKs to 
produce the required number of functional platelets. Where inducible pluripotent stem cells 
are being expanded, pluripotency markers will be used to indicate potential for differentiation, 
with the absence of any MK markers on pluripotent cells, the assumption was made that 
pluripotency acts as a surrogate measure for forward programming potential. 
In this chapter a Quality Target Product Profile (QTPP) for an in vitro derived platelet product 
was developed followed by the identification of CQAs which relate to the cell phenotype. In 
addition to cell quality, yield is also identified as an important attribute to measure. Therefore, 
assays to measure cell quality (using phenotype) and yield (using cell counting methods) are 
developed and compared. 
To draw meaningful conclusions from experiments and adequately test the presence of CQAs, 
assays which test cell culture attributes must be reliable and repeatable and the limitations 
of these tests must be understood. In this work, most assays are used to measure either cell 
number or phenotype. The technology tool used most for phenotype analysis is flow 
cytometry because it allows for single cell analysis and is a well-established technology for 
process development, manufacture and clinical applications. For cell counting automated 
methods are preferred since they are rapid, eliminate or greatly reduce operator variation 
and are therefore more easily validated and repeatable. The automated cell counting 
platform the Nucleocount-3000 and flow cytometry were used in this work. 
3.1.1. Chapter objectives 
• Develop a QTPP for an in vitro manufactured platelet product and the CQAs required 
to deliver the QTPP 
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• Rationally determine a set of in process CQAs that megakaryocyte progenitors require 
to enable delivery of the QTPP  
• Develop robust and repeatable assays to determine cell culture characteristics that 
are relevant for measuring cell properties relevant to manufacturing outputs including: 
o Phenotype analysis 
o Cell counting (using NC-3000 and flow cytometry) 
3.2. Development of a Quality Target Product Profile 
Using a template provided by the Cell and Gene Therapy Catapult, Table 3-1 shows the 
developed QTPP. The attributes for the product was based on platelet transfusion units 
sourced from volunteer donors as this is the current clinical standard. 
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Table 3-1: Quality Target Product Profile (QTPP) of in vitro derived platelets for intravenous transfusion 
developed using guidelines produced by the Cell and Gene Therapy Catapult. 
Overview 
Primary 
Indication and 
Usage 
Platelet transfusions are the most immediate way to treat thrombocytopenia 
(low platelet blood counts). Platelets produced from “forward programmed” 
megakaryocytes would be used as an alternative platelet transfusion unit 
where suitable donor platelets are not available. 
Description of 
proposed drug 
substance 
Functional, in vitro derived platelets suitable for transfusion. 
Description of 
proposed drug 
product 
A single platelet transfusion which has 3-5× 1011 platelets in 180-300 mL 
(average 210 mL) [107]. 
Mechanism of 
Action 
Prophylactic platelet transfusions are administered to thrombocytopenia 
patients who have a platelet blood count of less than 1 × 1011 platelets/L in 
order to prevent bleeding [108]. The platelet infusion increases the 
concentrations of blood platelet to normal levels which prevents bleeding. 
Description of 
raw and starting 
materials 
Dox inducible FOP-iPSCs, DMEM/F12, Celgenix SCGM , FGF2, Activin-A, BMP-4, 
SCF, TPO, Doxycycline hyclate 
QTPP element Target Justification 
Dosage form Cell suspension [108]. Donor derived platelet transfusion units are 
delivered in a cell suspension [108]. 
Formulation 
(excipients) 
Cell suspension in 210 mL 
of saline-adenine-glucose-
mannitol  [109]. 
Current NHS platelet transfusion units are stored 
in blood plasma derived from donors when 
donating blood platelets. However, using 
donated plasma does not overcome the supply 
chain and biosafety advantages of in vitro 
derived platelets for transfusion. Saline-adenine-
glucose-mannitol solutions have been used as 
storage substitutes for platelet units [109] and is 
regularly used for red blood cell storage for up to 
45 days[110]. 
Strength / 
Potency 
3-6 ×1011 platelets per 
transfusion unit [107], 
[108]. 
This is the average range for current clinical 
platelet transfusion units [107], [108]. 
Container 
Closure System 
Storage requires n-butyryl 
tri-n-hexyl citrate (BTHC) 
or tri- (ethylhexyl)-
This is the clinical standard for donor derived 
platelet transfusion units [111]. 
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trimellitate–plasticized 
polyvinyl chloride (PVC) 
bags [111]. 
Route of 
Administration 
Intravenous infusion. Intravenous infusion is the current clinical 
practice for donor derived platelet transfusion 
units. 
Storage and 
Stability 
(including in-use 
stability) 
Transfusion units are 
stored at 20°C - 24°C 
under constant horizontal 
agitation and can be 
stored for up to 7 days in 
the UK [111]. 
This is the established clinical protocol for 
platelet transfusion unit storage [111]. 
Release strategy Stage 1 (immediately after 
platelet production and 
irradiation, prior to 
storage): 
Sterility testing 
Marker expression [112]: 
CD42a+, CD42b+, Calcein-
AM positive, CD62P- 
Stage 2 (after 7 days 
storage): 
Swirl testing  
CD42a, CD42b are markers are essential for von 
Willebrand factor adhesion and therefore 
platelet functionality [113]. 
CD62P is a measure of platelet activation, which 
should not be present in platelet transfusion 
units. [114]. 
Swirl tests are routinely conducted is hospitals by 
holding a platelet transfusion unit to the light, 
and gently agitating to observe the scattering of 
light. If transfusion units do not scatter the light, 
this indicates they should be discarded as 
platelets have become activated [115]. 
 
3.2.1. Identification of Critical Quality Attributes 
Currently there is no straightforward in vitro test to prove conclusively the functionality of 
platelets or conclusive predictors that megakaryocytes will produce functional platelets. To 
prove the derivation of function platelets from FOPMKs, Moreau et al used mouse models to 
should that FOP-derived platelets incorporated in mouse thrombus [116] which would be 
impracticable for a batch release criteria, and is not useful as an assay to test the platelet 
production potential of a MK. Lack of CQAs is a known issue for cell-based therapies and are 
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caused by lack of biological understanding and consequently lack of available process 
analytical technologies due to the complexity of such products [117], [118].  
Functional platelets must be able to respond to Von Willebrand factor in order to initiate 
adhesion to damaged blood vessels and subsequent aggregation and therefore initiate 
clotting [119]. The glycoprotein IIb/IIIa (CD41a/CD61) and Ib-IX-V (CD42a/CD42b) respond to 
Von Willerand factor and therefore its presence on MKs (for subsequent platelet production) 
would be required to produce function platelets [113]. Therefore, in the absence of a direct 
assay to measure the potential of a MK to produce functional platelets expression levels of 
CD41a, CD42a, CD42b were measured. 
If it were possible to use early differentiation markers as accurate predictor of end stage 
outputs this could lead to cost savings through early identification in a manufacturing setting 
of conditions that were going to lead to outputs that were outside the acceptable end product 
specification. Monitoring changes in early stage differentiation markers (CD34 and CD235a in 
this case) could enable the application of resources to keep a process “on-track” to achieve 
the right end stage yields and purities modifying the process control variables to bring the 
process back on the right trajectory. Therefore, the expression of CD34 and CD235a will be 
tracked throughout differentiation to monitor the progression of forward programming as an 
early indicator of cell phenotype trajectory. 
When culturing iPSCs prior to induction the above markers will not be expressed. The 
technology is newly developed and so specific markers to measure the programming 
potential of Dox-inducible iPSCs. In the absence of these specific markers, pluripotency 
markers Oct3/4 [56], NANOG [56], TRA-1-81 [64] were measured. A flow cytometry assay is 
developed in Section 3.3.2.5 to measure these markers. 
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3.3. Flow cytometry 
Flow cytometry passes through a linear fluid stream and uses light to measure the properties 
of those cells. These properties can be either intrinsic such as size and granularity, or extrinsic, 
measured by targeting markers with fluorescent particles. Each particle that passes through 
a light stream is recorded as an “event” and has the values of the different output signals 
recorded. In this way, it is possible to gain high throughput single cell analysis. This section 
details the development of flow cytometry assays to measure the CQAs identified in Section 
3.2.1. 
3.3.1. Optic capture settings 
There are many established methods for selecting flow cytometry optic capture settings. This 
section shows the outcomes of using different methods to create optical settings for flow 
cytometry assays to ascertain FOPMK characteristics and describes advantages and 
disadvantages for each method. 
3.3.1.1. Setting PMT voltages using the first log decade 
For MEP (Panel 1) and MK maturity (Panel 2), shown in Table 3-2 and Table 3-3 respectively, 
PMT voltages were selected by setting the negative populations in the first log decade. This 
method was used historically to determine correct PMT voltages, ensuring that the 
autofluorescence of the target particles was low compared to the signal (as shown in Figure 
3-1 and Figure 3-2). This is adequate in some situations (for example when using 
fluorochromes with shorter wavelength emissions and when there is large separation 
between positive and negative populations as this overcomes the large variance caused by 
signal noise) but is not universally optimal [120]. Single stained cells were used to calculate 
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the compensation matrix for the MEP and MK maturity panels, shown in Table 3-3 and Table 
3-4. 
 
Table 3-2: Megakaryocyte Erythroid Progenitor (MEP) – Panel 1 
Marker/ 
attribute 
Fluorochrome Relative 
Brightness 
Laser PMT - filter Voltage 
Viability DAPI Data not 
available 
Violet B – 450/40 165 
CD235a PE Bright Blue D – 575/26 270 
CD42a FITC Moderate Blue E – 530/30 280 
CD41a APC Bright Red C – 660/20 425 
Cell size FFS N/A Blue N/A 125 
Granularity SSC N/A Blue F 350 
 
Table 3-3: MK maturity panel – Panel 2 
Marker/ 
attribute 
Fluorochrome Relative 
Brightness 
Laser PMT - filter PMT 
voltage 
Viability DAPI Data not 
available 
Violet B – 450/40 170 
CD42b PE Bright Blue D – 575/26 290 
CD42a FITC Moderate Blue E – 530/30 280 
CXCR4 APC Bright Red C – 660/20 370 
Cell size FFS N/A Blue N/A 125 
Granularity SSC N/A Blue F 350 
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Figure 3-1: Single stained single FOPMK cells in the MEP panel used to calculate compensation matrix and 
2 cell lines stained with all antibodies as an example. 
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 Figure 3-2: Single stained single FOPMK cells in the MK maturity panel used to calculate compensation 
matrix and 2 cell lines stained with all antibodies as an example. 
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Table 3-4: Compensation matrix for MEP panel (Panel 1) 
 
 
Table 3-5: Compensation matrix for MK maturity panel (Panel 2) 
Fluorochrome -% fluorochrome Compensation 
APC FITC 3.04 
DAPI FITC 0.86 
FITC PE 6.98 
APC PE 4.14 
DAPI PE 0.00 
FITC APC 0.00 
PE APC 0.00 
DAPI APC 0.00 
FITC DAPI 8.43 
PE DAPI 5.84 
APC DAPI 4.91 
 
Figure 3-1 and Figure 3-2 show the single colour stains, an unstained control and examples of 
full colour analysis. In the single colour stains the lack of overlap into the other channels from 
the fluorochromes shows qualitatively that only a small amount of compensation will be 
required to remove overlap. This is reflected in the compensation matrices shown in Table 3-4 
and Table 3-5.  
The two example samples show that the difference between cultures that highly express 
measured attributes and those that express low levels of these attributes can be distinguished 
using this method. However, the major disadvantage of setting PMT voltages qualitatively by 
Fluorochrome -% fluorochrome Compensation 
APC FITC 1.92 
DAPI FITC 0.72 
FITC PE 0.00 
APC PE 1.11 
DAPI PE 0.00 
FITC APC 0.00 
PE APC 0.00 
DAPI APC 0.00 
FITC DAPI 4.59 
PE DAPI 7.93 
APC DAPI 1.30 
3-56 
 
placing the unstained sample in the first log decade is that low expression cannot be easily 
distinguished from negative expression, leading to poor resolution sensitivity. 
3.3.1.2. Using calibration beads to define PMT voltages 
Resolution sensitivity, the ability to resolve dimly fluorescent populations at the lower end of 
the scales, can be defined using the percentage robust coefficient of variation (%rCV) of dim 
particles, where the %rCV is more statistically resilient to data outliers than %CV [121]. Using 
flow cytometry calibration beads, such as SPHERO™ 8 peak beads, the optimum voltage for 
adequate separation for dimly fluorescent particles can be determined. This is achieved by 
[120]: 
• increasing the PMT voltage at set intervals 
• selecting the second peak  
• calculating the %rCV  
• Plotting the PMT voltage against %rCV 
• finding the point of inflection 
The results are a combination of instrument settings and fluorochrome properties, and 
accurate results depend on appropriate storage of SPHERO™ bead reagent. Figure 3-3 shows 
examples of 2 fluorochromes, APC and APC Cy-7. It shows the increased resolution with 
increasing PMT voltage and highlights the difference between fluorochromes since the 
second APC peak can be resolved at 500 V whereas the APC-Cy7 second peak is still not 
resolved at 700 V. 
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Figure 3-3: Histograms show increasing voltage for APC and APC-Cy7 fluorochromes on SPHERO™ beads 
allows resolution of fluorescent populations of varying brightness. Using a PMT voltage of 700 it was still 
not possible to separate the second peak form the dim peak in the APC-Cy7 channel.  
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A comparison of all fluorochrome channels is shown in Figure 3-4. Each fluorochrome should 
theoretically have a smooth asymptotic curve similar to Pacific Orange and Blue. However, 
PE-Cy7 demonstrated a linear relationship between %rCV and PMT voltage up to 600 V then 
a step change. At this point the second peak could be resolved for the first time, causing a 
sharp reduction in %rCV. 
 
Laser PMT Fluorochrome Optimal PMT voltage range Relative brightness 
Blue A PE-Cy7 650-700 Bright 
  B PE-Cy5 500-550 Very bright 
  D PE 500-550 Bright 
  E FITC 500-550 Moderate 
Red A APC Cy-7 Not determined Dim 
  C APC 500-550 Bright 
Violet A Pacific Orange 400-450 Dim 
  B Pacific Blue 350-400 Moderate 
 
1
10
100
1,000
100 200 300 400 500 600 700 800
%
rC
V
PMT Voltage
PE-Cy7
PE-Cy5
PE
FITC
APC Cy-7
APC
Pacific Orange
Pacific Blue
Figure 3-4: Characterising the sensitivity of each channel of the BD FACS CANTO. Plotting %rCV and PMT 
voltage was used to determine the optimal voltage for resolving dimly fluorescent populations by 
identifying the inflection point. (A) shows %rCV of the second peak of SPHERO™ beads and PMT voltage (B) 
Inflection points identified to determine optimal range with fluorochrome attributes. 
(A) 
(B) 
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A disadvantage of this method is that not every fluorochrome is associated with a calibration 
bead, particularly newer, more stable and mostly brighter fluorochromes. For example, both 
BD Horizon™ BB515 and FITC are excited by the blue laser and detected using PMT E, yet 
BB515 is considered a “very bright” fluorochrome and FITC only “moderately” bright, 
therefore BB515 would require a lower voltage to detect lowly expressed markers (equivalent 
to a dim particle since fewer fluorochromes are attached). 
3.3.1.3. Using BD Cytometer Setup and Tracking (CS&T) software to define PMT voltages 
BD Cytometer Setup and Tracking (CS&T) software tracks the cytometer performance by 
tracking the voltages required to separate dimly fluorescent particles on specialist CS&T 
beads, and sets the value based on 10 times above the electronic noise of the instrument. 
These suggested values can also be used as a starting point and can then be reduced to bring 
the fluorescence within the linear cytometer range. However, the issue of fluorochrome 
specificity does not apply because the dim bead population is set to the auto fluorescence of 
lymphocytes when being excited by that laser channel. However, this could result in bright 
fluorochromes fluorescing higher than the readable scale. This highlights the importance of 
choosing the correct brightness of fluorochrome to match the expression of the target antigen. 
For long term FOPMK cultures CD235a was mostly negative and CD42b expression correlates 
with CD42a, so a third panel was developed which to include CD41a, CD42a and CXCR4. To 
obtain the PMT voltages, the CS&T suggested PMT voltages were used as a starting value. 
Voltages were then decreased to bring the values within the linear detection range. The 
resulting single stained samples and fluorochromes are shown in Figure 3-5. 
The need for compensation is shown in Figure 3-5 (A) when considering the single stained 
FITC control spill over into the PE channel as the median PE fluorescence shifts from 394 to 
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2480 despite there being no PE present in the sample. In contrast, there is little spill over from 
other fluorochromes into the APC channel. The median value for the single stained APC 
population is 1890 compared to 120 when using FITC and PE stained controls. The calculated 
compensation values are shown in Table 3-7. 
 
  
Figure 3-5: Panel 3 utalised condensed panel to capture MK phenotypic changes in a single assay. PMT 
voltages were set by using the CS&T values. Here single cells stained with a single fluorochromes were used 
for compensation. 
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Table 3-6: Fluorochrome details and PMT settings for Panel 3. 
Marker / 
attribute 
Fluorochrome / 
light scatter 
Relative 
Brightness 
Laser PMT - filter PMT 
voltage 
Viability DAPI Data not 
available 
Violet A – 525/50 350 
CD42a PE Bright Blue D – 575/26 470 
CD41a FITC Moderate Blue E – 530/30 533 
CXCR4 APC Bright Red C – 660/20 580 
Cell size FFS N/A Blue N/A 180 
Granularity SSC N/A Blue F 400 
  
Fluorochrome -% fluorochrome Compensation value 
PE FITC 9.00 
APC FITC 0.00 
DAPI FITC 0.01 
FITC PE 1.94 
APC PE 0.06 
DAPI PE 0.04 
FITC APC 0.00 
PE APC 0.00 
DAPI APC 0.00 
FITC DAPI 2.39 
PE DAPI 1.10 
APC DAPI 0.35 
 
Both the Panel 1 and Panel 3 measure CD41a and CD42a expression with different 
fluorochromes and used different methods of PMT voltage settings. Figure 3-6 compares the 
results from these assays using cells from equivalent culture. The FS/SS voltages for the MEP 
assay were set lower than required to ensure population shifts in size and granularity were 
adequately captured, however this lead to a loss of resolution around the target population, 
hence the voltages were increased which resulted in better resolution of the target 
population (Figure 3-6 A).  
Table 3-7: Compensation values for Panel 3 - a condensed version of MEP and MK maturity panels 
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CD42a expression changes throughout 1st generation, non-Dox inducible FOPMK culture and 
typically decreases past 90 days post FOPMK derivation from iPSCs when monitored using a 
FITC-conjugated antibody [5]. The culture represented in Figure 3-6 is late stage (day 127) and 
the expression level shown in Figure 3-6 b on FITC (which is a moderately bright fluorochrome) 
is in line with this, particularly considering the low PMT voltage used – the SI between positive 
and negative population was 1.46 calculated using equation (1-1). When using PE, which is a 
Figure 3-6: Comparison between of the same cell sample analysed with MEP assay (panel 1) and combined 
assay (panel 3) shows the effect of fluorochrome selection and PMT voltage setting on perceived marker 
expression. (a) FS/SS voltages determined the separation between populations of a different 
size/granularity. (b) Use of a PE-CD42a provided better separation than a FITC-CD42a conjugated antibody, 
and APC-CD41a provides better separation than FITC-CD41a conjugates. (c) Isotype control for MEP panel 
showed adequate compensation and low background signal whereas the isotype control for the combined 
panel shows that there was either a positive correlation between non-specific binding for CD42a/41a, 
compensation issues, or changing autofluorescence. 
(a) 
(b) 
(c) 
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relatively bright fluorochrome when excited with the blue laser, a higher separation is 
achieved with a corresponding SI of 29.3. 
The isotype control shown in Figure 3-6 for the MEP panel shows low background 
fluorescence and no obvious trends between the APC and FITC overlap, whereas there was a 
trend with increasing FITC and PE background signal. This could be attributed to inadequate 
compensation, for example, by misplacing the control gates used to calculate compensation. 
It could also have been a true increase in non-specific binding between the two antibody 
conjugates, particularly as they are co-expressed. Where possible, co-expressed antibodies 
should be measured using fluorochromes which are excited by different lasers to reduce 
compensation issues. The increased FITC and PE background signal may have been caused by 
changing autofluorescence of the populations also. This could have been tested by running 
an unstained sample alongside the full stained panel and the isotype control. 
3.3.1.4. Use of Application settings and target boxes for setting PMT voltages 
The methods described thus far for setting PMT voltage settings do not account for variation 
of the cytometer over time. BD CS&T software checks performance to ensure reproducible 
performance day to day and variations in performance can be adjusted by creating and 
applying “Application Settings”.  
CS&T software measures five critical performance metrics [122]: 
• Robust standard deviation of electronic noise (rSDEN) 
• Relative detection efficiency for each detector (Qr)  
• Relative optical background (Br)  
• Robust coefficient of variation for each setup bead (rCV) 
• Linearity maximum channel (the maximum acceptable signal level for good linearity) 
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The CS&T tracking uses dim (equivalent autofluorescence to lymphocytes), medium and 
bright standard beads to characterise the flow cytometer. Part of this characterisation is 
defining PMT voltages that place the dim beads outside 10 times the rSDEN, therefore ensuring 
these measurements are not dominated by electronic noise or optical background. To set 
Application Settings, the rSDEN for each channel were obtained from a current CS&T report 
and the values multiplied by 2.5 to obtain target values (Table 3-8). The 2x rSDEN values became 
the target rSD for the unstained FOPMK target cell population. Target rSDEN were not specific 
to which fluorochrome is being used in each PMT channel – it depended upon the properties 
of that PMT channel.  
With Application Settings, it is critical to ensure that the stained population remains within 
the linear range of the detector, so the measured fluorescence must not exceed the maximum 
value for that channel. Since the measured fluorescence is both dependent on the 
fluorochrome brightness and the marker expression level it was possible that the Application 
Settings would have required adjustment once marker expression through different stages of 
forward programming was acquired. 
Table 3-8: Exported CS&T report values from 14th March 2017, including 2.5 times the rSDEN and resulting 
PMT voltage settings 
Laser Detector 
Example 
Parameter 
Linearity 
Min 
Channel 
Linearity 
Max 
Channel 
Electronic 
Noise 
Robust SD 
2.5 
rSDEN 
Set 
PMT 
voltage 
Blue FSC FSC N/A N/A N/A    
Blue F SSC N/A N/A N/A    
Blue E FITC 86 240270 25.8 64.5 400 
Blue D PE 79 241702 22.8 57 400 
Blue B PerCP 93 239414 23.8 59.5 400 
Blue A PE-Cy7 230 237197 25.9 64.75 550 
Red C APC 46 238645 20.5 51.25 550 
Red A APC-Cy7 47 239047 20.5 51.25 550 
Violet B DAPI 76 245676 20.4 51 300 
Violet A BV510 59 244454 18.8 47 300 
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Robust standard deviations in each channel were recorded by increasing the PMT voltage by 
50 V increments, as shown in Figure 3-7. The voltage required to distinguish the signal from 
the electronic noise (the inflection point) was negatively correlated with the channel capture 
wavelength; i.e. the DAPI channel which captures wavelengths close to 440 nm required the 
lowest PMT to achieve the target rSD, whereas the APC-Cy7 channel which captures 
wavelengths close to 680 nm required the highest PMT voltage to achieve the target rSD. This 
indicates that higher noise levels correlate with lower frequency channels so bright 
fluorochromes should be used or these channels should be used when a dump channel is 
required. 
 
 
 
Figure 3-7: Establishment of Application Settings for an 8 colour FOPMK assay; rSD did not increase until a 
PMT voltage threshold was achieved, PMT voltages which placed unstained populations in the required 2.5 
time rSDEN are above this inflection point. Legend shows example parameters for the flow cytometer used 
for this work. 
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3.3.2. Comparison of methods for setting optical capture settings 
Section 2.6.4 describes four methods for setting PMT voltages which are summarised in Table 
3-9. Since each method produces a slightly different recommended PMT voltage setting 
understanding the advantages and disadvantages of each method is key to determining which 
method to use. 
Setting the PMT voltage based on minimising autofluorescence produces low background 
signal, but does not always lead to good separation since the positive target populations may 
be within the background noise and not easily distinguishable (see MEP panel in Figure 3-6b), 
and although was widely employed for use with analogue cytometers this method is now 
largely outdated [120]. Using SPHERO™ beads to set PMT voltages minimises the effect of 
background noise but relies on the specific fluorochrome conjugates, and is therefore limited 
in its uses. Furthermore, this method produced comparatively high recommended PMT 
voltages (Table 3-9) which could lead to positively stained populations falling outside of the 
cytometer linear detection range. 
CS&T reports recommend settings based on placing the rSD of the fluorescence values for 
dim 10 times the rSDEN [122], which ensures minimal interaction with background noise and 
is not fluorochrome specific, but is PMT specific. However, the CS&T recommended settings 
fluctuate day to day (albeit by small amounts). This is dependent on cytometer maintenance, 
laser fluctuations, and environmental conditions, such as room temperature and humidity. 
The use of Application Settings can mitigate fluctuations and can ensure comparability 
between cytometers. However, performance is monitored only daily, and can shift 
throughout the day. How intra-daily performance fluctuations affect data is unknown, but can 
be monitored by using SPHERO™ or CS&T beads intermittently throughout the day. 
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Table 3-9: Comparison of the different methods for setting PMT voltages / optical capture settings 
Laser Detector 
Example 
Parameter 
PMT voltage (V) 
Method 1 Method 2 Method 3 Method 4 
Blue E FITC 280 500 535 400 
Blue D PE 270 500 509 400 
Blue B PerCP  500 552 400 
Blue A PE-Cy7  650 622 550 
Red C APC 425 500 584 550 
Red A APC-Cy7 
 Not 
determined 
518 550 
Violet B DAPI 165 400 404 300 
Violet A BV510  350 478 300 
 
Using the established best practises described throughout Section 2.6, fluorochromes were 
selected for phenotypic markers with the aim to comprehensively characterise 1st generation, 
non-Dox inducible FOPMKs in a single panel (Panel 4) shown in Table 3-10. Application Settings 
were used to determine PMT voltages and beads were used to calculate the compensation in 
each channel (shown in Table 3-11). Antibody titrations were performed to find the optimum 
concentration where there were amenable cell populations as shown in Figure 3-8. Antibody 
titrations could not be performed where they were markers which were not expressed 
(CXCR4 and CD49b). 
Table 3-10: Comprehensive panel for 1st generation FOPMK charectorisation or latter stage of 2nd 
generation Dox-inducible FOPMKs  (Panel 4) 
Marker/attribute Fluorochrome Relative 
Brightness 
Laser PMT - 
filter 
PMT 
voltages 
FSC     220 
SSC     385 
CD42a BV421 Very Bright Violet B – 450/40 400 
CD41a BV510 Moderate Violet A – 525/50 449 
CD49b PE Bright Blue D – 575/26 549 
CD42b BB700 Very Bright Blue B – 695/40 500 
CD235a PE-Cy 7 Bright Blue A – 780/60 544 
CXCR4 APC Bright Red C – 660/20 305 
Viability Fixable viability dye 
780 
No data 
available 
Red A – 780/60 357 
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Table 3-11: Calculated compensation values used for Panel 4 (outlined in Table 3-10). 
Fluorochrome -% Fluorochrome Spectral Overlap 
BB700 PE 21.00 
PE-Cy7 PE 5.45 
APC PE 0.03 
FVS780 PE 0.01 
BV421 PE 0.01 
BV510 PE 0.01 
PE BB700 1.07 
PE-Cy7 BB700 59.78 
APC BB700 4.63 
FVS780 BB700 21.11 
BV421 BB700 0.00 
BV510 BB700 0.11 
PE PE-Cy7 0.31 
BB700 PE-Cy7 2.00 
APC PE-Cy7 0.01 
FVS780 PE-Cy7 9.38 
BV421 PE-Cy7 0.04 
BV510 PE-Cy7 0.04 
PE APC 0.00 
BB700 APC 0.67 
PE-Cy7 APC 0.25 
FVS780 APC 13.17 
BV421 APC 0.01 
BV510 APC 0.01 
PE FVS780 1.41 
BB700 FVS780 1.85 
PE-Cy7 FVS780 4.33 
APC FVS780 0.76 
BV421 FVS780 3.04 
BV510 FVS780 3.15 
PE BV421 0.00 
BB700 BV421 0.00 
PE-Cy7 BV421 0.00 
APC BV421 0.00 
FVS780 BV421 0.00 
BV510 BV421 9.22 
PE BV510 0.09 
BB700 BV510 0.06 
PE-Cy7 BV510 0.02 
APC BV510 0.02 
FVS780 BV510 0.00 
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Figure 3-8: Antibody titrations of (A) CD42b, (B) CD42a and (C) CD41a. Antibody concentrations were varied 
with respect to the manufacturer’s recommended concentration (i – vii). There were two   populations of 
CD42b expression, one positive and one negative, making it possible to calculate the optimal SI. However, 
there was only one population of CD42a and CD41a therefore the recommended concentrations were 
used. 
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Antibody titrations were performed for CD41a, CD42a and CD42b as shown in Figure 3-8. The 
only marker that had two populations of expression was CD42b, so this was the only marker 
for which the SI could be calculated. Therefore, for CD41a and CD42a the recommended 
concentration was used for assays. Across all markers increased antibody concentrations 
increased fluorescence but higher concentrations can lead to non-specific binding, which is 
reflected in the Sensitivity Index (SI) calculation as shown in Figure 3-9. SI is a measure of 
measurement sensitivity as it indicates the separation between positive and negative 
populations. It is calculated using Equation 3-1 [123]: 
𝑆𝐼 =  
𝑚𝑒𝑑𝑖𝑎𝑛 𝑠𝑖𝑔𝑛𝑎𝑙 − 𝑚𝑒𝑑𝑖𝑎𝑛 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
(84𝑡ℎ 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑖𝑙𝑒 𝑚𝑒𝑑𝑖𝑎𝑛 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 −𝑚𝑒𝑑𝑖𝑎𝑛 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)/0.995
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The maximum SI achieved was at an antibody concentration of 5 µg.mL-1, and at higher and 
lower concentrations similar suboptimal population separations were achieved.  
  
Figure 3-9: SI index for CD42b concentrations showed the optimal concentration was 5 µg.mL-1 which was 
half of the manufacture’s recommended concentration. 
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3.3.2.1. Adjustment of panels to overcome issues associated with green fluorescent protein 
The use of green fluorescent protein (GFP) in flow cytometry panels can be challenging. GFP 
is associated with the expression of the forward programming factors and therefore its 
expression level is set. It cannot be titrated, as with antibody concentration for example. The 
following section describes assays developed either to incorporate its expression in the panel 
(thus gaining more information about the expression level of the forward programming 
genetic cassette) or exclude it to reduce issues of spectral overlap with other fluorochromes.  
3.3.2.2. Reduced colour panel for 2nd generation forward programming  
The use of Panel 4 for early stage (prior to day 10) 2nd generation Dox-inducible FOPMKs was 
challenging since there was large overlap into the violet A channel, which was being used to 
measure BV510 – CD41a, by GFP as shown in Figure 3-10. Therefore, a smaller panel was 
developed which did not use the FITC and BV510 channels and utilised only essential FOPMK 
markers CD41a, CD42a and CD235a as an early indicator of lineage trajectory. The PMT 
voltages were set using Application Settings as detailed in Section 3.3.1.4. The compensation 
matrix (Table 3-13) was calculated using a combination of single stained capture beads for 
phenotypic markers, cells stained with viability stain and unstained cells. 
Table 3-12: Fluorochrome details and optical settings for Panel 5 which was reduced colours, without GFP 
or BV510 channels, for characterising inducible FOPMKs  
Marker/attribute Fluorochrome 
Relative 
Brightness 
Laser PMT - filter 
PMT 
voltages 
FSC         180 
SSC         380 
CD235a PE-Cy7 Bright Blue A – 780/60 549 
CD41a APC Bright Red C – 660/20 525 
Viability 
FVS780 
No data 
available 
Red A – 780/60 544 
CD42a BV421 Very bright Violet B – 450/40 306 
 
3-72 
 
Table 3-13: Compensation matrix for Panel 5 described in Table 3-12. 
Fluorochrome -% Fluorochrome 
Spectral 
Overlap 
APC PE-Cy7 0.02 
APC-Cy7 PE-Cy7 9.64 
BV421 PE-Cy7 0.04 
PE-Cy7 APC 0.19 
APC-Cy7 APC 9.79 
BV421 APC 0.01 
PE-Cy7 APC-Cy7 3.48 
APC APC-Cy7 0.62 
BV421 APC-Cy7 0.26 
PE-Cy7 BV421 0.00 
APC BV421 0.00 
APC-Cy7 BV421 0.00 
 
  
Figure 3-10: Spectral overlap from GFP into the 525/50 channel skewed BV510-CD41a measurement. 
skewed-CD41a  which was used to capture-CD41a  which was used to capture BV510 florescence. 
fluorescence. (A) Unstained samples showed GFP expression in the BV510 channel. (B) Stained samples 
show CD41a expression on the background GFP expression. (i) Cells at Day 2 post Dox addition expressed 
high levels of GFP and low levels of CD41a expression, which can only be discerned from comparing stained 
and unstained cells. (ii) There is still a high level of background GFP fluoorescence at Day 10. Flow cytometry 
assays for Dox-inducible FOPMKs should not include the BV510 fluorochrome.  
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3.3.2.3. Early stage forward programming comprehensive panel 
To increase the information gained from FOPMK cultures, including GFP expression, which 
was linked to the expression of the forward programming genetic cassette, and CD34 as a 
marker of early haematopoietic lineage trajectory, the panel was expanded to include more 
fluorochromes. As in Panel 5, Application Settings (Section 3.3.1.4) were used to set PMT 
voltages, but due to the high fluorescence of GFP the voltages of the FITC channel was 
decreased. In order to keep the compensation values low (and minimise noise introduced 
through high compensation values), the voltages of other channels were decreased also. This 
reduced sensitivity but allowed GFP and more parameters to be measured than in Panel 5. 
This highlights the importance of the balance between numbers of parameters measured, 
noise, sensitivity and resource required for implementation is for process development assays.  
 
Table 3-14: Fluorochrome details and optical settings for characterising early stage inducible FOPMK panel 
(Panel 6). 
Marker/attribute Fluorochrome 
Relative 
Brightness 
Laser PMT - filter 
PMT 
voltages 
FSC         180 
SSC         380 
GFP 
  
No data 
available 
Blue E – 530/30 390 
CD41a PE Bright Blue D – 575/26 304 
CD34 PerCP-Vio700 Moderate Blue B – 695/40 320 
CD235a PE-Cy7 Bright Blue A – 780/60 346 
TRA-1-81 APC Bright Red C – 660/20 346 
Viability 
FVS780 
No data 
available 
Red A – 780/60 318 
CD42a BV421 Very bright Violet B – 450/40 240 
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Table 3-15: Compensation settings for Panel 6 (assay described in Table 3-14). 
Fluorochrome channel -% Fluorochrome Spectral Overlap 
PE GFP 2.48 
PerCP-Vio700 GFP 0.17 
PE-Cy7 GFP 0.02 
APC GFP 0.00 
FVS780 GFP 0.00 
BV421 GFP 0.05 
GFP PE 5.33 
PerCP-Vio700 PE 13.29 
PE-Cy7 PE 1.47 
APC PE 0.00 
FVS780 PE 0.07 
BV421 PE 0.06 
GFP PerCP-Vio700 0.04 
PE PerCP-Vio700 0.04 
PE-Cy7 PerCP-Vio700 31.11 
APC PerCP-Vio700 1.01 
FVS780 PerCP-Vio700 3.06 
BV421 PerCP-Vio700 0.00 
GFP PE-Cy7 0.91 
PE PE-Cy7 1.30 
PerCP-Vio700 PE-Cy7 5.20 
APC PE-Cy7 0.00 
FVS780 PE-Cy7 4.37 
BV421 PE-Cy7 0.00 
GFP APC 0.05 
PE APC 0.05 
PerCP-Vio700 APC 1.20 
PE-Cy7 APC 0.14 
FVS780 APC 6.67 
BV421 APC 0.07 
GFP FVS780 0.00 
PE FVS780 0.00 
PerCP-Vio700 FVS780 0.00 
PE-Cy7 FVS780 11.50 
APC FVS780 0.86 
BV421 FVS780 0.00 
GFP BV421 0.03 
PE BV421 0.00 
PerCP-Vio700 BV421 0.01 
PE-Cy7 BV421 0.00 
APC BV421 0.00 
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3.3.2.4. Snapshot panel for early stage FOP 
To increase resolution for early- (<day 10) to mid-stage (<day 18) Dox-inducible FOPMKs, a 
reduced colour panel was devised that included GFP, CD34, CD235a and CD41a – Panel 7. 
Optical capture settings are shown in Table 3-16 and were again developed using Application 
Settings. Compared to Panel 6 (Table 3-14), the PMT voltages were higher due to the lower 
number of parameters, which increases sensitivity. Compensation was calculated using single 
stain beads, cells stained with DAPI and unstained cells. 
Table 3-16: Fluorochrome details and optical capture settings for reduced panel to characterise early stage 
FOPMKs produced by the inducible iBOBc line (Panel 7). 
Marker/attribute Fluorochrome 
Relative 
Brightness 
Laser PMT - filter 
PMT 
voltages 
FSC         230 
SSC         420 
GFP 
  
No data 
available 
Blue E – 530/30 502 
CD235a PE Bright Blue D – 575/26 379 
CD34 PerCP-Vio700 Moderate Blue B – 695/40 418 
CD41a APC Bright Red C – 660/20 530 
Viability DAPI 
No data 
available 
Violet B – 450/40 280 
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Table 3-17: Compensation matrix for Panel 7 shown in Table 3-16. 
Fluorochrome 
-% 
Fluorochrome 
Spectral 
Overlap 
PerCP FITC 0.00 
APC FITC 0.00 
DAPI FITC 4.61 
FITC PE 6.30 
PerCP PE 19.08 
APC PE 0.25 
DAPI PE 0.01 
FITC PerCP 0.03 
PE PerCP 0.00 
APC PerCP 3.36 
BV421 PerCP 0.00 
FITC APC 0.00 
PE APC 0.00 
PerCP APC 0.30 
DAPI APC 0.00 
FITC DAPI 10.04 
PE DAPI 1.38 
PerCP DAPI 0.74 
APC DAPI 0.2820135 
3.3.2.5. iPSC Panel development 
Pluripotency markers NANOG, Oct 3/4 and TRA-1-81 were selected to measure the 
pluripotency of iPSC cells during expansion prior to forward programming via induction of the 
FOP genetic cassette with Dox. Optical capture settings were defined using Application 
Settings and are shown in Table 3-18. The compensation matrix was calculated using stained 
capture beads, viability stained cells and unstained cells and is shown in Table 3-9. 
Table 3-18: Fluorochrome details and optical capture settings for iPSC phenotype monitoring (Panel 8). 
Marker/attribute Fluorochrome 
Relative 
Brightness 
Laser 
PMT - 
filter 
PMT 
voltages 
FSC         140 
SSC         350 
NANOG PE Bright Blue D – 575/26 430 
Oct 3/4 PerCP Dim Blue B – 695/40 470 
TRA-1-81 APC Bright Red C – 660/20 502 
Viability FVS780 
No data 
available 
Red A – 780/60 450 
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Table 3-19: Compensation settings for Panel 8 (assay described in Table 3-18). 
Fluorochrome -% Fluorochrome Spectral Overlap 
PerCP PE 17.60 
APC PE 0.02 
APC-Cy7 PE 0.00 
PE PerCP 0.00 
APC PerCP 1.79 
FVS780 PerCP 2.09 
PE APC 0.01 
PerCP APC 1.32 
FVS780 APC 5.31 
PE FVS780 0.00 
PerCP FVS780 0.32 
APC FVS780 1.02 
 
3.3.2.6. iPSC antibody titrations 
Antibody titrations were performed with all pluripotency markers to determine the optimal 
concentration of antibody stain to use. Figure 3-11 (A) shows each antibody stained with 
decreasing concentration relative to the manufacturer’s recommended concentration, with 
both positive and negative populations. The positive and negative populations are gated and 
were used to calculate the SI using Equation 3-1 and are shown for each stain concentration 
in Figure 3-11 (A). Both APC-TRA-1-81 and PE-NANOG had the highest separation at the 
manufcturers concentration, whereas there was better separation between populations for 
PerCP-Oct3/4 at 25% of the manufacturer’s recommended concentration. The difference in 
SI highlights the importance of antibody titrations for high sensitivity assays. 
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3.4. Cell counting characteristics of the culture system 
Ideal cell counting methods are accurate, consistent, precise and able to distinguish between 
cell populations that are viable and non-viable. An in-depth review of methods for measuring 
viability is beyond the scope of this chapter, but can was reviewed by Cook and Mitchell [124]. 
It is assumed here that a cell with an integral membrane is viable and is capable of replication. 
Membrane integrity is commonly determined by cells’ ability to exclude nuclear stains such 
as DAPI. Other characteristics associated with programmed cell death, apoptosis, are 
decreased cell size and increased granularity [125]. Figure 3-12 shows three different FOPMK 
cultures in varying cell states relating to cell size, granularity of proportion of cells permeable 
to DAPI. In (a), minimal cells are present in the high SS / (high granularity) population and 
greater than 97% of the population negative for DAPI. The same culture expanded for five 
days without a medium exchange is shown in (b). Here the cells are shown shifted to lower 
FS, showing a decreased size, and became more granular.  
The proportion of DAPI positive cells concurrently increased to more than 50% which shows 
that the cells are likely to be undergoing apoptosis [126]. In both (a) and (b) the singlet cell 
population had a larger proportion of DAPI+ cells compared to the doublet population, and in 
(a) 31% of cells are doublets, whereas in (b) only 16% of cells are doublets, which indicates a 
relationship between cell viability and the number of doublets in culture.  
 
Figure 3-11: Antibody titrations for antibodies used in iPSC Panel 7; (A) NANOG, (B) OCT 3/4 and (C) TRA-
1-81. Antibody concentrations were varied with respect to the manufacturer’s recommended 
concentration (i – vii) There were two populations of relatively high and low expression for each marker, 
which allowed stain indices to be calculated. (D) Stain index for each of the antibodies and the optimal for 
each stain highlighted with a red box. 
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Figure 3-12: Flow cytometry data showing FOPMK cultures in different states. (a) Cells in this state were  
larger in size and less granular with a lower proportion of DAPI permeable cells. (b) Culture with a higher 
proportion of DAPI permeable cells were smaller size and more granular. (c) Culture contains a high 
proportion of cells with high granularity but this population did not appear DAPI positive. (i) FS/SS profiles 
show cell size and granularity. (ii-iii) Histogram plots of fluorescence of single cells (ii) and doublets  (ii)  in 
the DAPI channel. (iv) DAPI positive single and doublet populations overlaid on FF/SS profiles. 
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In Figure 3-13 (c) there were a high proportion of cells with a high SS profile which were not 
DAPI positive. This culture had been expanded over a three week period, compared to five 
days between (a) and (b) and it is assumed that these cells were non-viable and the A-T 
regions within the DNA - which DAPI binds to [127] – had decayed preventing binding. If this 
is the case non-viable cells could be split into two categories, cells that have recently become 
non-viable and cells that are long term non-viable. Cromatin breakdown of long term non-
viable cells has been noted in the literature previously [128]. Further data would need to be 
gathered in order to test this hypothesis. Since this effect could impact measurement of cell 
populations it could impact efforts to quantify cell culture dynamics. As a conclusion is was 
therefore decided that DAPI exclusion assays appeared to be useful in short term cultures for 
identifying viable cells, but must be treated with caution over longer time periods. To ensure 
that DAPI exclusion is an appropriate measure for viability, the high SS population  was 
monitored regularly to ensure it continued to stain positive for DAPI (data not shown).  
Often it is practical and beneficial to work with different pieces of cell counting equipment. 
Reasons for this include comparability, measurement speed and convenience. Confirming 
assay results through different methods gives increased confidence and comparability of 
results obtained through different counting methods is critical if a piece of equipment or 
process moves to a different manufacturing facility. Furthermore, a different number of 
measurements may need to be taken and the speed at which they are required might change, 
favouring one piece of equipment over another, or a piece of equipment might become 
unavailable on a certain day.  
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Figure 3-13: Cell counts obtained from the Nucleocounter NC300, and HTS module through the HTS (a) 
shows a linear relationship between HTS and NC-3000 measurements, however the measurements are 
offset. (b) & (c) show the distribution of cell counts taken from the mean on HTS and NC-3000 respectively 
and are normally distributed. 
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Figure 3-13 shows a comparison between cell counts taken using the HTS system on the BD 
FACS Canto II flow cytometer and the NC-3000. The linearity of the measurements shows that 
they are within the range of 5 × 105 and 2.5 × 106 cells.mL-1 and the distribution of the data in 
(b) and (c) show both counting methods have no discernible difference from the normal 
distribution. 
The proportional offset between the HTS system and the NC-3000 could be caused by physical 
attributes of the equipment, for example, the Nucleocounter A2 slides might have been made 
smaller than the stated volume used in the assay, causing an apparent increase in the 
concentration of cells, or a slight off-set in the HTS aspiration lines could mean that 16% of 
the sample is lost each time. Since there is an absence of an absolute “truth” reference 
material for cell counting assays it is very difficult to determine the absolute true 
measurement for cell counts [129].  
Although the standard deviation of the measurements from the HTS system was 1.58 × 105 
compared to 1.88 × 105 cells.mL-1 using the Nucleocounter measurement system, the 
variation as a proportion to the mean was more similar; 12% and 13% respectively. This 
indicates that the inherent variation for each piece of equipment was very similar or that cell 
sampling effects were the dominant cause of the deviations from the predicted value from 
each measurement system. 
It is not desirable to wash the cells used for cell counting protocols after staining with DAPI, 
as this extra processing step could add multiple failure modes. For example, through washing 
cells may be lost adding variability or offset and extra processing time is added which may 
detrimental to cell samples. Therefore, it was important to assess whether the proportion of 
DAPI stained cells changed with increased incubation times. 
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Figure 3-14 shows the counts of sample from the same cell culture with increasing time 
exposure to DAPI over 50 minutes. There was no increase in the proportion of non-viable cells 
across the time period, showing that FOPMKs suspended in a concentration of 1 μg.mL-1 DAPI 
were stable with regards to DAPI permeability over this time period. However, (b) shows an 
increase in the total cell concentration with time. This could have been an artefact of sampling, 
for example cells settling to the bottom of the flask after being mixed. Since each count took 
approximately 2 minutes to run, the samples were run in the same order as the time sequence, 
Figure 3-14: Over a 50 minute period at room temperature permeability to DAPI did not increase. (a) 
Cell counts of viable (DAPI non permeable), non-viable (DAPI permeable) and total (sum of viable and 
non-viable) cells from equivalent culture show consistent cell numbers over a 50 minute period. (b) 
Residuals from the mean value show an increase in total cell number with time  
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which governed the exposure time. Therefore, the increase in cell number with time could 
have been a result of the run order on the HTS system. Experiments which required large 
sample numbers to be run in succession had their run order tracked in future experiments to 
ensure the run order was not introducing bias in to the counts. 
To test whether sample mixing was the cause of the decreased counts across time, FOPMKs 
were mixed well and placed into a 50 mL centrifuge tubes. Cells were sampled from the top 
of the tube carefully whilst avoiding disturbing or mixing the tube. Figure 3-15 (a) shows the 
cell concentration of the samples over this period. The concentration decreases by a third 
within the first minute, but it is not clear whether this is a real effect. The initial measurements 
Figure 3-15: FOPMKs settle over time if cultures are not mixed. (a) Cell concentration over time shows a 
decrease in both viable and non-viable cells of a third during the first minute, then a steady decline over 
the next 24 minutes (b) the proportion of viable cells in the cell counts remains approximately consistent, 
therefore the settling rates of viable and non-viable populations appears to be consistent. (c) Image shows 
visible cell pellet at the bottom of the 15 mL centrifuge tube over the 25 min period. 
3-86 
 
were assumed to have been higher because the samples were taken close to the meniscus of 
the medium, where there may have been a higher concentration of cells, since it is 
documented that cells gather at surface boundaries [130]. If the rapid settling of cells was a 
true effect this could affect the main measurements of the FOPMK culture system, whereas 
the slower rate of settling from 1-25 minutes produced a reduction in cell number by around 
16%, which over this time frame is negligible., since measurements would be taken within 2 
minutes post mixing. 
Viable and non-viable cells appeared to settle at the same rate as shown in Figure 3-15 (b). 
Therefore, any settling would not allow for selective advantage of viable and non-viable 
populations so measurements would likely show the true proportion of cells, even if the 
absolute concentration was offset. In Figure 3-15 (c) a visual cell pellet can be seen which 
formed after the 25-minute period. This confirms that cell settling took place but since the 
pellet would be less dense than a pellet produced by centrifugation, comparison is flawed and 
therefore it cannot be visually determined from the image whether rapid settling occurred. 
Determining culture dynamics requires precise high temporal resolution cell counts and so 
counts that are biased within a certain time window would be problematic. Figure 3-16 shows 
that following a medium exchange FOPMKs temporally adhered to standard tissue culture 
treated plastic (STCP) within an hour post-seeding. This did not occur when using ultra-low 
attachment (ULA) plasticware . After 24 hours the cells recorded from both STCP and ULA 
were equivalent, suggesting the cells lifted off of the plastic. After 48 hours the STCP complete 
exchange appeared to have more cells present, this may have been caused by removing 
medium for cell counts in the early stage of culture whilst retaining cells, since they were 
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adhered to the plastic. This means that the cells have been concentrated, rather than 
outperforming the ULA or partial exchange STCP. 
  
  
Figure 3-16: FOPMKs temporarily adhered to standard tissue culture plastic (STCP) following a medium 
exchange. This effect was alleviated by using ultra-low attachment (ULA) tissue culture plastic. (a) 
Approximately 75% of cells attached to STCP within the first hour following a medium exchange, but within 
24 hours the cell counts of the cultures using ULA and STCP were equivalent. Data shows N=2 ±STD. (b) Main 
effects plot from statistical analysis software Minitab showing linear relationships between the proportion 
of medium exchanged, viable cell starting density, time in culture and the percentage of cells attached. 
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After four hours the cell counts from the partial exchange STCP cultures were equivalent to 
the ULA cultures, which suggested there was a positive effect from retaining a proportion of 
the cell growth medium in an exchange to prevent attachment. If spent medium affected the 
cells attachment properties, it was hypothesised that it was factors released by the cells into 
the medium causing the behaviour change. If this was correct, cell density would also 
determine attachment rate, since more cells would release more factor. Indeed, Figure 3-16 
(b) shows that there are linear relationships between proportion of exchange, cell seeding 
density and time, which supports this hypothesis and explained difference in STCP cultures in 
(a). 
From this work it appears that FOPMKs show similar growth profiles whether cultured using 
STCP or ULA plasticware. From the perspective of the ability to monitor growth dynamics 
using high temporal resolution cell counting methods, ULA prevented attachment issues that 
might bias counts in the 24 hour post-seeding. It has also been reported that ULA plasticware 
increases primary human MK viability and promotes polyploidy development [131]. Therefore,  
ULA tissue culture plastic should be used for culturing suspension FOPMKs. 
3.4.1.  Cell counting issues when using iPSCs 
Two cell counts were taken from iPSC wells with target seeding densities of 1000, 5000 and 
9000 cells.cm-2 prior to seeding wells (i.e. cell counts were taken from a pooled vessel) and 
immediately after cells and medium suspensions had been placed into wells. The cell counts 
shown in Figure 3-17 demonstrated that across all seeding densities and all wells that the post 
seeding counts were higher than the pre-seeding counts.  
It is hypothesised that the uplift in cell number was caused by cell aggregates disassociating 
and becoming visible on the flow cytometer. Despite the use of TrypLE to reduce cell clumping, 
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doublets and the edge of a triple cell population were observed on the FSC/SSC profile (data 
not shown). The pre-seeding count cell count may not have been mixed as thoroughly as the 
post-seed count (although this seems unlikely since effort was taken to mix the cells 
thoroughly first). Whatever the underlying mechanism, it is difficult to find a reason to suspect 
cells were over counted in the post-seed count, since generally cells are more likely to be lost 
through liquid handling. Therefore, it is assumed that the post-seeding count was more 
accurate and was therefore used where possible to calculate cell losses in the first day of 
culture in relevant sections (see Section 6.6). Even if this were not true, consistent use of post-
seeding cell counts would provide comparability between experiments. 
  
Figure 3-17: Cell counts for iPSC cells seeded at a target density of 1,000 (wells 1 and 4) 5,000, (wells 
2 and 5) and 9,000 (wells 3 and 6) cells.cm-2 show that in all cases measured cell counts were higher 
post-seeding than pre-seeding. 
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3.5. Conclusions 
This chapter presents a QTPP for FOPMK, in vitro derived platelet transfusion units and 
proposes CQAs. Corresponding assays are developed to measure CQAs quantities of FOPMKs 
(both 1st generation non-inducible lines and 2nd generation Dox-inducible FOPMKs) and iPSCs.  
The QTPP was developed using the current clinical standard of platelet transfusion units 
derived from volunteer donors, with additional markers added (CD41, 42a/b, CD62P) to 
ensure the correct identity of platelets. These markers are not routinely monitored currently, 
probably because the use of apheresis for collecting platelets is a long established process 
that reduces the contamination of platelet units by other blood cells [132].  
However, the development of a QTPP based on platelet transfusion units still presents 
challenges in establishing CQAs that can be used for process development in a production 
process that requires cells to differentiate and therefore change marker expression 
throughout production. A detailed literature search found no assay  that could predict the 
ability of MKs to produce a certain number of platelets. Therefore, assays were developed to 
measure established lineage trajectory and platelet functional markers (CD34, CD235a, 
CD41a, CD42a, CD42b) in the case of FOPMKs or pluripotency markers (TRA-1-81, NANOG, 
Oct3/4) for iPSC expansion. Once assays become available that directly link to platelet yield 
and quality from FOPMKs, these should be measured also, and this would allow further 
tailored process improvements and corroboration of original assays However, these assays 
should give a good starting basis for measuring FOPMK functionality and can thus be used to 
make informed process risk decisions. 
Different methods for setting PMT voltages for flow cytometry assays were explored. Using 
Application Settings to establish baseline PMT voltages required more resource to set-up 
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initially compared to other methods (such as first log decade or use of CS&T bead suggested 
values), but often produced voltages that required minimal adjustment (expect in the case of 
GFP in extended Panel 6, Table 3-14, due to the high fluorescence of GFP, which was 
challenging to accommodate on an extended panel without loss of sensitivity through 
reduced PMT voltages). Assay sensitivity through the enhanced separation of population was 
enhanced through antibody titrations. In addition to the enhanced sensitivity, assay costs 
were also improved in half of antibodies titrated, since the highest Sensitivity Index was 
achieved at lower concentrations than the manufacture’s recommendation. 
Cell count methods were developed using different equipments (BD FACS CANTO and NC-
3000) . Both methods were found to produce cell count measurements that were normally 
distributed around the mean and were calibrated for comparability between assays. The 
permeability of viability stain, DAPI, was monitored over a period of 50 mins at room 
temperature and was found to be stable, which increased assay flexibility.  
A cell count measurement issue was noted during the use of standard tissue culture plastic 
when FOPMKs temporarily attached. The attachment was dependent on proportion of 
medium exchange performed and cell density. To avoid cell counting issues related to cells 
attaching to standard tissue culture plastic, ultra-low attachment tissue culture vessels were 
used throughout the rest of the project. 
When seeding iPSCs, a discrepancy in cell counts before and after seeding was recorded. It 
was assumed that the higher cell counts were more accurate, since the loss of cells through 
liquid handling was more plausible than the creation of cells. Regardless of the “true” count, 
cell counts post-seeding were used to ensure comparability between experiments. 
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3.5.1. Future work 
The cell therapy industry has previously suffered due to a lack of meaningful CQAs. Since cell 
products are so complex, it is often challenging to link CQAs to MOA [118]. Once the process 
of platelet production from FOPMKs is more thoroughly understood and defined any noted 
CQAs should be recycled back into the process of QTPP definition. 
Flow cytometry assay development was shown to be complex and subjective. Methods such 
as Application Settings have been developed to ensure greater comparability between 
experiments and sites, but subjectivity in set-up remains inherent. The choice of 
fluorochromes combinations is also highly subjective, comparisons between manufacturers 
and out comes on different pieces of equipment are not readily available. As the cell therapy 
industry matures, flow cytometry assay comparability, accuracy and sensitivity will become 
pressing issues and there are already programmes that are attempting to address some of 
these issues [133]. 
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4. The application of mechanistic 
modelling tools to determine the 
system productivity of non- doxycycline 
inducible forward programmed 
megakaryocytes 
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4.1. Introduction 
This chapter focuses on the production of FOPMKs from the first generation process where 
iPSCs were targeted with a cocktail of 3 viral vectors which individually contain transcription 
factors GATA1, FLI1 or TAL1 and created a semi-immortalised megakaryocyte line which 
proliferated in vitro for around 90 days [5]. Figure 4-1 summarises this process and was 
devised based on publications by Moreau [5] and Dalby [134].  
The use of viral vectors is an industry bottleneck, with wait-times for GMP vectors of up to 18 
months and vectors have a high COGs. Therefore, achieving acceptable process costs for in 
vitro platelet production will be dependent on optimising the expansion phase of FOPMKs to 
produce a high yield of cells per input genetically programmed iPSCs, with respect to resource 
consumed, which are of sufficient quality for platelet production. 
In order to define how a process will affect product quantity and quality many factors must 
be measured, controlled or in some way considered. These are likely to have complex and 
interacting relationships. A qualitative description of dynamics includes the nature of 
processes such as growth inhibition and/or cell death, the nature of population changes, and 
whether these mechanistically relate to operations such as media provision and other culture 
system attribute. These dynamic culture characteristics are critical to determining a 
manufacturing strategy [135]. This chapter presents proof of concept for a methodology, 
using FOPMKs as a clinically relevant case study, where key process dynamics, that are critical 
for cell expansion, are identified through high temporal resolution cell culture experiments 
and quantified using ODE based, dynamic, mechanistic models. 
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4.1.1. Chapter Objectives 
- Qualitatively identify culture dynamics which affect FOPMK expansion system 
productivity 
- Identify candidate mechanisms for observed culture dynamics 
- Quantify key culture dynamics using a  novel mechanistic modellingframework 
- Validate model applicability to scalable culture systems 
4.2. Materials and methods 
Cell line derivation and culture was performed as described in Section 2.3 & 2.4. Two cell lines 
were used for this work, BOB and FFDK; the experiments conducted with each are outlined 
below in Table 4-1. 
Figure 4-1: Summary of first generation FOPMK derivation and expansion. The expansion phase of FOPMKs 
is critical to achieving acceptable COGs for an in vitro manufactured platelet product. 
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Table 4-1: Table showing the cell line used in each section. 
Cell line BOB FFDK 
Section used in 4.3.1 
Error! Reference s
ource not found.  
4.3.4  
4.3.5  
4.4.2 
4.5.1 
4.5.2 
4.5.3 
4.5.4 
4.5.5 
4.3.3 
4.4.1 
4.4.3  
Error! Reference s
ource not found. 
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For medium comparison in Section 4.4.3, Iscove’s modified Dulbecco’s medium (IMDM) base 
medium was used which was supplemented with: 
• IMDM with GlutaMAX-I (Invitrogen, Paisley,UK) 
• 1.5 % human AB serum (Sigma-Aldrich, Dorset, UK) 
• 0.1% insulin (Sigma-Aldrich, Dorset, UK) 
• 2% human albumin serum (Invitrogen, Paisley,UK) 
• 0.4% heparin (Sigma-Aldrich, Dorset, UK) 
• 100 ng.mL-1 SCF (R&D Systems, Abingdon, UK) 
• 40 ng.mL-1 TPO (R&D Systems, Abingdon, UK) 
Cell counting was performed using flow cytometry and described in Section 2.5.2. Flow 
cytometry sample preparation, equipment used, staining and acquisition is described in 
Sections 2.6.1 - 2.6.3. The flow cytometry assays and cell counting assays used are described 
in Section 3.3.1, and the assays used are identified in relevant sections and figure legends 
associated with flow cytometry data. 
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Design of experiments were conducted as detailed in Section 2.8.1. The number of factors, 
levels of factors, outputs and whether a centre point was included is detailed along with the 
results of the DOE outputs in the relevant sections. 
4.2.1. Dynamic modelling framework 
The dynamic modelling framework used here is described in detail by Stacey et al. [100] and 
also in Section 2.9.  
4.3. Qualitative growth dynamics of the culture system 
4.3.1. Initial system assessment 
The standard operating procedure provided by our collaborators for medium supply was a 
partial medium exchange every 3-4 days [5] (see also Section 2.2.2). Using this method, 
Moreau et al. noted qualitatively variable net expansion rates. Therefore, this culture method 
was repeated to determine baseline performance which is shown in Figure 4-2. High viability 
cultures were maintained for the first 48 hours, after which point the number of viable cells 
diverged from the total number of cells. Despite medium addition, the proportion of viable 
cells did not recover. 
4.3.2. Distinguishing between time and cell.time culture limitations 
It was assumed that non-viable cells do not proliferate, and only viable cells were capable of 
cell growth, so non-viable cells were created by conversion from viable cells. Therefore, after 
48 hours it was hypothesised there was a change in culture conditions which caused an 
increased conversion rate of viable cells to non-viable cells. It was unlikely that cell density 
caused the rapid conversion of viable to non-viable cells, since the cell number reset at 72 
hours would have triggered an increase in the number of viable cells.  
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This led to the hypothesis that a component in the medium was causing the enhanced 
conversion. This may have either been decay of a component which was critical for 
maintaining cell viability or the production of a component which was toxic to cells. The 
production/decay rate may have either been a function of time or a cell mediated metabolism 
which was a function of the product of cell number and time (cell.time). To distinguish 
between a time or cell.time conversion rate mediator, cells were cultured using various cell 
seeding densities and proportions of medium exchange at zero hours. No further medium 
was supplied to the cultures. Figure 4-3 shows high-temporal resolution cell counts. Viable 
Figure 4-2: Established medium supply regime did not support consistent expansion over 200 hours. (a) 
Green dashed lines show a medium addition to decrease the cell seeding density to the starting density of 
5 × 105 cells.mL-1. Data show N=2 ±STD. (b) Average viability decreased across the culture period. 
Medium additions 
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cell concentrations increased for cell cultures seeded at higher densities until 60 hours, after 
which the viable cell concentration declined. The decline in concentration happened 
approximately 20 hours later for cultures that underwent a complete medium exchange 
compared to a partial medium exchange.  
This shows that medium exhaustion, rather than effects related from cell density such as 
contact inhibition or mass transfer limits, promoted conversion to non-viable cells and that 
the volume productivity of the system was 1.48 ± 0.28 × 106 viable cells.ml-1 (based on the 
high and low density, complete exchange cultures). In addition to conversion of viable to non-
viable cells, the plateau in viable cell concentration at 60 to 80 hours, with a relatively small 
increase in total cell concentrations demonstrated that growth inhibition related to medium 
exhaustion was also likely to be present. 
 Since the conversion of viable cells occurred later in time in the lower density cultures, the 
promotion of conversion was likely to be linked to a cell.time mediator rather than time alone. 
However, the cause of growth inhibition may have been more complex. Since growth 
inhibition occurred in both high density and low density cultures at around the same time of 
60 hours, this may have been linked to a time related inhibition, for example decay of medium 
components [136] [96]. Comparison between partial medium and complete medium 
exchanges would not distinguish between a time and cell.time mediator, because the 
proportion of medium remaining from a partial exchange may have decayed also. However, 
cell death was a higher risk to process outcome than growth inhibition, and therefore 
understanding the growth inhibition mechanism was of a lower priority. 
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Figure 4-3: Viable FOPMKs were converted to non-viable cells due to medium exhaustion. (a) Cultures 
seeded at higher concentrations reached a peak concentration of viable cells earlier than cultures seeded 
with lower cell concentrations. Lower medium supply also led to deceasing viable cell concentrations 
earlier than culutres with a complete medium exchange. (b) Non-viable cell concentrations increased with 
concurrent decrease in viable cell concentrations, showing a conversion of viable to non-viable cells. 
(c) %viable cells acros time.Data  shows cell line BOB, N=2 ± STD. 
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4.3.3. The relationship between growth rate and cell seeding density at seeding 
The relationship between growth rate promotion and cell seeding density was complex. 
Figure 4-4 shows the number of population doublings over a 48-hour period following a 
complete medium exchange increased for cultures seeded between 1.5 × 104 to 1.5 × 106 
cells.mL-1. It was hypothesis that the improvement in growth rate was derived from cell 
released factors which promoted growth; factors which would have been removed during a 
complete medium exchange. 
In order to understand the relationship between cell seeding density and promotion of 
growth rate, cells were seeded at 5 × 104 and 2 × 106 viable cells.mL-1 and a high temporal 
resolution growth curve was conducted. In Figure 4-5 cultures seeded at lower cell densities 
had associated higher growth rates than cultures seeded at higher cell concentrations. The 
cultures seeded at 5 × 104 cells.mL-1 with a complete medium exchange had an average 
growth rate of 0.0151 h-1, but in Figure 4-4 the equivalent cultures had an average growth 
rate of 0.005 h-1, around a third of that observed in Figure 4-5. 
Figure 4-4: Increasing viable cell seeding density from 1.5 × 104 to 1 × 106 cells.mL-1 increased the number 
of population doublings which occurred over a 48 hour period. Cell line used was FFDK. 
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 The cultures used were from the same FOPMK derived cell line (FFDK) and had been cultured 
for around 130 days since FOPMK derivation, and therefore were assumed to be equivalent 
cultures. The experiment in Figure 4-4 was conducted using 96 well plates, whereas Figure 
4-5 was conducted using 6 well plates; the difference in observed growth rates may be linked 
to  different mass transfer limits of the two culture platforms, either in terms of dissolved 
oxygen concentration or localised concentration gradients of nutrients and metabolites 
formed around the cells. These limitations may also account for the lower growth rate 
observed at the higher culture density of 2 × 106. Since the growth rate was consistently lower 
over the 48 hour period this cannot be attributed to the same accumulation of factor that 
caused the growth inhibition and death in Figure 4-3. 
Investigating the differences in mass transfer limits is of limited value to defining a 
manufacturing strategy which would likely rely on large-scale reactor systems, such as stirred 
tank vessels. However, many process development experiments are conducted using static 
Figure 4-5: Cultures seeded at 5 × 104 had on average ~30% faster growth rates than cultures seeded at 2 
× 106 viable cells.mL-1 over 48 hours. Growth rates between culture which had partial and complete 
medium exchanges had little difference in growth rates. Cell line used was FFDK, data shows N=2 ±STD. 
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culture platforms due to their ease of use, ability to use small cell numbers and reagents, 
therefore it was important to develop and understanding of the limits of the culture platforms 
used and how they might impact the culture dynamics. 
4.3.4. Adjusted medium supply regime to control density 
It was hypothesised that since medium exhaustion caused rapid cell death, increasing the 
medium supply would lead to sustained, stable cell growth. Compared to the growth rate 
fluctuations shown in Figure 4-2, the growth rate achieved was higher and more stable in 
Figure 4-6. The adjusted medium supply was based on addition of fresh medium to maintain 
cell densities between 5 × 105 and 1 × 106 cells.mL-1. This density would likely be outside of 
mass transfer limitations, and addition of medium would negate the risk of possible effects 
from removing positive conditioning factors from the medium, which would occur in a 
complete exchange. It was assumed that growth factor decay could be mitigated by adding 
double concentrated growth factors as in the established SOP. Using this method, a high 
proportion of viable cells (Figure 4-6a) was maintained, in contrast to Figure 4-2; again 
showing medium supply controlled the conversion of viable to non-viable cells.  
The linear increase in cumulative population doublings with time shown in Figure 4-6b shows 
a stable growth rate across the culture period of approximately 0.019 h-1 was achieved, but 
there was an oscillation in the residual error of the cumulative number of population 
doublings from the trend line across time (Figure 4-6c). This indicated that a higher growth 
rate than 0.019h-1 was achieved, but it is unclear whether this could be sustainable across the 
culture period. 
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Figure 4-6: Culture volume was doubled by the addition of fresh medium once the concentration of viable 
cells exceeded 1 × 106 cells.mL-1. (a) Cell concentration changes with time show maintenance of a high 
proportion of viable cells using the adjusted medium supply. (b) A linear relationship between cumulative 
population doublings and time shows a consistent growth rate of 0.019 h-1 from 50 to 420 hours. (c) 
Residuals of cumulative population doublings with time show a pattern of oscillating growth rate over the 
culture period, indicating that higher growth rates might be achievable with adjusted medium supply. Cell 
line used was BOB. 
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4.3.5. Changes in FOPMK phenotype across the culture period 
Thus far, this work has been focused on FOPMK growth rate changes, however cell quality is 
a critical process output. As discussed in Section 3.2.1, cell phenotype is used here as a 
surrogate measure for cell quality. Figure 4-7 shows that FOPMK phenotype trended over a 
culture period of 35 days. Two competing hypothesises are that this trend was a function of 
medium supply, or the observed trends were inherent to FOPMKs. This trend was not 
investigated further using FOPMKs derived from the 1st generation forward programming 
process since the technology moved on to second generation inducible system. Section 5 
describes how supply of specific components impacted cell phenotype. 
  
Figure 4-7: FOPMK phenotype trends over a month-long culture period. It is unclear whether this is related 
to medium supply or is inherent. Cell line used was BOB. 
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4.3.6. Qualitative culture dynamics summary 
A summary of the observed culture dynamics for the system is shown in Figure 4-8. The most 
critical aspect with respect to controlling an FOPMK manufacturing process was the rapid 
conversion of viable to non-viable cells which was an effect of cell.time mediated medium 
exhaustion. Since growth medium will contribute to a significant proportion of the COGs of 
large scale allogeneic cell therapies [73], the number of cells that a volume of medium can 
support over a given amount of time (i.e. medium productivity) will be a large determining 
factor of the end stage COGs. Therefore, there were two aspects to follow as part of 
developing an understanding of FOPMK proliferation to inform an FOPMK manufacturing 
strategy. The first was elucidating the factor causing rapid cell death, which could lead to 
medium modification to increase the productivity and therefore drive costs down. The second 
was to quantify the culture dynamics observed thus far and develop a control strategy based 
around medium supply.  
This two pronged approach was critical because elucidating the factor causing FOPMK death 
is unlikely to be straight-forward: Previous work by our group has shown that traditional 
Qualitative culture dynamics summary: 
• A stable doubling rate was achievable. 
• Modification of the cell culture milieu by FOPMKs led to promotion of cell death, 
not purely cell density or medium decay with time. 
• FOPMKs converted rapidly to non-viable cells as a response to medium 
exhaustion, rather than simple growth inhibition, which is a critical control 
window issue. 
• Cells were also likely subject to growth inhibition related to medium exhaustion 
and cell density (complex and potentially multiple mechanisms, for example: mass 
transfer limitations or cell contact, and culture platform dependent). 
• Growth rate after medium exchange appears to be related to density in a non-
simple way – relatively minor effect. 
Figure 4-8: Summary box of observed qualitative culture dynamics colour coded to show confidence, green 
being the points with the most certainty, and red being the points which are least certain. 
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bioprocess limitations such as glucose, lactate and ammonium are not primary inhibitors in 
the production of red blood cells [58] and since megakaryocytes are closely related in the 
hematopoietic linage it is not unreasonable to expect similar metabolic behaviour. 
Furthermore, the growth medium used for FOPMK production is a chemically defined, and 
although this is beneficial in terms of regulatory compliance and consistency [38], it means 
the proprietary medium is a black box system which limits possibilities of medium 
development. 
Quantitatively defining the dynamics of the FOPMK culture system would allow for an 
improved production strategy based simply on medium supply and does not rely on 
identifying complex culture limitations and arbitrary values could be assigned to, for example, 
medium exhaustion factors, which can then be used to calculate relative sensitivities. This de-
risks research into the manufacturing strategy because even if the limiting factor cannot be 
identified it can still be controlled. 
The rest of this chapter forms the foundation of the assessment of culture limitations and 
quantitative assessments of culture dynamics using an in-house developed, novel mechanistic 
modelling platform. 
4.4. Identifying culture limiting factors 
4.4.1. Growth factor concentration 
Growth factors SCF and TPO are required for FOPMK proliferation [5]. To determine whether 
the concentration of these cytokines impacted the FOPMK culture dynamics, varying 
combinations of growth factors were used with two difference cell seeding densities. Figure 
4-9 shows that there was little difference in growth caused by different growth factor 
concentrations. 
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In the lower density cultures, as shown in Figure 4-9a, the lowest combination of both SCF 
and TPO deviated from the other cultures from 40 hours, this could be as a result of growth 
factor decay with time. This is less clear in the higher density cultures in Figure 4-9a, but 
normalising for seeding density variations and plotting the doubling times (Figure 4-9b) also 
showed that the lowest cytokine concentration combination underperformed in the high 
density cultures. However, the middle combination also underperformed. There is also a 
relatively high variation between biological repeats. It is unclear whether this was linked to 
mass transfer limitations as observed from Figure 4-5.  
Since the effect of growth factor concentration was small (and not statistically significant), it 
was not prioritised for further assessment. However, to ensure it is not a limiting factor, the 
highest combination of growth factor concentrations was used in further work. 
Here, these nutrients/metabolites were monitored over the cultures shown in Figure 4-3 and 
are displayed in Figure 4-10. Over the 150 hours, only 20% of the baseline glucose was 
depleted showing that glucose concentration was not limiting the cultures. Compared to 
limiting values assessed on a red blood cell system [58], neither lactate nor ammonium were 
likely to be causing rapid cell death, although they may be contributing to growth inhibition. 
Fresh medium contained a comparatively high concentration of ammonium (1.5 mmol.L-1), 
which suggests that glutamine present in the medium is degrading overtime. The medium 
used was well within the manufacturing date of expiry, so might be indicative of other 
degradation occurring within the culture time frame. In order to define the effect of these 
metabolites on the FOPMK cultures, a dose response experiment could have been performed 
in future work, but was not included in this work, since the 2nd generation FOPMK system did 
not demonstrate the same medium exhaustion effects (see Section 5).  
4-109 
 
 
Figure 4-9: Concentration of SCF and TPO have a complex and interacting effect on FOPMK proliferation, 
but this is minimal compared to cell death effects. (a) Viable cell concentrations show the largest difference 
between the lowest concentrations of SCF and TPO and the highest concentration in the low density 
cultures, however the difference is minimal. (b) Doubling times over 60 hours for low density cultures and 
40 hours for high density cultures normalise for deviations in culture seeding densities and show minimal 
difference between growth factor concentrations. Cell line used was FFDK, data shows N=3 ±STD. Legend 
key : LD – low seeding density, HD = high seeding density, 20, 30, 40 show concentration of TPO (ng.mL-1), 
50, 75, 100 show concentration of SCF (ng.mL-1). 
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4.4.2. Common nutrient metabolite limitations 
In different cell culture systems, such as MSCs, glucose, lactate and ammonium limitations 
are often limiting factors that inhibit growth [137].  
 
Figure 4-10: Concentration of (a) glucose, (b) lactate and (c) ammonium across the culture period of 150 
hours. These were unlikely to be causing cell death at these concentrations. Cell line usd was BOB, Data 
shows N=2 ±STD. 
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4.4.3. Comparison of culture media 
Since FOPMK death dynamics are linked to medium exhaustion, it was likely that different 
media compositions would have different effects on FOPMK growth and inhibition. A 
comparison is shown in Figure 4-11 between Cellgro-based medium and a supplemented 
Iscove’s modified Dulbecco’s medium (IMDM) based medium (see Section 4.2 for materials), 
used for the growth of red blood cells [138][58]. High growth factor supplemented Cellgro 
SCGM contained 100 ng.mL-1 SCF and 40 ng.mL-1, and the low growth factor supplemented 
Cellgro SCGM contained 50 ng.mL-1 SCF and 20 ng.mL-1.  
From 20 hours onwards, the high growth factor (HGF) cultures (both Cellgro and SCGM) 
contained a higher number of viable cells compared to the low growth factor (LGF) cultures, 
supporting the differences shown in Figure 4-9, suggesting a promotion of a higher growth 
rate in response to cytokine availability.  
However, HGF Cellgro cultures reached a peak in viable cell concentration at 50 hours, 20 
hours prior to LGF Cellgro concentrations, suggesting HGF cultures promoted higher growth 
and either the presence of more cells, or possibly promotion of exhaustion as a result of a 
higher growth rate, limits the medium productivity.  
The IMDM-based medium outperformed Cellgro cultures from 60 hours, and the same spike 
in non-viable cells was not observed in the IMDM-based cultures. The increased 
concentration of viable cells in IMDM-based cultures suggests that this system has a higher 
medium productivity. However, Figure 4-11b shows that non-viable cells decay in the IMDM-
based system, which could mask possible death dynamics.  
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4.5. Developing mechanistic hypotheses underpinning FOPMK culture dynamics 
There are many ways in which qualitative relationships between process parameters and 
process outcomes can be modelled. Structured approaches to process development applied 
to cell therapy manufacturing, such as Quality by Design approaches (QbD), have traditionally 
Figure 4-11: Comparison of cell culture media Cellgro SCGM (chemically defined) and an IMDM base 
medium supplemented with human serum. The IMDM-based supported cell growth for a longer period 
than Cellgro SCGM and cultures did not experience the same spike in non-viable cell concentrations. 
(a) Viable cell concentrations show same observed peaks in Cellgro-based cultures, and a higher 
concentration of viable cells was achieved with IMDM-based cultures. (b) A spike in non-viable cell 
concentrations was observed in Cellgro cultures but was less pronounced in IMDM-based cultures. Cell 
line used was FFDK, data shows average cell counts ±STD.  
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focused on statistical, empirical methods to map the relationships between process 
parameters and process outcomes. By treating culture systems as “black-boxes” they provide 
limited process insight, and single-time points used for analysis can often result in the models 
failing over longer time courses due to the dynamic and complex nature of cell therapy 
systems. Mechanistic models are hypothesis-driven and the underlying mechanisms must be 
identified and mathematically expressed. As such they are more robust over the longer time 
courses and can offer enhanced process development capabilities through better sensitivity 
and risk analysis functions.  
It was shown in Section 4.3 that FOPMK cell death is promoted by medium exhaustion. The 
chapter aims to quantify this relationship and suggest courses for improved medium supply, 
using a dynamic mechanistic modelling. 
4.5.1. Cell death in response to medium exhaustion 
The aim of developing mechanistic models is to describe behaviour with simplest mechanisms 
that adequately represent the FOPMK culture system in order to define a manufacturing 
process. Models with higher numbers of parameters risk over parameterisation. Over-
parameterisation generally produces better fit models, but it is more requires more 
computational power, more resource to collect data to adequately parameterise variables, 
and potentially limits the extrapolation potential of the model (if the parameterisation of 
variables are only valid for the data set collected) [139].  
In Section 4.3, it was observed that the highest priority culture dynamics identified were the 
cell growth and conversion of viable cells to non-viable cells (cell death) in response to a 
cell.time mediated medium exhaustion. Such a response is well documented in the literature; 
exhaustion could occur either through the release of toxic metabolites, such as lactate and 
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ammonium, or through depletion of essential nutrients [128]. Since growth inhibition was 
more challenging to “observe” when combined with the conversion of viable to non-viable 
cells, it was not included in the first instance. 
The first model developed described is depicted in the Di-graph in  
Figure 4-12 (a). The underlying dynamic equations, concepts and data fitting methods are 
described by Stacey et al. [81] and also briefly in Section 2.9. 
Whether the root cause of cell death is nutrient depletion or toxic metabolite build up, this 
model structure is still applicable to describe the phenomena – but as the inverse (as 
described by Stacey et al. [100]). In this case, a cell released factor was attributed to cell death 
– but the model would still apply if nutrient depletion occurred and optimised medium supply 
as an output from the model would still be applicable. 
To parameterise the model, cell density data from short-term, high temporal resolution, high 
density cultures with a complete medium exchange was used, as shown in Figure 4-12. 
Therefore, no conditioning factor was present at time zero and possible effects due to low 
density effects are mitigated. It was assumed that there was no decay of non-viable cells, no 
decay of cell conditioning factor as short-term data was over a period of 150 hours and there 
was no growth inhibition present. 
There were systematic deviations between the cell density experimental data and the 
parameterised model fit as shown in  
Figure 4-12 (b). The model predicted the number of non-viable cells well, however the viable 
cell density was much lower, since a lower growth rate was fitted, presumably to enable 
adequate fitting of the conversion rate of viable to non-viable cells to produce the non-viable 
cell fit. 
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The deviation of modelled cell density compared to experimental data suggests that 
maximum growth rate was likely to be higher than the parameterised growth rate obtained 
from the model fit in  
Figure 4-12 (c). Furthermore, growth inhibition was observed as noted in Section Error! 
Reference source not found. and Figure 4-8 (however its effects were not easily observed) it 
was hypothesised that growth inhibition could account for the lack of fit. Therefore, growth 
inhibition was included in the next model iterations. 
 
Figure 4-12: Model containing cell death in response to a medium exhaustion produced a systematic 
deviation from the viable cell concentration data. (a) Di-graph showing mechanistic hypothesis being tested 
using novel mechanistic modelling framework. (b) Model fit to experimental data shows deviations in the 
viable cell density over the culture period. The model under predicted viable cell concentration until 80 
hours and then over predicted viable cell concentration. The non-viable cell concentration was accurately 
predicted. (c) Values of parameters fitted by StemCAD, where the response is the sum of the squared errors 
from the model and the data. 
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4.5.2. Cell death and growth inhibition in response to the same factor 
It was assumed that both growth inhibition and conversion of viable to non-viable cells were 
driven by the same medium exhaustion parameter, which was a function of cell.time, as 
illustrated in the Di-graph (Figure 4-13 a). Using the same experimental data used to fit the 
model as in  
Figure 4-12, the parametrised fit using the model adjusted to consider growth inhibition 
showed no systematic deviations of the pattern in the residual error between the 
experimental data and the model fit. Compared to  
Figure 4-12, a faster growth rate of viable cells was fitted in Figure 4-13, with decreased 
threshold and sensitivity, giving a better fit of viable cells. Furthermore, the sum of the 
squared error (Response – noted in  
Figure 4-12 and Figure 4-13 c) decreased through inclusion of growth inhibition from 1.56 × 1011, 
to  3.33 × 1010, demonstrating a better overall fit of the model to the experimental data. 
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Figure 4-13: Model of short-term data based on hypothesis that a cell released factor inhibits growth and 
promotes conversion of viable to non-viable cells. (a) Di-graph depicting mechanistic hypothesis. (b) There 
is no systematic deviation between the model and the experimental data, showing model produced a good 
fit to experimental data. (c) Fitted parameters of model rates. 
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4.5.3. Model validation over longer culture periods 
To validate the model and parameterisation of the short-term growth kinetics, the same 
model and parameterisation was applied to a longer culture period (350 vs. 150 hrs), which 
included a series of partial medium exchanges (experimental data used is shown in Figure 
4-6). However, as shown in Figure 4-14 (a), the number of non-viable cells was systematically 
under-predicted by the parameterised model and the highest values of viable cells achieved 
in the experimental data were not predicted by the model. 
In order to trouble shoot the discrepancies in behaviour between the long- and short-term 
culture dynamics, the model was parameterised using the long-term culture experimental 
data. The resulting model fit is shown in Figure 4-14 (b) and the parameterisation in Figure 
4-14 (c). This re-parametrisation produced a better model fit (shown by the proximity of the 
experimental data to the model). However, it was parameterised differently, as shown in Table 
4-2. 
Table 4-2: Comparison of fitted parameters from the short-term and long-term experimental data 
Parameter Short-term culture Long-term culture 
Maximum growth rate (h-1) 0.034 0.028 
Maximum conversion rate (h-1) 0.018 0.006 
Toxin conversion threshold (U.mL-1) 3.9 1.6 
Toxin conversion sensitivity 1.5 1.6 
Creation rate of toxin (U.cell-1.h-1) 4.5 × 10-8 6 × 10-8 
Toxin growth inhibition threshold (U.mL-1) 2.5 6 
Toxin growth inhibition sensitivity 0.6 0.5 
 
Compared to the short-term, the long-term parameterised model had a lower maximum 
growth rate, conversion rate and conversion rate threshold and a higher creation rate of toxin 
and toxin growth inhibition threshold. The parameters produced from the long-term culture 
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model fit were then overlaid on the short-term data as a validation step. The re-
parameterisation produced a good fit until 50 hours, suggesting that the rapid death is not 
captured in the long-term model.  
The short-term data set recorded cell numbers over 150 hours without a medium exchange, 
whereas a medium exchange was performed at 50 hours in the long-term data set. Therefore, 
it was possible that the response of viable cells to the higher level of medium exhaustion 
(which was produced in the short-term data) was not adequately captured by the long-term 
experimental data set.   
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Figure 4-14: There is systematic deviations between the fitted models of short-term and long-term 
FOPMK data. (a) Parameters from the short-term model were used with the long-term data as an 
attempted validation step. The model under predicted the concentration of non-viable cells and viable 
cells. (b) Parameters were fit to the long-term model which removed systematic deviations. (c) Fitted 
values showed long-term data had a lower threshold compared to short-term models and a lower 
maximum conversion rate. (d) The long-term parameters were used with the short-term data 
producing a good fit for the first 50 hours, suggesting the rapid conversion is not accurately modelled 
in the long-term data. 
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4.5.4. Expanding model fit to include both long- and short-term culture data 
To diagnose the differences in the short-term and long-term data, the model was expanded 
and re-parameterised using both data sets.  
The parameterisation led to a good model fit for the long-term viable cell data closely as 
shown in Figure 4-15 (ai), however slightly under-predicted maximum cell concentrations 
(also demonstrated in Figure 4-14 d). As shown in Figure 4-15 (bi), the parameterisation led 
to a good model fit to viable cell densities in the short-term culture, prior to inhibition and 
conversion, suggesting that the same maximum growth rate was applicable to both the long-
term and short-term data (also shown in Figure 4-14 d).  
There was a systematic deviation between the non-viable cell density experimental data and 
fitted model as shown in in Figure 4-15 (aii and bii). Non-viable cell concentrations were over 
predicted in the long-term model, and were over, then under, predicted in the short-term 
model. 
To determine whether the there was a decay of non-viable cells over the long-term data, a 
decay rate of non-viable cells was included as an addition model parameter. However, the fit 
drove the parameter to very low values (<1×10-15 h-1) (data not shown). Furthermore, 
including a parameter to capture conditioning factor decay with time did not improve fit 
either. Again, because the parameter was driven to very low values (<1×10-15 h-1) (data not 
shown). Therefore, it was unlikely that the decay of non-viable cells or the decay of toxin were 
causing the systematic deviations of the model fit to the experimental data as shown in Figure 
4-15. 
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Figure 4-15: Fitting both the long-term (a) and short-term (b) data with the same model parameterisation 
produces systematic deviation with respect to non-viable cell concentrations. (c) Fitted toxin 
concentrations across the time frame. (d) Fitted parameters show a high conversion rate, high threshold 
with a low sensitivity and a low threshold for growth inhibition.  
 
4.5.5. Fitting the model with a reduced short-term data set 
It was hypothesised that the long-term and short-term data were more useful to 
parameterise different growth dynamics. There was a much higher concentration of 
conditioning factor in the short-term data set past 150 hours which was not present in the 
long-term data and so the model may not be complex enough to deal with the response of 
viable cells to the different range of toxin concentrations present in the short- and long-term 
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experimental data. As death rate rapidly increased in the short-term data set there could have 
been multiple failure modes which accelerated the cell death rate. Therefore, only the first 
80 hours of the short-term data was included, and the model was parameterised again. 
The re-parametrised model using the reduced short-term data set produced a better fit to 
long-term data and parameters were closer to the parameterised produced when using the 
long-term data only. This may have been influenced by the lack of short-term data to fit the 
Figure 4-16: Short-term data only included up to 80 hours as after this point the mechanisms that 
govern cell conversion may not be applicable. Further experimental data will be needed to confirm this 
hypothesis. (a) Long-term data and fitted model shows good prediction of both viable and non-viable 
cells (b) Reduced short-term data and fitted model fits viable cells well, however still diverges from 
non-viable cell concentration data. (c) Fitted values are closer to values produced by long-term data fit 
alone. 
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model too – since the fitting is based on a least squares method, fewer data points would 
allow the model to skew towards the data set with the most points.  
4.6. Model validation using scalable stirred suspension platform 
It was hypothesised that static cultures could be used to parameterise models and these 
models could be applied to scalable, stirred suspension culture systems to identify similarities 
and differences between the mechanisms underpinning cell expansion in different culture 
platforms. A similar approach has been taken by Kiparissides et al. [80]. 
Experimental data from static cultures was used to parameterise the cell growth, death and 
inhibition model (depicted by Di-graph in Figure 4-13 a). The resulting parameters are shown 
in Figure 4-17 (a) and compared with the final combined short- and long- term data in Table 4-3.  
Table 4-3: Comparison of finalised parameters for the short- and long- term model using cell line BOB and 
the static model parametrised using cell line FFDK. 
Parameter Short-and long-
term combined 
model (cell line 
BOB) 
Static culture 
model (cell line 
FFDK) 
Maximum growth rate (h-1) 0.026 0.014 
Maximum conversion rate (h-1) 0.01 0.05 
Toxin conversion threshold (U.mL-1) 52 13 
Toxin conversion sensitivity 0.006 0.06 
Creation rate of toxin (U.cell-1.h-1) 4 × 10-8 1.1 × 10-7 
Toxin growth inhibition threshold (U.mL-1) 3 11 
Toxin growth inhibition sensitivity 7.5 16 
 
In the FFDK data set there was a lower growth, higher maximum rate of conversion of viable 
to non-viable cells and a lower conversion threshold compared to the model parameterised 
using BOB. Whereas the growth inhibition threshold was higher in the FFDK model. This 
resulted in higher conversion rates of viable to non-viable cells in the FFDK culture system 
4-125 
 
whereas growth inhibition was more likely to occur the BOB culture system for equivalent 
concentration of toxin. It is unclear what the root cause of the parameterisation differences 
was but it was likely that multiple mechanisms were being represented as one medium 
exhaustion dynamic (for example, time decay of medium components, interacting nutrient / 
metabolic consumption / production kinetics) that could be dependent on cell line differences 
or variation in medium lots (and response of the medium to storage). To elucidate the 
differences in behaviour, additional measurements would be needed (for example glucose, 
amino acids, fatty acids, ammonium, lactate, growth factor concentrations) to determine 
whether the metabolic profile of the two cell lines was causing the difference, or whether it 
was a difference in medium lots. Furthermore, medium development work should be 
conducted on a non-proprietary-defined system (which is ideally comprised of recombinant 
components only to ensure batch-to-batch consistency), that can be deconstructed as the 
effect of each component on the system can be measured. 
The model fit parameterised on the static system is shown in Figure 4-17 (b), and the 
parameters achieved from the static system are the fitted parameters were applied to a drip-
fed batch stirred suspension culture Figure 4-17 (c) as a form of validation. There was a good 
fit to the viable cell data (i) as shown since there was a lack of systematic deviations between 
the experimental data and the model. In both the static and the drip-fed batch systems the 
number of non-viable cells were systematically under-predicted, suggesting that there was 
higher growth and death rates than the model was capturing. The toxin concentration for 
both systems remained similar (Figure 4-17 iii). Overall this preliminary model data set suggests 
the two platforms were comparable and there are no obvious detrimental factors caused by 
a stirred suspension system to FOPMKs.  
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Figure 4-17: Model parameterised using data collected using (a) static culture platform and (b) applied to 
the suspension culture data showed that similar culture dynamics are found in both systems. Cell line used 
was FFDK, data shows N=2. 
 
4-127 
 
4.7. Conclusions and Future Work 
This chapter aims to present a proof of concept study for a methodology to identify and 
quantify key process dynamics for a cell expansion system, using 1st generation FOPMKs as a 
clinically relevant case study.  
The first section of this chapter identifies medium exhaustion, which was a function of 
cell.time, was causing a conversion of viable to non-viable cells as being the major culture 
limitation. The system productivity limit was 1.48 ± 0.28 × 106 viable cells.ml-1. Growth 
inhibition, resulting from complex and multiple mechanisms such a mass-transfer limitations, 
cell contact or medium exhaustion, was also identified. From this a brief assessment of the 
possible factors that caused the critical processing issues (cell death) was conducted, which 
indicated that glucose lactate, ammonium or growth factor concentrations were unlikely to 
be limiting. Since the medium used consisted of proprietary base, a small study was 
undertaken with non-proprietary IMDM-based medium, which sustained growth longer than 
the proprietary medium. Furthermore, a small study was conducted using the Ambr-15 
bioreactor system, which showed that the culture dynamics identified in static platforms (cell 
growth and conversion to non-viable cells) were broadly conserved. 
A model using ODE equations were used to express the cell growth and death in response to 
medium exhaustion. Cell growth and death alone was not sufficient to explain fit adequately 
to the culture dynamics, therefore growth inhibition in response to the same exhaustion 
causing cell death. Short- and long- experimental data was used to parameterise the model. 
A second cell line was used, and the parameterisation of the models created with the two 
different cell lines were compared, and the model was validated using a fed-batch stirred 
suspension platform. 
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This chapter showed that by dynamic, mechanistic models could be used to adequately model 
cell expansion and culture limitations. Limited model validation and robustness tested was 
applied here. Goodness-of-fit metrics are widely debated and challenged in modelling fields 
[140]. Here, systematic deviations of experimental data from the model fit were informally 
analysed and used as the main goodness-of-fit metric. In published work using this platform 
[81] and in models developed in Section 6, residual error is plotted and R2 values are reported. 
Further experimental work to define the components causing cell growth inhibition or refine 
and validate the culture dynamics model was not undertaken since the technology moved 
onto the 2nd generation FOPMK system. To gain further insights into the causes of cell death 
the following would have been completed: 
• Assessment of the impact of lactate, ammonium and glutamine concentrations on 
FOPMK growth dynamics through the additions of known concentrations. 
• Assessment of cytokine profiles across a culture period to identify possible limiting 
factors. 
• Oxygen consumption evaluation as an assessment of the possible limitations in 
stirred-tank culture systems.  
The culture dynamics described are complex and interacting, therefore qualitative 
assessments to provide improve production strategies are not straightforward but are 
essential. Here the foundation of a quantified models of FOPMK culture behaviour using the 
data are presented. To further develop the models presented in this chapter, the following 
questions would need to be addressed:  
i. Was the difference between the short-term and long-term data caused by experimental 
specification in long-term data? 
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• The long-term data contained serial interventions. Small errors in each may have 
caused a build-up of errors resulting in significant deviations. 
• Differences in static culture platforms (for example, T-flasks and well-plates), 
noted in Section 3.3, could be causing variation, for example in mass transfer 
coefficients, which are not described in the model. 
ii. Was the difference caused by behaviours in the long-term data set that are not modelled 
currently?  
• For example, the medium exchange is a partial exchange over 400 hours and it 
could be possible that other nutrient decay is affecting the culture system. 
iii. Are cell populations being modelled are inherently different and therefore cannot be 
described by a common model? 
• If no secondary short-term data sets matched the collected data set, this would be 
the most likely explanation for model deviations.  
In order to answer these questions, further experimental work could have included: 
1. Hypothesis driven experiments to allow in depth discussion of what changes dynamically 
in the culture FOPMKs and identify culture productivity limitations. This would include 
cytokine arrays and common nutrient / metabolite screening. 
2. Monitoring phenotypic rate of change over the longer term to address whether 
phenotypic cycles are connected to feed regime or completely independent and whether 
this correlated to changes noted in (1). 
This would culminate in the unification of the modelling and the measurement driven 
approaches into a single process which can be used for detailed manufacturing insight. 
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However, the forward programming technology that produced the cell types presented in this 
chapter evolved, making further iterations to the above data sets of limited value. To create 
the 1st generation FOPMKs, PSCs were transduced with 3 transcription factors, each contained 
within their own lentiviral vectors. This created a multi-clonal population that could 
proliferate for over 90 days. In the 2nd generation of forward programming iPSCs were 
targeted with an inducible genetic cassette therefore cells could be cultured as iPSCs and 
forward programming could be induced with the simple addition of Dox to the culture 
medium. This second generation of cells only expanded for around 30 days, and therefore the 
long-term, stable expansion was likely to be less critical. Also, the population of the 2nd 
generation FOPMKs were more homogeneous and so there may be different culture dynamics. 
Therefore, the subsequent chapters focus on the application of both statistical and dynamic 
modelling tools to the culture of inducible iPSCs and the forward programming using 2nd 
generation FOPMKs. 
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5. Application of Quality by 
Design to forward 
programming of doxycycline-
inducible iPSCs to define 
system productivity limits 
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5.1. Introduction 
In the original forward programming approach described by Moreau et al. [116] a cocktail of 
lentiviral vectors delivered three transcription factors – GATA1, FLI1 and TAL1 to PSCs to 
initiate “forward programming” which transformed iPSCs to FOPMKs (defined as CD41a+ cells) 
in around 15 days. These FOPMKs could be cultured for a period of around 90 days post 
transduction [116]. This process produced high yields of MKs per input PSC (2 × 105 MKs.PSC-
1), yields much higher than previously achieved using non-genetically engineered, directed 
differentiation methods (see Section 1.3.3 for a broader discussion). This system had 
manufacturing disadvantages in that population heterogeneity could arise from the individual 
expression (or 2 of 3) of the transcription factors, and once a population was transduced it 
was committed to terminally differentiation with a limited (if extended) proliferative capacity.   
In the second generation of this process (currently unpublished), a TET-ON system was 
introduced, which incorporated a tetracycline-responsive promoter, GFP, GATA1, TAL1 and 
FLI1. Post transduction cells were cultured with the same method as non-programmed PSCs. 
The genetic cassette was activated by adding doxycycline hyclate (Dox – a tetracycline 
derivative) to the culture medium, which induced forward programming. Currently 
production of GMP lentiviral vectors is a bottleneck for the gene editing field. Therefore, 
including a Dox-inducible cassette forward programming method reduces reliance on 
repeated genetic modification processes, since the FOP-cassette can be present, but silent, in 
a phenotype that is indefinitely expandable, whereas genome modification in the first 
generation FOPMK needs to be repeatedly conducted as it immediately creates a system with 
limited proliferative capacity. The linked gene-expression also overcomes some of the issues 
of population heterogeneity. 
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The graphic shown in Figure 5-2 demonstrates the difference between the two programming 
methods. Section 4 focuses on defining the system productivity limit of the expandable, stable, 
MK line generated using the 1st generation process using a novel mechanistic modelling tool. 
In the 2nd generation process, developing a control strategy to produce megakaryocytes from 
pluripotent stem cells is more critical since this will be repeatable with the same cell line with 
reduced heterogeneity.  
Figure 5-1: Graphic to represent the 1st and 2nd generation of forward programming approaches. The first 
generation produced polyclonal FOPMKs which proliferated for around 90 days. The second generation 
was derived using a single cassette which incorporated all 3 transcription factors with a TET-ON promoter 
and GFP. A single clone was selected to produce an inducible iPSC line. 
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Figure 5-2: Process flow diagram for SOP of FOPMK programming process of inducible iPSCs derived from 
Moreau et al. operating procedures (currently unpublished and described in more detail in Section 2.3.2). 
Four different media are required which contain several different supplements. 
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As described in Section 3, a quality by design approach is driven by system risk assessment. 
From the risk assessment exercise, the impact of the highest risk variables were selected for 
experimentation to quantify relationships between control variables and CQAs. Design of 
experiments (as discussed in Section 1.4.1) is a powerful methodology which can define 
simple linear or curvilinear relationships between experimental variables and responses in an 
experimentally efficient manner. The value of design of experiments is dependent on some 
understanding of variable ranges and key risks, hence the risk assessment is important to 
ensure the response is practically more modellable. 
A key step in process development for manufacture is technology transfer between sites 
either due to contracting out of development stage or changes of scale or geography. Such 
tech transfer steps often give rise to significant problems due to, for example, unknown 
variables, differences in available processing equipment, operator variability, communication 
challenges, and accurate record keeping. However, technology transfer exercises are a 
valuable opportunity to gain insight in, and experience of, process risks and can therefore be 
used to inform subsequent targeted experimental design. 
In this chapter the challenges in a Quality by Design approach to megakaryocyte precursor 
manufacture are evaluated. A technology transfer exercise of the second-generation FOPMK 
process from the originating laboratory to our development laboratory was undertaken. A 
series of transfer runs were conducted to provide the input to a structured risk assessment 
for initial DOE. This was the necessary first step towards a platelet manufacturing process, 
where the production of FOPMKs from inducible iPSCs must be acceptable for production, in 
terms of economic, quality and risk constraints. 
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5.1.1. Chapter Objectives 
- To apply the CQAs and assays developed in Section 3 to a process transfer, risk 
assessment and DOE improvement exercise. 
- To conduct a technology transfer exercise between laboratories. 
- To collate information to inform a risk assessment of key manufacturing controls. 
- Identify opportunities for process changes that would improve manufacturability, and 
related manufacturing controls. 
- To apply the most valuable design of experiment approach that accounts for the 
known attributes and behaviours of the process. 
- Provide process recommendations to the originator laboratories, as well as a reasoned 
requirement/methodology for further development. 
5.2. Materials and Methods 
Cell line derivation and culture was performed as described in Sections 2.3.1 & 2.3.2. Cell 
counting was performed using flow cytometry and described in Section 2.5.2. Flow cytometry 
sample preparation, equipment used, staining and acquisition is described in Sections 2.6.1-
2.6.2 - 2.6.3. The flow cytometry assays and cell counting assays used are described in Section 
3.3.1 and the assays used are identified in relevant sections and figure legends associated 
with flow cytometry data. 
Design of experiments were conducted as detailed in Section 2.8.1. The number of factors, 
levels of factors, outputs and whether a centre point was included is detailed along with the 
results of the DOE outputs in relevant sections. 
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5.3. Rationale for analytical strategy in process transfer 
Chapter 3 describes the surface markers and associated assays for monitoring megakaryocyte 
quality that will be applied to monitor process transfer. However, there are other process 
attributes that are critical to delivering the QTPP. In particular, the consistency of the number 
of cells produced per input iPSC and per unit volume of medium (or specific component 
amount added) impacts on product quality since the minimum dose must be achieved to 
satisfy release criteria at a sustainable cost. Furthermore, changes in growth rate or 
population doubling level may indicate the production of an off-target cell type or production 
of cells that are metabolically different, which in-turn could act as a surrogate measure for 
changing functionality. Variability in growth rates could also lead to changes in process state 
with knock on consequences for phenotype or yield. Therefore, in addition to the 
phenotypical markers identified above, growth rate and population doubling levels will be 
monitored.  
5.4. Evaluation of transfer protocol to generate inputs to Risk Assessment 
The technology originator provided an outline protocol for the culture of the 2nd generation 
FOPMK cells, which is detailed in Section 2.3.2, and outlined as a schematic diagram in Figure 
5-2. Stable, Dox-inducible iPSC clones can, theoretically, be cultured indefinitely as PSCs. 
Section 4 addresses the culture of inducible PSCs, and this chapter focuses on seeding cells 
for, and then inducing, forward programming through addition of Dox to the culture medium. 
Firstly, the performance of the system during tech transfer is described in terms of growth 
rate, phenotype, and longevity of proliferation, and associated risks are identified. Secondly, 
the first 10 days of the differentiation process are assessed due to the specific challenges of 
controlling a process transitioning from adherent cells to suspension cells. Finally, 
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observations are made on the operational regime during transfer, in particular medium 
exchange and cryopreservation. 
5.4.1. Growth rate 
The cell number with time for two tech transfer experiments are shown in Figure 5-3. The net 
growth across the run were comparable with tech Transfer Experiment #1 produced an 
average net growth rate of 0.168 days-1 (A), compared to 0.166 days-1 in Tech Transfer 
Experiment #2. This rate was also comparable to the reported growth rate of the 1st 
generation programming method over a period of 90 days [116], but low compared to other 
stem cell systems – for example HSCs differentiating to red blood cells have a reported growth 
rate of 0.0462 hr-1.  
The pattern in residual errors between the recorded cell numbers and the exponential trend 
line, shown in Figure 5-3 (Aii) and to a lesser extent (Bii) until day 22, suggest that there were 
periods of higher and lower growth rates, rather than a constant lower growth rate, which 
would have produced a random residual value with time. If the periods of higher growth rates 
could be sustained without periods of lower growth, this could lead to a higher system 
productivity (cells produced per unit time) which would decrease facility costs in a 
manufacturing setting. This is important since facilities can contribute up to 40% of the costs 
of cell therapy manufacture [141]. However, this would have to be considered alongside the 
effect of growth rate on total production of desired cell type and the medium provision to the 
system.  
In Tech Transfer Experiment #2, cells were cultured over 31 days is shown in Figure 5-3 (Bi). 
Cells expanded until Day 22 post Dox addition, after which time the growth rate slowed, as 
shown in (Bii) where the recorded cell numbers deviated from an exponential fit.  
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Process Risk 1: The transfer identified that whilst total growth was comparable as seen by 
growth rates calculated over the full transfer period, growth rate at any given time was 
inconsistent with random residuals (to an exponential fit) in transfer 1 and an apparent 
systematic path of higher growth to lower growth in transfer 2. Such inconsistent growth 
would make it impossible to keep culture/manufacturing environment in a closely defined 
Figure 5-3: Cell densities recorded over the two tech transfer experiments following the transfer protocol 
produced a consistent net growth rate. Net growth rates were achieved by fitting exponential trend lines 
to cell density data in Tech Transfer Experiment #1 (Ai) and Tech Transfer Experiment #2 (Bi) show net 
growth rates of 0.168 day-1 (equivalent to tD= 4.1 days) and 0.166 day-1 (equivalent to tD= 4.2 days) 
respectively. (Aii) Residual plots of the average cell count with respect to the exponential model show that 
in Tech Transfer Experiment #1 the model underestimated cell number at days 10, 12 and 25, but over-
estimated cell number at days 21 and 23, therefore suggesting that the growth rate was not constant across 
the time-period. (Bii) Residual plots show cell growth rate was constant until day 22, after which time there 
was a rapid decrease in cell expansion. For (A) data show N=3 biological replicates originating from a single 
culture at Day -1, ±STD, and for (B) data show N=1. 
5-140 
 
optimal range with a fixed process (i.e. without the expense of online monitoring and control) 
and would therefore likely to lead to variable process outputs. 
5.4.2. Phenotype 
To understand the phenotype trajectory of the cells, CD235a, CD41a and CD42a were tracked 
through both tech transfer experiments, CD42b expression was additionally tracked in Tech 
Transfer Experiment #2 as shown in Figure 5-4. Data was obtained using optical capture 
settings in Table 3-12 (panel 5) for Tech Transfer Experiment #1 and Table 3-10 (panel 4) for 
Tech Transfer Experiment #2. Cells followed the literature established differentiation route 
[46], [47], with CD235a expression increasing first and then decreasing, followed by increasing 
CD41a expression and latterly by increasing CD42a expression showing that megakaryocytes 
had been produced from the inducible PSC line. A small proportion of cells expressing CD42a 
did not express CD42b (since the loss of CD42b has been associated with apoptosis [142] 
CD42b- populations should be minimised). 
In Tech Transfer Experiment #1 (Figure 5-4 A), by Day 18 over 98% of cells were CD41a+ and 
by Day 25 over 90% of cells were double positive for CD41a and CD42a. Whereas in Tech 
Transfer Experiment #2 (Figure 5-4 B) only 62% of cells were positive for CD41a by day 20 post 
Dox addition, rising to 86% at day 26. The same parameters were used for both tech transfer 
experiments (as outlined in Figure 5-2), except for the freshness of the Dox. In Tech Transfer 
Experiment #2 the Dox has been stored in at 4⁰C for 2 months. It was hypothesised that the 
reduction in the proportion of cells expressing the right target phenotype was due to decay 
of Dox leading to reduced efficacy as a promoter of the transcription factors. 
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Process Risk 2: Similarly to the variable growth rate, a variable phenotypic output to the extent 
seen in the transfer runs would inevitably lead to out of specification clinical product. It is 
unclear from the transfer whether the phenotypic variability is driving growth rate variability 
or vice versa, or whether the two are entirely independent (although this seems unlikely as 
cells with different phenotypes are recognised to have different growth properties). An 
analysis of variation between the transfer runs identifies Dox control (storage and other 
factors effecting exposure concentrations) as a high priority experimental variable for 
impacting product purity. 
To provide an in-depth comparison of tech transfers for a deeper understanding of the 
population shifts across time, and to discuss how these may be evaluated with respect to 
subsequent investigation of process control variables, flow cytometry plots are shown for 
each tech transfer experiment in more detail in the following sections. 
Figure 5-4: Cell phenotype changes over time showed that CD235a increased and decreased with time 
(indicating a transitioning progenitor population), CD41a expression reached a plateau, CD42a expression 
increased later than CD41a and a high proportion of CD42a+ cells were also CD42b+. (A) A higher proportion 
of cells expressed CD41a in Tech Transfer Experiment #1 at Day 18 compared to Day 20 in (B) Tech Transfer 
Experiment #2. Data show pooled phenotyping from 3 biological replicates originating from a single culture 
at Day -1 in (A) and N=1 in (B). Phenotype assays used were (A) Panel 5 and (B) Panel 4. 
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5.4.2.1. Detailed phenotype of Tech Transfer Experiment #1 
The cell population decreased in size with time as shown in Figure 5-5 A-Fi as the forward 
scatter profile decreased. The high side scatter – low forward scatter population also 
increased. This population stained positive for non-integral membrane dyes (data not shown 
here, see discussion in Section 3.4) had high granularity, measured by side scatter magnitude. 
This combination of positive staining for membrane integrity dyes, a shift to higher side 
scatter and a decrease in forward scatter is an indication of apoptosis [143], showing that 
there was an increase in the proportion of non-viable cells with increased time since Dox 
addition. This increased cell death could indicate that FOPMKs matured and produced 
proplatelets (since there was also a high amount of debris seen in the low forward scatter – 
side scatter range which could represent proplatelets) as apoptosis has been linked with 
maturity previously [144], [145] (although that has been disputed [146]). Regardless of 
whether apoptosis is linked to maturity of megakaryocytes, this process aims to expand the 
megakaryocytes prior to platelet production, so loss of cells in this stage, whether through 
apoptosis or proplatelet formation adds to process inefficiencies unless a continual product 
harvest system is envisaged. Such a continuous harvest system would add a great deal of 
complexity and is an ongoing challenge for existing simpler biologic products. Furthermore, 
apoptotic cells in culture can inhibit proliferation in otherwise healthy cells [147].  
Process Risk 3: Cell debris are produced during the process that could be the consequence of 
death or premature maturation. This could also be a driver of inconsistent growth rates due 
to cyclical changes in populations. Process improvements should seek to minimise cell losses 
and debris creation where possible to target an efficient batch process, and the flow cytometry 
debris field could be a useful tool to monitor this. 
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Figure 5-5: Flow cytometry plots for Tech Transfer Experiment #1 shown in Figure 5-4 (A). A-F show 
increasing time points; (i) Forward scatter – side scatter plots show decreased forward scatter (and 
therefore cell size) and an increased proportion of events which are low forward scatter and high side 
scatter (small size and high granularity) indicating the proportion of apoptotic cells and cell debris increased 
with time. (ii) Cells initially increased their expression of CD235a and CD41a, with a proportion of cells 
appearing to transition straight to CD41a expression without first expressing CD235a. Over time cells 
mature by increasing CD41a expression and initially increasing, then decreasing CD235a expression. (iii) 
CD42a does not increase until after day 10, however there was slight changes in the fluorescence in the 
BV421 channel in the double negative gate, which was present in the unstained sample (data not shown) 
showing that the auto-fluorescence of the populations increased. In E and F, a new antibody lot of… 
5-144 
 
 
At Day 4 (Aii) most cells were double negative for CD235a and CD41a, but some began to 
express CD235a and CD41a. It appears that some cells expressed CD235a and then gained 
CD41a expression, whereas others moved to expressing CD41a without first passing through 
CD235a. However, the exact transition path is unclear because the cells could have first 
expressed CD235a and lost this expression prior to Day 4. Since the first measurement was 
taken at Day 4 the changes in phenotype between Day -1 and Day 4 were not recorded.  
Process Risk 4: There is uncertainty in the path that cells take to reach a given target 
phenotype, and the precise dynamics of marker expression. CD235a expression may be 
transient or not present at certain early stages. This uncertainty and potentially rapid change 
should be borne in mind if interpreting intermediate cell phenotypes as in process CQAs. 
For the phenotype analysis at Day 18, a new antibody lot of APC-CD41a was used and, 
although used at the manufacturer’s recommended concentration and the same 
concentration as the previous antibody lot, the fluorescence became higher than the 
detectable range. Since the two antibody lots were never used in parallel, it is not certain 
whether the shift was caused by the difference is antibody lot, or a genuine increase in CD41a 
expression. However, since a proportion of cells at Day 10 had a similar CD235a expression 
level, it is unlikely that the increase in APC fluorescence at Day 18 was linked to an increase 
in marker expression; the most probable cause was a difference in antibody lots. Furthermore, 
variability between antibody lots is a known issue [148]. 
[Figure 5-5 continued]…APC-CD41a was used which increased the MFI in the APC channel above the 
detectable range, demonstrating the importance of antibody titrations. The trend of CD41a expression 
is still conserved along with a small population of CD41a- cells showing that this data can still be used 
to determine %CD41a+. Optical Capture settings used was Panel 5 as detailed in Table 3-12. 
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Process Risk 5: Antibody lot variability may lead to differences in measured phenotypes 
between process batches that do not correspond to real differences. This is a broader issue 
relating to assay and analytical equipment control in development within and across sites. 
Within subsequent development experiments antibody lots were controlled. 
5.4.2.2. Detailed Phenotype of Tech Transfer Experiment #2 
As was seen in Tech Transfer Experiment #1, significant debris were also found in Tech 
Transfer Experiment #2 (Figure 5-6 i), which again demonstrated that the release of debris 
occurred during forward programming and confirmed Process Risk 3.  
Compared to Tech Transfer Experiment #1 at day 10, Tech Transfer Experiment #2 produced 
a much higher proportion of CD235a+/CD41a- at day 12 as shown in Figure 5-6 (Aii). At day 
18 a separate population which was high CD235a expression and CD41a/42a/42b- emerged. 
Furthermore, there was a red colouring to the cell pellet after centrifugation which indicated 
that these are contaminating erythroid cells rather than immature megakaryocytes (Figure 
5-6 E).  
Process Risk 6: CD235a appears to be expressed on megakaryocyte, “on-target” progenitor 
cells mid-differentiation, however expression reduces in the later stages of differentiation (Day 
18 onwards) or on-target megakaryocytes but increased on “off-target” erythroid lineages. As 
with Process Risk 4, this must be considered when developing process CQAs. 
Feedback from our collaborators suggested the large number of contaminating cells may be 
due to sensitivity to Dox exposure, since they had qualitatively found that using Dox which 
was made fresh and frozen led to better process outcomes. The product data sheet does not 
provide information on the shelf life of Dox dissolved in water stored in the fridge, therefore  
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Figure 5-6: Phenotype changes in Tech Transfer Experiment #2 shown in Figure 5-4 (B). By Day 26 >85% of 
cells were double positive for CD41a and CD42a. (A-D) show detailed phenotype changes with increased 
time since Dox addition, (i) Forward scatter / side scatter profiles show target cell profiles along with a 
population with increased granularity - at Day 31 (Di) there was a shift into the higher granularity 
population which coincided with lower net expansion, indicating an increase in cell death. (ii) Expression 
of CD41a and CD235a changed with time. At Day 12 (Aii) most cells are positive for CD235a and are gaining 
expression of CD41a. From Day 20 (Bii) two populations were present, one of which was CD235a+/CD41a- 
and the second was CD41a+ with decreasing CD235a expression and the former population decreases with 
time  and is not seen in Tech Transfer Experiment #1. (iii) Expression of CD41a and CD42a changed with 
time. At Day 12 cells expressed low levels of CD41a and CD42a, whereas from Day 20 (B, C, Diii) there were 
2 separate populations, one which was CD41a+/CD42a+ and the other CD41a-/CD42a-, the latter of which 
decreased across time. (iv) The proportion of cells expressing CD42a and CD42b increased with time. A 
small proportion of cells were an off-target phenotype CD42a+/CD42b-. (E) Red pellets at Day 20 indicate 
that there was a significant contamination from erythroid lineage cells. Flow cytometry acquisition was 
performed with Panel 4 (Table 3-10). 
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the decay rate of Dox with time would need to be assessed or verified for a manufacturing 
process that utilised Dox. This re-emphasised the focus on Dox as a key control variable. 
5.4.3. Proliferative longevity of cells 
The proliferative longevity of the cells potentially varied between the tech transfer 
experiments. In Tech Transfer Experiment #1 the cells expanded until day 27 post-Dox 
addition (Figure 5-3 A), after which time they were cryopreserved. In Tech Transfer 
Experiment #2, the cell number growth began to slow systematically after 22 days, as shown 
by the deviating cell number from the exponential growth curve (Figure 5-3 B). It is possible 
this discrepancy in expansion potential was caused by cell phenotype divergence associated 
with the risks identified (Figure 5-4, Figure 5-5 and Figure 5-6).  
Process Risk 7: Variable expansion per input iPSC increases process risk as the target number 
of FOPMKs required may not be reached. However, this is going to be a function of phenotype, 
so appropriate lineage and proliferation rate control would be expected to address variable 
longevity. 
5.4.4. Identifying analytical and process challenges during the day 0 to day 10 phase transition 
from adherent to suspension culture of target cells 
Cells began to lift from the culture plastic surfaces during the first 10 days of culture. To 
investigate the cell populations that were being released, the cells in the medium supernatant 
were collected and analysed as shown in Figure 5-7. Gating was applied on the forward scatter 
– side scatter flow cytometry profiles based on the target population identified in the 
attached cell cultures (Figure 5-7 A). However, even within these gates the target population 
was not visible until Day 8, instead there was a large population of debris. Figure 5-7B also 
shows that at Day 2 there were large numbers of small, very granular cells (yellow arrows 
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show examples) whereas at Day 10 cells were larger and less granular cells (blue arrows show 
examples). This suggests that early in the culture the cells released are apoptotic debris, but 
suspension cells later in the culture are part of the target population. Also, at day 2 there was 
evidence of structures with proplatelet-like morphology (small and elongated) but since they 
did not express the right phenotypic markers it was unlikely the structures were functional 
platelets. 
The number of attached cells compared to suspended cells is shown in Figure 5-7 C. At Day 2, 
26% of the total cells are suspension cells. However, this figure is obtained by placing the 
target cell gate on the suspension cells and at days 2-6 the target population was not 
discernible from the debris (since there was a large amount of debris and a small number of 
target cells). Therefore, the recorded number of suspension cells could be an increased value 
based on gating only (i.e. a measurement error) and not representative of the actual number 
of target cells.  
Process Risk 8: Target cell counts prior to day 8 are difficult to distinguish from the high 
amount of debris, therefore quality indicators within this period may lead to inaccurate 
conclusions about process outputs and challenges interpreting the impact of control variables. 
Subsequent experimental work will space the phenotypic analysis at regular intervals to 
reduce risk of phenotypic misinterpretation at specific timepoints; also, although time-
consuming, subsequent experiments will need to be conducted for a sufficient differentiation 
time course to validate that early stage effects translate to end of process. 
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Figure 5-7: Medium supernatant from Day 2 – 10 post Dox addition showed a high proportion of debris (A) 
Graphs show flow cytometry forward scatter – side scatter profiles of medium supernatant for Day 2 (i), 
Day 4 (ii), Day 6 (iii), Day 8 (iv) and Day 10 (v), showing cultures had a high proportion of debris compared 
to target cells, but this improved at Day 10. (Data show N=3 ± STD) (B) Light microscopy images of cells at 
Day 2 (i) and Day 10 (ii); cells at Day 2 were smaller and granular (examples shown with yellow arrows) and 
cells at Day 10 were larger and less granular (examples shown with blue arrows). Scale bar shows 50 µm. 
(C) Graph shows number of cells in each well that were attached were greater than the number of cells 
suspended in the medium supernatant at each time point, but the difference is much smaller at Day 10. 
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Since similar debris was not seen in iPSC cultures (data not shown) it was likely that the debris 
was released in response to Dox addition. It is unclear whether this was caused by the 
activation of the forward programming transcription factors, or whether it was a response to 
Dox which can be toxic to cells [149]. However, since debris is present in FOPMK long term 
cultures (data not shown) and megakaryocytes shed their membranes to produce platelets or 
platelet like particles, it was probable that the release of debris was caused by activation of 
the forward programming transcription factors. The effect of debris on the culture is not 
known, but may be indicative of process inefficiencies, since the debris is lost biomass, as 
noted in Section 5.4.2.  
The effect on the cultures of the large amount of released debris is unclear. It is uncertain 
whether small, granular cells become target cells, or whether these small cells decay and 
target cells are generated from a different progenitor cell source. The secretion of paracrine 
factors from the debris could have either a positive, negative or no effect on the cultures. This 
reflects a general problem when tracking cell populations vs. individual cells, and the 
disentangling of these effects must be considered in experimental design. 
Process Risk 9: Particulates such as cell debris can affect cells in culture due to co-released 
intracellular factors or directly through membrane interactions. Retention of debris will be 
affected by the medium exchange operations, both volume and fluid handling methodology. 
Any approach should be evaluated for consistency and fraction of debris transfer.  
5.4.5. Operational regime observations: Bulk medium supply 
As noted in Section 2.3.2, a combination of partial and complete medium exchanges were 
performed. Where a complete medium exchange was performed all toxic metabolites and 
decayed medium components were removed and replaced with fresh. However, all released 
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target cells were also removed and any remaining “used” medium was also removed, 
reducing process efficiency. It should be noted that this point in the process the cell numbers 
and the volumes used were very low compared to the end of the process, since the number 
of cells (and therefore culture volume) increased exponentially with time, therefore focusing 
on the medium efficiency and the volumetric productivity at this point will have little impact 
on the overall process economics. For example, it is estimated that at least 10 population 
doublings are required for maturation, which would result in this part of the process 
contributing 0.1-0.5% to total process productivity (unweighted for length of process stage or 
specific productivity of stage). 
Doubling the culture volume at Day 4 may lead to mass transfer limitations depending on the 
cell’s oxygen consumption rate and whether the higher volume depth creates a hypoxic 
environment for the cells [74]. To determine whether the higher volume would restrict the 
mass transfer rate of oxygen to the system, the oxygen transfer rate (kLa) of the bioreactor 
at relevant medium volumes and the oxygen consumption rates of the cells would also need 
to be determined. 
Where a 50% medium exchange was performed (day 6 & 8), half the medium was removed, 
centrifuged and resuspended in fresh medium with double concentrated factors. This process 
intervention had a greater number of process steps, and since half the suspended cells were 
exposed to centrifugation this could increase the variability within the system. The advantage 
of this exchange was the retention of unexhausted medium and some cell debris was 
removed, whilst retaining target cell populations, but also retaining some apoptotic cells. 
Process Risk 10: Doubling the culture volume at day 4 reduces the kLa in the current culture 
system (planar well plates / T-flask systems), which may lead to mass transfer limitations. 
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Process Risk 11: The medium exchange regime is currently relatively arbitrary. Complete 
medium exchange removes target cells and therefore potentially lowers process efficiency. It 
also wastes unused medium if conducted prematurely, and may remove beneficial factors, 
therefore lowering process efficiency. A partial medium exchange potentially increases 
process variation by exposing half the suspended cells to centrifugation and may retain 
detrimental or positive factors. In short, medium exchange controls are likely to be critical in 
reducing variation in process outcome, and optimisation of operational timings and volumes 
will drive process costs and quality. 
5.4.6. Effect of cryopreservation 
Cells from Tech Transfer Experiment #1 were cryopreserved at Day 27 post Dox addition. As 
shown in Figure 5-8, only 17% of cells were initially recovered on thaw and cell numbers did 
not recover in culture. It is unclear whether cells of this general lineage were intolerant to 
cryopreservation (which seems unlikely since the method was used previously for long term 
FOPMKs as described in Section 2.4.1), or whether it was an aspect of cell state largely 
orthogonal to lineage such as proliferative or metabolic state the cell state. 
Process Risk 12: Given that a standard cryopreservation protocol was applied, this suggests 
that cells may have different sensitivities to cryopreservation at different process points, and 
would need to be considered if manufacturing logistics required a cryopreservation banking 
step at an intermediate point in product differentiation. This is yet to be determined and is an 
unknown process risk. 
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5.5. Summary of Risk Assessment and selection of control variables for Design of 
Experiments 
The process risks outlined in Section 5.4 can be grouped into two types, risks that relate to 
the effect of control variables on product quality and purity and risks that relate to the 
interpretation of characterisation assays. The risks can be summarised as follows: 
Operation and control risks that impact product quantity and quality 
• Medium exchange controls are likely to be critical in reducing variation in process 
outcome, and optimisation of operational timings and volumes will drive process costs 
and quality (Process Risk 11). 
• Inconsistent growth rates across differentiation trajectory within process transfer 
experiments leading to variable outcomes (Process Risk 1). 
• Differences in phenotype between differentiation runs leading to variable outputs 
most likely linked to Dox supply (Process Risk 2). 
Figure 5-8: Seventeen percent of cells were recovered from cryopreservation and cell number did not 
recover. 
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• Variable expansion potential per iPSC is likely to be a function of phenotype changes 
which is in-turn a function of medium and component supply (Process Risk 7). 
• Debris creation and control through bulk medium supply has unknown effects (Process 
Risk 3, Process Risk 9 and Process Risk 11). 
• Mass transfer limitations of the systems are currently unknown (Process Risk 10). 
Characterisation risks 
• The utility of culture characteristics early in the differentiation process as surrogate 
measures for end of process outcomes (cell yield, purity) is currently challenging. Cell 
counts are difficult to achieve prior to day 8 (Process Risk 8). Also more investigation 
is required to enable the use of CD235a as a differentiation trajectory marker since it 
is expressed variably in early differentiation (Process Risk 4), on megakaryocyte on-
target cells mid-differentiation (around day 10) and on off-target cells later in the 
differentiation process (around day 18) (Process Risk 6). Although time and resource 
consuming, late stage differentiation outputs are required to make meaningful 
conclusionse in a process development context. 
• Assays within and across sites for process development and manufacturing must be 
kept as consistent as possible (Process Risk 5). 
Characterisation risks relate to the interpretation of cell states at different part of the process. 
Following the risks identified in the technology transfer runs, assays were kept as consistent 
as possible within experiments (for example, the same antibody lots were used). Examining 
the biochemical pathways and mechanisms of action that drive megakaryocyte 
differentiation was beyond the scope of this work, therefore understanding the dynamic 
changes in early differentiation marker (CD235a) expression was not investigated but 
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continued to be monitored through further experiments. The rest of this section relates to 
understanding control variable impact on process outcome. 
The driving force behind process control variable risks relate to medium utilisation, either 
specific cytokine / compounds or more generally bulk medium supply depletion, both of 
which depend on the number of cells present. The control variables identified as relating to 
medium supply and utilisation during the tech transfer process are listed in Table 5-1, along 
with their set points and potential risks of over and undersupply, in order to prioritise 
variables for further investigation.  
Seeding density and provision of supporting milieu cannot be separated as the former 
determines specific cell activity. Dox was repeatedly highlighted as a high-risk system 
component in the process transfer. TPO and SCF were used for the duration of the process 
and have also been relatively arbitrarily altered in historic versions of the process, suggesting 
the potential for more serious process impact. These were therefore selected as next 
priorities, but a preliminary study was conducted (see Section 5.5.1) to determine whether 
they are investigated further. Activin A, FGFb, and BMP maybe influential but are considered 
lower priority for investigation due to literature base, briefer application, and application at 
a process stage that will require less intensification. Therefore, seeding density, bulk medium 
and Dox provision were prioritised for a DOE approach with SCF and TPO as potential 
candidate variables for inclusion depending on the outcome of the short study. A DOE 
approach was selected because of its efficiency for examining the effect of many variables, 
despite its limitations of defining effects empirically rather than mechanistically.  
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Table 5-1: Summary of process control variables and list of the potential effects of over and under supply. 
Control variable SOP set points for protocol transfer Potential effects (relative to optimal) 
Seeding density 12,500 cells.cm-2 High densities – medium exhaustion, surface area limitations 
Low densities – wastage of growth factors (time decay), inefficient 
utilisation of facilities. 
These effects are not intendent to seeding density and are affected by 
the medium supply. 
Bulk medium supply Combination of partial and complete 
exchanges as listed in Section 2.2.2 and 
outlined in Figure 5-2. 
High – Increased costs as bulk medium not fully utilised, dilution of 
released positive paracrine factors. 
Low- Toxic build-up of metabolites / nutrient exhaustion leading to 
growth inhibition and cell death which decreases process efficiency and 
increases cost. 
These effects are not intendent to bulk medium supply and are affected 
by the supply of cytokines and seeding density. 
Dox concentration 0.25 µg.mL-1 High – toxic to cells [149] 
Low – inefficient reprogramming 
Dox exposure time Until day 10 High – toxic to cells [149] 
Low – inefficient reprogramming 
TPO concentration 100 ng.mL-1 until day 10 then reduced 
to 20 ng.mL-1 
High – increased cost, potential signal silencing or toxicity issues 
Low – sub-optimal cell growth and phenotype 
SCF concentration 25 ng.mL-1 
Activin-A concentration 10 ng.mL-1 
FGF2 concentration 10 – 20 ng.mL-1 
BMP4 concentration 10 ng.mL-1 
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5.5.1. Preliminary Screening of sensitivity of the culture to SCF and TPO 
To examine the effect of growth factor concentrations, as previous data had suggested that 
the combination concentration of SCF and TPO may affect the growth of cultures (see Figure 
4-9), various concentrations of SCF and TPO were used to test the impact on the growth and 
phenotype of late-stage FOPMKs shown in Figure 5-9. This was tested over 4 days at day 32 
after Dox addition in Tech Transfer Experiment #2. Cells originated from the same culture at 
day 32 and underwent a complete medium exchange with Cellgenix SCGM supplemented 
with various concentrations of SCF (1, 15.5, 50.5, 85.5 and 100 µg.mL-1) and TPO (0.4, 6.2, 
20.2, 34.2 and 40 µg.mL-1) making a total of 25 combinations of SCF and TPO. Conditions were 
performed with duplicate wells. Cell counts were performed at 70 and 91 hours post seeding 
and phenotype analysis (using Panel 4 was used, as described in Table 3-10) was performed at 
91 hours post seeding on five conditions (combinations of highest and lowest concentrations 
as well as a centre point). 
The cell densities across 91 hours for the lowest (1 ng.mL-1) and highest (100 ng.mL-1) SCF 
concentrations and all concentrations of TPO used are shown in Figure 5-9 A. The trend across 
all conditions was cell growth until 70 hours followed by cell death from 70 to 91 hours. Since 
it was across all conditions, there is no evidence that this trend was caused by changing 
growth factor conditions. As shown in Figure 5-3 (B), there was less expansion later in the 
cultures by day 32 so meaningful conclusions about the effect of growth factors on cell 
expansion cannot be determined from this experiment. It is possible that growth factor 
concentrations may have different impact on cell expansion at different points in the 
differentiation trajectory, but that was not tested here. 
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The detailed flow cytometry analysis shown in Figure 5-9 C-G shows forward scatter / side 
scatter profiles (i), viability of gated cells (ii), CD235a / CD41a expression (iv), CD41a / CD42a 
expression and (v) CD42a / CD42b expression for combinations of highest and lowest growth 
factor concentrations as well as the centre point. 
Compared to the conditions with high and mid concentrations of TPO (Figure 5-9 B, D and E) 
the condition with low TPO concentrations (C and F) had: 
• High side-scatter profiles (i) which were therefore more granular which is indicative 
of cell death. 
• A lower proportion of viable cells (ii). 
• A higher proportion of CD235a+/CD41a- cells (iii). 
• A lower proportion of CD42a+/CD41a+ cells (iv). 
• A higher proportion of CD42a+/CD42b- cells (v). 
All the attributes listed above are non-desirable and an indication of low quality. This 
qualitative analysis did not show the same magnitude of effect of SCF. To quantify the effect 
of SCF and TPO exposure on phenotype, CD41a expression after 91 hours was input into a 
DOE analysis, the parameters for which are shown in Table 5-2. A two level, two factor design 
with a centre point was analysed with stepwise, backwards elimination (α>0.1 was used for 
removal). 
Table 5-2: DOE inputs and observations for quantifying effect of SCF and TPO concentration on phenotype 
following exposure of 91 hours to a complete medium exchange with different concentrations of growth 
factors. 
Parameter High level Low level 
TPO concentration 40 ng.mL-1 0.4 ng.mL-1 
SCF concentration 100 ng.mL-1 1 ng.mL-1 
Output Percentage of CD41a positive cells 
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The main effects plot shown in Figure 5-10 (A) shows that increasing the concentration of 
both SCF and TPO increased the proportion of CD41a+ cells, however only TPO was 
statistically significant (P = 0.07). This quantified, statistically significant effect combined with 
the qualitative effects on cell size, granularity and viability led to TPO being prioritised for 
further investigation. 
 The R2 (adj) value obtained from this model was 62.3% showing that approximately 37% of 
the variation in the expression of CD41a could not be explained by TPO concentration changes 
alone. A proportion of this variation could be due to changes in SCF concentration (which 
were not included in the model). 
The lack of impact of SCF on cell phenotype from 1 – 100 ng.mL-1 suggests that a much lower 
SCF concentration may be tolerated in cell cultures at the later stage. This would decrease 
production costs. However, the effects of lower the SCF concentrations would need to be 
tested further, as lower concentrations over the long term may cause different effects. It 
could be, for example, that there was residual SCF present attached or absorbed into the cells 
and this takes longer than 4 days to decay. It is also possible that the more mature FOPMKs 
(CD41a+) do not respond to SCF, since cells may lose responsiveness to SCF as they mature 
Figure 5-9: Cells were grown for 26 days (as shown in Figure 5-3Error! Reference source not found.) and w
ere then exposed to different combinations of SCF and TPO concentrations. (A) examples of various 
concentrations of TPO at two SCF concentrations (i) 1 ng.mL-1 and (ii) 100 ng.mL-1 (data show N=2, ±STD). 
There was little difference between treatments with respect to cell numbers.(B-F) Detailed flow cytometry 
analysis. (i) Forward scatter, side scatter plots show that lower concentrations of TPO (C, F) and to some 
extent the low SCF/high TPO (E), shows a decrease in the target cell phenotype. (ii) Cell viability was higher 
with high and mid-range TPO concentrations (B, D, F) as in (i). (iii) shows two distinct populations – 
CD235a+/CD41a- and CD41a+ (iv) The largest proportion of off target phenotype (CD42b-) was again 
produced using the lowest concentrations of TPO. Flow cytometry Panel 4 was used, as described in Table 
3-10. 
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[150], so only a small, more progenitor population of cells are affected when SCF is removed, 
hence the small difference in expression. If this is the case, the removal of SCF may have  
consequences for the long-term proliferation as the progenitor population may become 
exhausted at lower SCF concentrations and therefore would not repopulate the culture. Since 
Figure 5-10: DOE analysis of exposure to different concentrations of SCF and TPO showed that only TPO 
had a statistically signicant (P<0.1) effet on CD41a expression. (A) main effects plot showed that both SCF 
and TPO concentrations increased CD41a expression (although SCF was eliminated from the model). (B) 
DOE output showed that TPO was statistically significant variable (P<0.1). 
A 
B 
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the protocol standard concentration of 25 ng.mL-1 was well within the concentration tested 
here, and statistically significant effects were not seen, SCF concentration was not deemed a 
priority for further study at this time. Given the indication of potential effects and the 
potential cost savings from reducing SCF it should be considered for future follow-on studies. 
5.6. Using Design of Experiments to test the effects of process variables on forward 
programming outcomes 
The risk assessment in Section 5.5 identified bulk medium and growth factor provision as high 
priorities for further assessment for understanding manufacturing constraints. Of those 
factors identified a subset of Dox, TPO and seeding density were selected as the highest 
priority for further investigation with a Design of Experiment approach (as justified in Section 
5.5 and 5.5.1). Seeding density is a mechanistic indicator; if it is significant and interacts with 
cytokine concentration in a particular way, it would indicate whether density was affecting 
the system by consumption of the other control variables or an alternate undefined paracrine 
effect. Timing of Dox removal from the culture (Day 10 removal or continued 
supplementation) was included as a further DOE condition as it was hypothesised that 
retaining Dox past Day 10 might promote continued proliferation and on-target phenotype 
maintenance. Table 5-3 details the DOE experimental parameters and measured responses 
and XX details the DOE experimental conditions.  
5-163 
 
Table 5-3: High and low levels of DOE parameters and measured responses. 
 
 
 
  
Parameter High level Low level 
Seeding density 5,000 cells.cm-2 20,000 cells.cm-2 
Dox concentration 0.25 µg.mL-1 1 µg.mL-1 
Dox removal at day 10 Continued supplementation Discontinued 
supplementation 
TPO concentration 100 ng.mL-1 25 ng.mL-1 
Output Cumulative number of population doublings 
Net growth rate 
CD41a expression at day 18 
CD41a expression at day 10 
CD34 expression at day 4 
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Table 5-4: Cells were cultured at various seeding density and reagent concentrations to better understand 
the cell proliferation and differentiation trajectory through forward programming. Table details different 
treatment conditions. The original 8 conditions were split at day 10, and cultures were treated by removing 
Dox or continuing supplementation from day 10 onwards. 
Condition Target seeding 
density at day -1 
(cells.cm-2) 
[Dox] 
Day 0-10 
(µg.mL-1) 
[TPO] 
Day 0-10 
(ng.mL-1) 
Dox 
Day 10+ 
(µg.mL-1) 
[TPO] 
Day 10+ 
(ng.mL-1) 
1 5 × 103 0.25 25 0.25 20 
2 2 × 104 0.25 25 0.25 20 
3 5 × 103 0.25 100 0.25 20 
4 2 × 104 0.25 100 0.25 20 
5 2 × 104 1 25 1 20 
6 5 × 103 1 25 1 20 
7 5 × 103 1 100 1 20 
8 2 × 104 1 100 1 20 
11 5 × 103 0.25 25 0 20 
12 2 × 104 0.25 25 0 20 
13 5 × 103 0.25 100 0 20 
14 2 × 104 0.25 100 0 20 
15 2 × 104 1 25 0 20 
16 5 × 103 1 25 0 20 
17 5 × 103 1 100 0 20 
18 2 × 104 1 100 0 20 
 
Growth and phenotypic responses were analysed and used as model outputs. Section 5.6.1 
describes and discusses the growth response over the first full 19 days, as well as separately 
over day 3-19 (where the latter had a more reliable initial measured cell value to avoid any 
error of initial seeding. 
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5.6.1. DOE analysis of cell proliferation to Day 18 
The effect of the control variables on cumulative number of population doublings by Day 18 
as determined from the DOE output is shown in Figure 5-11. The main effects plot (Figure 
5-11 A) shows that TPO and Dox concentrations had a positive correlation with the cumulative 
number of population doublings, whilst seeding density had a negative impact.  
There was a statistically significant interaction between Dox and TPO concentrations (Figure 
5-11 B), where the lower number of cumulative population doublings caused by using low 
Dox was offset by using the higher concentration of TPO. The pareto chart (Figure 5-11 C) 
shows that seeding density had the highest effect on the cumulative number of population 
doublings – its standardised effect was more than double the other model terms. In order of 
magnitude this was followed by Dox, TPO, and the interaction of Dox and TPO (Figure 5-11 C). 
It was further hypothesised that a distinct effect of variables may be observed on growth 
between D10 and D18 compared to an analysis over the full experimental duration. To 
quantify these effects the number of cumulative population doublings from day 10-18 were 
analysed but no control variable reached the α ≤ 0.1 threshold. This suggests that legacy 
effects of treatments prior to Day 10 of culture had a minimal impact on the proliferation of 
cultures from Day 10 -18.  
The effect of Dox on cumulative number of population doublings over the full-time course to 
D18 is shown for each individual condition in Figure 5-12. The removal of Dox at D10 was not 
significant (P>0.1 in DOE model), so wasn’t included in the model and therefore is not shown 
on the main effects plot (Figure 5-11 A). However, a higher level of variability was observed 
in the Dox- conditions as shown by the larger error bars for the number of population 
doublings between day 10 and day 18 for the Dox- data (conditions 11-18) in Figure 5-13.  
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Figure 5-11: DOE output summary for cumulative population doublings until Day 18. DOE analysis was 
performed using statistical software package Minitab with stepwise backwards elimination (a=0.1) applied 
for a 2-level, 4-factor, factorial design (A) Main effects plot shows mean cumulative population doublings 
was decreased with increasing seeding density, increased with increased Dox concentration between Day 
0 -10, and increased TPO concentration between Day 0-10. (B) Interaction plot shows that TPO 
concentration had a larger increase on the cumulative population doublings at lower Dox concentrations. 
(C) Pareto chart shows that the seeding density had the greatest impact on the number of cumulative 
population doublings. Removal of Dox at Day 18 was included in the analysis but did not reach the α=0.1 
threshold and is therefore not shown in the outputs. 
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Figure 5-13: The average number of population doublings from Day 10 – 18 were similar or slightly higher 
in cultures which had Dox removed (11-18) compared to those which retained their original Dox treatment 
concentrations, however the removal of Dox caused an increase in variation, as shown by the relative size 
of the error bars (data shows N=3, ±STD). 
Figure 5-12: The average cumulative number of population doublings from day -1 to 18 show Dox 
concentration increased cumulative PDs. The impact was higher in low TPO cultures (conditions 1 & 6, 2 & 
5), than when comparing high TPO conditions (3 & 7, 4 & 8). 
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Furthermore, the average CV for Dox- conditions was 10.8% compared to 2.2% for Dox+ 
conditions. The variation of a process is important in a manufacturing setting as a higher 
variation increases the risk of not meeting the QTPP specification and so increases costs. It 
was therefore hypothesized that if only the Dox+ data was analysed the noise would be 
reduced and new statistically significant effects could be observed within the remaining half 
of the experiment design space. Further, due to concern about the dependence of cumulative 
population doublings on the initial seeded cell value, a different method of growth 
assessment using multiple data points to calculate net growth rate was evaluated. 
5.6.1.1. DOE analysis of cell proliferation to Day 18 using Dox+ only data and net growth rate 
response 
Comparing the proliferation of the cultures by considering the cumulative number of 
population doublings over the 18 days (Figure 5-12) shows that culture condition 6, followed 
by 7, proliferated the most. However, this was significantly influenced by large differences in 
the number of population doublings from Days -1 to 2 across conditions. This difference could 
be caused by incorrect cell counts at Day -1, since here a single cell count for each condition 
was obtained by measuring the cells that were remaining in the pooled solution used to fill 
each vessel and were not taken from the wells directly. In section 3.4.1, it was shown that cell 
counts using this method can be inaccurate. Furthermore, there was large proportional 
variation observed between the number of cells recorded biological replicates (maximum CV 
was 18.8%) by day 18 suggesting evolving noise over the experimental time course. Rather 
than using the cumulative number of population doublings based on seeded and terminal 
values, the gradient of the graph of cumulative number of population doublings against time 
was used, since this uses multiple data points and reduces the influence of error in any 
individual data point.  
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Table 5-5: Dox+ conditions used for to calculate net growth rate 
Condition Target seeding 
density at day -1 
(cells.cm-2) 
[Dox] 
Day 0-10 
(µg.mL-1) 
[TPO] 
Day 0-10 
(ng.mL-1) 
Dox 
Day 10+ 
(µg.mL-1) 
[TPO] 
Day 10+ 
(ng.mL-1) 
1 5 × 103 0.25 25 0.25 20 
2 2 × 104 0.25 25 0.25 20 
3 5 × 103 0.25 100 0.25 20 
4 2 × 104 0.25 100 0.25 20 
5 2 × 104 1 25 1 20 
6 5 × 103 1 25 1 20 
7 5 × 103 1 100 1 20 
8 2 × 104 1 100 1 20 
 
Cumulative population doublings across time are shown in Figure 5-14 for each condition 
individually detailed in Table 5-5, along with linear trend lines and the residual error of the data 
points from the trend lines. The gradient of the trend lines were used to calculate net growth 
rate (shown in Figure 5-15). For all conditions, except 2 and 4 (Figure 5-14 Bi and Di 
respectively), the R2 value was greater than 0.9, indicating that greater than 90% of the 
variance of the data from its mean can is accounted for by the linear trend line. In general 
there is no evidence on the pattern of residuals in the conditions with high R2 values, except 
that the growth was slower from day 10 to 14 where the residuals show that the number of 
population doublings were underestimated at Day 14 in all conditions. At Day 10 cells were 
passaged and transferred to ULA tissue culture plastic and so the lower growth rate may have 
been caused by the cells going through a transition phase and adapting to suspension culture, 
which has been reported in ESC cultures [151]. Additionally, enzymatic passage has been 
noted to cause low levels of cell damage [152], which may have contributed to the inhibited 
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growth between Day 10 and Day 14. Jager et al. [152] noted that using TrypLE to passage (as 
used here) was the least harmful method, obtaining the highest post-passage cell viability and 
low apoptotic cells compared to mechanical methods. Therefore if the cells need to be 
removed from tissue culture plastic for expansion, lag may be inherent to this part of the 
process and cells did recover after this time point, as seen by rising residuals aat Day 18 
(Figure 5-14 A-H ii). This may be overcome by using suspension cultures to produce FOPMK 
cultures. Furthermore, condition 7 (G) deviated least from a constant growth rate model. This 
indicates that consistent growth may be achieved if the input variables are optimal. 
However, in conditions 2 and 4 the lower R2 values appear to be caused by an additional 
systematic deviation from the model seen as trends in the residuals (Figure 5-14 Bii and Dii) 
where there was no expansion of cells between day 2 and 14. 
The summary of the calculated growth rates is shown in Figure 5-15 (A) , and the equivalent 
doubling times shown in (B). The graphs used for these calculations are also shown in Figure 
5-14. This shows that conditions 3, 6, and 7 had very similar net growth rates (0.011 hr-1). All 
three of these cultures were seeded at low density and had high concentrations of either TPO, 
Dox or both. This indicates that there was a cell mediated decay rate of TPO and Dox (since 
higher density cultures had lower net growth rates, which suggests inhibition) and that by 
using higher levels or either Dox of TPO the potential growth inhibition due to a lower 
concentration of the other was offset. Since this growth rate was so similar, this was likely to 
be the highest growth rate of this system and is equivalent to a doubling time of 3.82 days. 
This is still low for mammalian cell cultures, possibly because the cells were transitioning into 
more mature cell types and the net growth rate was likely to be offset by some levels of cell 
death, seen by the debris in the flow cytometer in the high side scatter region. 
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5.6.1.2. Quantifying the effect of Dox concentrations, TPO concentration and seeding density 
on net growth rate for Dox+ conditions 
The effect of input variables (Dox and TPO concentrations and seeding density) were 
quantified using DOE software, Minitab, as shown in Figure 5-16. (A) shows the main effects 
of each variable when the others were set at a constant (mean) value. This shows that TPO 
and Dox concentrations had a positive correlation with net growth rate, whilst seeding density 
has a negative impact on growth rate. Furthermore, the seeding density had a higher 
magnitude of impact (across the experiment range) on the net growth rate compared to TPO 
and Dox concentrations. 
Figure 5-14: Cumulative number of population doublings against time for individual conditions (i) and 
residuals of data from model (ii). (A-H) show conditions 1-8. In all cases the number of population doublings 
was less than the linear model at Day 14, possibly due to the required passaging at Day 10. Conditions 2 
and 4 (B and D) did not grow between Days 4-14, but recovered from Day 14 onwards, suggesting that if 
growth is prevented it could be recovered in latter stages. Condition 7 (G) produced the most consistent 
growth rate across the culture period. 
Figure 5-15: Summary of the net growth rates achieved calculated using a trend line of cumulative 
population doublings with time (shown in Fig. Figure 5-14) (A) Net growth rates achieved over the culture 
period show similar growth rates for conditions 3, 6 and 7, suggesting this is possibly the highest achievable 
net growth rate. (B) Equivalent doubling times for growth rates shown in (A) show that cultures varied 
between a net doubling rate of 7 to 3.8 days. 
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Interactions between the variables were also statistically significant. The interaction plots (B) 
demonstrate that when low TPO concentrations were used, higher Dox concentrations 
increased growth rate. However, there was little effect of increasing TPO concentrations at 
high Dox concentrations. Therefore, it is hypothesised that the response of the cells to Dox 
and TPO (with respect to growth rate) are linked through either the same biochemical 
pathways or independent biochemical pathways that produced the same growth rate effect. 
Figure 5-16: DOE output summary for cumulative population doublings until day 18 with Dox+ conditions. 
DOE analysis was performed using statistical software package Minitab with stepwise backwards 
elimination (a=0.1) applied for a 2-level, 3-factor, factorial design (R2 adj. = 95.7%). (A) Main effects plot 
shows mean of net growth rate was increased with higher concentrations of TPO and Dox but lowered with 
increased seeding density. (B) Interaction plots show that TPO had a greater effect on the net growth rate 
when lower Dox concentrations were present and increased Dox concentrations only increased 
proliferation at higher cell concentrations. (C) Pareto chart shows all parameters included in the statistical 
model for which α ≥ 0.1; out of these parameters seeding density had the greatest impact on proliferation. 
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There was also a significant interaction between seeding density and Dox concentrations, 
which showed that at lower seeding densities, the concentration of Dox did not affect the 
proliferation, yet at higher seeding densities an increased Dox concentration increased the 
net growth rate, indicating that Dox degradation was cell-mediated, leading to the cultures 
with more cells experiencing a lower Dox concentration which decreased net growth rate. 
This presumes there was a dose-dependent net growth rate response to Dox; evidence for 
this dose-dependent relationship is indicated by the main effects plot in Figure 5-16 (A), 
where Dox concentration correlated to increased growth rate (as discussed above). The effect 
of the interaction of TPO and seeding density was not included in the model, since this effect 
did not reach the α threshold of 0.1, suggesting that there was a lower rate of (or no) cell 
mediated TPO degradation. 
The Pareto Chart in Figure 5-16 (C) shows the standardised effects of the model terms. The 
alpha value to remove was set at 0.1, hence any terms with greater than 10% risk that an 
association between the term and net growth rate exists when there is no association were 
removed. Of these effects, only seeding density and TPO concentration were statistically 
significant at the traditional threshold of P < 0.05. However, there is still a greater than 90% 
chance that there was an association between each of the model terms Dox, Dox*seeding 
density, and TPO*Dox and removing them for the model may lead to overlooking inputs that 
have a true effect on net growth rate. 
The R2 adjusted value for this model is 95.7%, meaning that, when adjusting for the number 
of model terms, this model explains all but 4.3% of the variance of net growth rate with 
respect to the model variables. However, the noise in this data set is underestimated due to 
the method of fitting the net growth rate. As shown in Figure 5-14, the cumulative number of 
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population doublings from triplicate biological replicates were used to plot a linear model 
(calculated as shown in Figure 5-14), the gradient of which was used to derive the net growth 
rate for each condition. This method has averaged measurement system error and growth 
rate variation to calculate one input value into the model and, as described above, the growth 
rate was not consistent across the experiment. This means that the variability in the data is 
likely to be higher than reported here, which would also impact on the significance level of 
the model terms. However, if more data were input (i.e. three biological repeats for each 
growth rate) the DOE model would have more information input and so the significance 
values may be increased.  
5.6.1.3. Comparison between using cumulative population doublings and net growth rate the 
to assess the impact of control variables on proliferation 
Here, two analyses were used to understand the effect of control variables (Dox removal, Dox 
concentration, TPO concentration and seeding density) on proliferation of cells during 
forward programming. The first analysis used the number of cumulative population doublings 
(Figure 5-11) as an output and the second used net growth rate (Figure 5-16) . In both cases 
seeding density had the highest impact on proliferation. Seeding density could either have 
limited proliferation through bulk medium or surface area limitations. Bulk medium 
limitations might have either been a build-up of toxic metabolites such as lactate and 
ammonium [153], [154] or lack of nutrients such as glucose or amino acids [155]. Since there 
was a difference caused by seeding density, it is unlikely that the time-decay of reagents in 
the bulk medium caused these differences as the conditions would have been exposed to the 
medium for the same time. 
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In this system, assessing the impact of surface area limitations is complex, since the cells were 
adherent until Day 10, at which point they were enzymatically treated and cultured as 
suspension cells (see Figure 5-2). However, the Dox high density cultures achieved harvest 
densities of between 4 and 5 × 105 cells.cm-2 whereas the low Dox cultures achieved densities 
of only 1 & 3 × 105 cells.cm-2 as shown in Figure 5-17. Therefore, either surface area limitations 
did not occur (because if surface area had caused these limitations, the same harvest densities 
would have been achieved) or Dox allowed the cultures to achieve higher local cell densities. 
The order of magnitude of standardised effect for the significant variables was different when 
comparing the two methods of assessing proliferation. The variable with the second highest 
impact on cumulative number of population doublings was Dox concentration (Figure 5-11 C), 
whereas the variable with the second highest impact on growth rate was TPO (Figure 5-16 C).  
 
 
  
Figure 5-17: Cell harvest density from day -1 to day 10 shows that cultures were not limited by surface area 
since the higher cell densities cultures (2, 4, 5 & 8) achieved very different final harvest densities at day 10. 
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Both methods for measuring proliferation showed an interaction between Dox and TPO 
concentrations, where higher Dox conditions with low TPO concentration proliferated at a 
similar rate to conditions treated with high TPO concentrations. The cost per unit volume of 
high TPO medium was approximately 73% higher (based on approximate costs of research 
grade reagents) compared to the low TPO medium, whereas the cost of Dox was very low so 
there was no difference between the low and high Dox medium. If higher growth rates can 
be achieved by lowering TPO concentration but using higher Dox then this could have a large 
impact on process economics (assuming there is no significant effect on cell phenotype / 
quality). 
When measuring proliferation by comparing growth rates, the interaction between seeding 
density and Dox is statistically significant. At low seeding densities the Dox concentration did 
not impact the growth rate of cells, whereas (as shown in Figure 5-16 B), whereas at higher 
seeding densities higher concentrations of Dox increased growth rate (as discussed in section 
5.6.1.2) which also supports the hypothesis that Dox decay is cell-mediated. This effect was 
not statistically significant when comparing proliferation using the number of cumulative 
population doublings and was therefore removed from the model since stepwise, backwards 
elimination was applied. The lack of statistical significance was either due to the large noise 
associated with the biological repeats in the Dox- conditions or differences in cell loses 
between day -1 and 2 were less impacted by this interaction meaning the total number of 
cumulative population doublings changed less. 
5.6.2. Assessing the impact of control variables on phenotype 
To understand the correlation between of proliferation and phenotype, a scatter diagram was 
plotted using all conditions to Day 18 of the cumulative population doublings vs. the 
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proportion of on-target (CD41a+) and off-target (CD41a-/CD235a+) cells. As shown in Figure 
5-18, there was a positive correlation between proliferation and on-target (CD41a+) 
phenotype and a negative correlation between proliferation and off-target phenotype 
(CD235a+, CD41a- at day 18), which suggests that the conditions that support the best growth 
also support on-target phenotype, demonstrating that growth factors are tailored to target 
populations. 
  
Figure 5-18: Correlations of population doublings with phenotype. An increase in the number of population 
doublings correlated with increased in the proportion of cells with target phenotype (A) and a decrease in 
the number of cells correlated with off-target phenotype (B). Flow cytometry Panel 6 was used, as 
described in Table 3-14. 
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5.6.2.1. Qualitative impact on cell maturity markers 
The phenotype of all conditions at Day 18 is shown in Figure 5-19. Figure 5-19 (A) shows 
qualitatively that the high Dox cultures (conditions 5-8) had a higher proportion of CD41a+ 
cells. Compared to the cultures which had Dox removed at Day 10 (Dox-) (11-18), the Dox+ 
equivalent cultures had a lower proportion of CD41a+ cells.  
Mature megakaryocytes do not express CD235a in vivo [156], therefore CD235a expression, 
inferred by median fluorescence intensity (MFI) in the PE channel for CD41a+ cells, was 
monitored to compare maturity, where it’s assumed that lower MFIs signify more mature 
cells. Only CD41a+ cells were monitored for PE-CD235a intensity since this would capture cells 
that were MK rather than erythroid-lineage committed. Maturity using this measure was 
similar across Dox+ cultures, except for conditions 7 and 8 (high Dox, high TPO and low and 
high density respectively) which had a lower average PE-MFI values. This suggests that high 
Dox and high TPO concentration promoted cell maturity. The MFI values for conditions 12 
and 13 (Dox-, low Dox, high and low density, low and high TPO respectively) had the highest 
MFI expression, indicating that maturity was inhibited in cultures which had Dox removed at 
day 10 and were treated with low Dox concentrations.  
The relative expression levels of CD34 for all conditions are shown in Figure 5-19 (C). Here 
cells treated with high concentrations of Dox (conditions 5-8) expressed the highest levels of 
CD34 expression and the Dox- cultures (conditions 11-18) expressed the lowest CD34 levels. 
CD34 expression is linked to progenitor cells in vivo [157] which could indicate that FOPMKs 
with higher CD34 levels have a higher proliferative capacity. However, CD34 expression on 
megakaryocytes from patients has been linked to higher levels of myelodysplasia (where  
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Figure 5-19: Phenotype of conditions at Day 18 of culture. (A) All conditions achieved at least an average 
of 70% of cell as CD41a+, with higher Dox treatment producing the highest and most consistent proportion 
of CD41a+ cells (conditions 5-8). Of the lower Dox treatment conditions, higher CD41a expression was 
achieved with higher TPO concentrations (Condition 3). The most variable outcomes were achieved when 
Dox was removed at Day 10 in the conditions with a lower amount of Dox initially (11, 12, 14), however, 
again this could be compensated for by using higher TPO concentrations as 3 and 13 both had 91% of cells 
which were CD41a+. (B) The median fluorescence intensity (MFI) of CD41a+ cells in the PE-CD235a channel 
gives an indication of maturity (with a lower expression of CD235a indicating a more mature phenotype). 
Qualitatively, conditions which produced lower proportion of CD41a+ cells also produced higher expression 
of CD235a in those cells, indicating an immature phenotype. Condition 7 produced the most mature 
phenotype, comparing this to condition 17, where Dox was removed at Day10, shows that continuing to 
supplement with Dox increased maturity. (C) CD34 expression shows higher levels of Dox maintained CD34 
expression, and removal of Dox produced the lowest expression at Day 18. High density cultures 
(conditions 5 and 8) showed the highest expression levels, but had comparably lower number of population 
doublings at this point (see Figure 5-12), indicating that CD34 might be a measure of growth potential. Flow 
cytometry Panel 6 was used, as described in Figure 3-13. 
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blood cells do not mature correctly) [158]. Therefore, it is not clear whether the differences 
in CD34 expression levels lead to a positive or negative outcome for maturity of FOPMK 
cultures and resulting platelet production. Since CD41a expression is directly linked to platelet 
functionality it was decided that effect of control variables on CD41a expression would be 
investigated further using a DOE analysis. 
5.6.2.2. DOE analysis of CD41a expression at day 18 
To more robustly determine the impact of control variables on CD41a expression a DOE 
analysis was performed using statistical software Minitab (parameters as described in Table 
5-3). The results of the DOE analysis are shown in Figure 5-20. The main effects plot (Figure 
5-20 A) shows that low seeding densities, high Dox, high TPO and Dox retention at Day 10 all 
increased the proportion of cells which were CD41a+. The statistically significant interactions 
(P<0.05) are shown in Figure 5-20 (B). The effects of low Dox concentration and Dox removal 
were mitigated at low densities and at high TPO concentrations.  
Furthermore, the effect of Dox removal was mitigated by using a higher concentration of Dox 
between D0 - D10 and a higher concentration of TPO. This suggested that TPO and Dox had a 
similar effect on the biochemical pathways that promote CD41a expression and that they 
were degraded at a rate proportional to the concentration of cells. The higher expression of 
the three transcription factors GATA1-FLI1-TAL1 have also been linked to MK lineage markers, 
whereas GATA1-TAL1 expression (without FLI1) have been linked to off target erythroid 
lineage [134], so it may be possible that low Dox / TPO concentrations do no promote high 
enough FLI1 expression for megakaryocyte lineage commitment. 
The Pareto Chart (Figure 5-20 C) shows that the main effects had the greatest impact on 
CD41a expression, and of the main effects, Dox concentration was the highest. Most 
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secondary, and one tertiary, effect were statistically significant (Dox concentration Day 0-
10*TPO concentration*Dox removal / BCD is shown since 0.1>P>0.05 and is therefore not 
statistically significant using the traditional metric of P<0.05) showing that the impact of the 
factors on CD41a expression is high complex and interacting. Furthermore, since the lack of 
fit error P value is 0.53 (P>0.05) no lack of fit was detected by the analysis.  
Compared to the outputs from the DOEs measuring proliferation (Figure 5-11 and Figure 5-16), 
more terms were shown to be statistically significant when using %CD41a+ as an output. This 
indicates that there was more noise as a ratio of experimental effect associated with methods 
used to measure proliferation. 
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Figure 5-20: DOE output summary for %CD41a+ cells at Day 18. DOE analysis was performed using 
statistical software package Minitab with stepwise backwards elimination (a=0.1) applied for a 2-level, 4-
factor, factorial design. The R2 (adj) fit of this model was 74.6%. (A) Main effects plot shows Dox 
concentration Day 0-10 had the greatest impact on mean %CD41a+ expression, with high Dox increasing 
the proportion of CD41a+ cells at Day 18. Seeding density at D-1 decreased the proportion of CD41a+ cells 
whereas TPO concentration Day 2-10 increased the CD41a+ proportion and Dox removal at Day 10 
decreased the mean proportion of CD41a+ cells (B) Interaction plots show that there were 5 statistically 
significant interactions affecting %CD41a+ proportion. (C) Pareto chart showed that the main effects had 
the highest impact on phenotype; Dox concentration Day 0-10 had the greatest effect followed by Dox 
removal and seeding density. Some secondary and tertiary interactions were also statistically significant. 
Flow cytometry Panel 6 was used, as described in Figure 3-13. 
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5.6.3. Expansion and phenotype trajectory of cultures past day 18 
The impact of control variables on cultures to mid-stage differentiation has so far been 
examined. Day 18 was chosen because it was apparent from the technology transfer runs that 
by this time point cells were likely to be committed to either MK or erythroid linages (as 
denoted by the expression of CD41 and CD235a). However, the impact on late stage 
differentiation (remaining expansion of cells and expression of mature phenotype markers 
CD42a/b) was unknown. It was experimentally impractical to continue all cultures past day 
18, and since seeding density was the variable with the highest standardised effect on 
proliferation (as measured by both cumulative number of population doublings and net 
growth rate) it was decided that one low and one high seeding density culture would be 
continued to be maintained past day 18. It was also decided that high TPO and high Dox 
conditions should be used since this combination of variables had proliferated most and 
produced the highest proportion of CD41a+ cells. Therefore condition 7 and 8 were selected 
for expansion to terminal differentiation or as close to this point as possible. Cultures were 
monitored for differences in expansion and phenotype trajectory, to determine whether 
growth rate and phenotype differences caused by seeding density converged or diverged.  
5.6.3.1. Proliferation of conditions 7 and 8 past day 18 
Figure 5-21 (A) showed cultures had similar net average growth rates until Day 26 (0.0118 and 
0.0120 hr-1 for conditions 7 and 8 respectively), although condition 7 underwent an average 
of 1.29 PDs extra that condition 7 over the 28 day period (Day -1 – 27). This suggests that 
either the cell counts at Day 0 were offset, impacting the cumulative number of PDs, or the 
growth inhibition that occurred between D-1 – 2 was not recovered later. At day 18 the net 
growth rate of the cultures was 0.0116 and 0.0099 for conditions 7 and 8 respectively (Figure 
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5-15) which also suggests that condition 8 regained some of the lost expansion from Day -1 – 
18. 
At day 14 the residuals show that condition 8 had a slower growth rate, but this was recovered 
later, suggesting this growth inhibition can be recovered later in the process, so avoiding 
growth inhibition is this stage (day 10 – 14) was less critical for process control than in the 
early stage (day -1 – 2), assuming that the early stage growth loss was a real effect rather than 
an cell count measurement effect. 
There was a systematic deviation of the data from the trend line representing exponential 
growth with a constant growth rate occurred from Day 27 onwards as shown in Figure 5-21 
(B). Cell growth did not occur in either Condition 7 or Condition 8 after day 27. The cause of 
this inhibition point is not known. As mentioned above, either the conditions had the same 
number of cumulative doublings which is not seen due to an offset in the cell counts at day -
1, or the cells only proliferate for a finite period post Dox addition. Since both these conditions 
had the same concentrations of TPO and Dox, it is unknown whether these variables would 
affect the maximum number of population doublings achievable or the maximum 
proliferation time post Dox addition. Some cell growth may have been returning at Day 37, 
however because culture volume was being used for sample analysis and the cells were not 
expanding, there were too few cells to continue the experiment. 
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5.6.3.2. Phenotype of long-term expanded cultures 
Between Day 32 and Day 37 the number of on-target cells decreased by 7% in Condition 7 
and by 9% in Condition 8 (Figure 5-22 A & B), showing that the lack of growth was concurrent 
with a decline in cell quality and cells also become smaller and more granular as shown in 
Figure 5-22 (iv), suggesting they were undergoing apoptosis. The MFI of fluorescence in the 
CD41a and CD42a channels also decreased and a double negative population was beginning 
to emerge (v, vi). This again shows that the quality of the cells was declining. 
  
Figure 5-21: Condition 7 and 8 were cultured to Day 37 after Dox addition. The linear increase in cumulative 
number of population doublings over time shows a maintained net growth rate from day 2 until day 27 
followed by a period of no net increase in viable cell number. (A) shows the rate of change in population 
doublings (trend line gradient) with time for condition 7 and 8 were similar, (0.4096 and 0.4168 PDs.day-1 
respectively) however the total number of population doublings were lower for condition 8 due fewer 
population doublings between day -1 and 2. This could either be an artefact of cell counting measurement 
(i.e. the recorded number of cells counted initially was higher than actually seeded, giving a lower number 
of population doublings), or the initial growth inhibition decreased the total reachable number of 
population doublings. (B) Plotting the residuals showing the difference between the constant growth rate 
trend line and the data shows the growth of cells was not maintained past day 27 of culture. Residuals for 
condition 8 show lower growth rate until day 14 then increasing growth rate until a growth inhibition at 
day 27. 
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The large number of small and granular cells, which were likely apoptotic bodies, could have 
released factors that promoted cell death and loss of on-target phenotype in other cells. 
Therefore, a Ficoll protocol was performed to separate the live cells based on an established 
protocol from our collaborators. However, I was unable to replicate it. Figure 5-23 shows that 
the Ficoll protocol failed to purify the target phenotype.  
 
 
Figure 5-22: Cell phenotype at Day 32 and 37. Bar charts shows average proportion of off target 
CD235a+/CD41a- cells (i) and proportion of target CD41a+/CD42a+ cells (ii) at Day 32 (A) (data shows 
average N=2 ±STD) and Day 37 (data shows polled analysis) (B). Across both cultures, the proportion of off-
target cells increased, and the proportion of on-target cells decreased across between Day 32 and 37, 
coinciding with a decrease in growth (see Figure 5-21). Exemplar flow cytometry plots show forward scatter 
– side scatter plots (iv), CD235a and CD41a expression (v), and CD42a and CD41a expression (vi) for 
conditions 7 (C,E) and 8 (D, F) at Day 32 (C, D) and Day 37 (E, F). Forward scatter – side scatter plots (iv) 
show a decrease in the proportion of target cells from Day 32 to Day 37, and target cells that remained 
were smaller in size. This decrease in size could also be attributed to lower expression levels of CD41a and 
CD42a, since it is possible that the smaller cells had the same receptor density (receptors per unit cell 
surface area) but a decreased size decreased the absolute expression. However, at Day 37 there appeared 
to be a lower expressing CD42a population emerging (Evi and Fvi), it’s unclear whether this was caused by 
decreasing cell size, is a signal of failing cell health or even whether a maturity even has occurred and 
caused the megakaryocytes to shed platelets. The increase in apparent CD235a+/CD41a- cells could be 
caused by the small sized cells shifting into the negative CD41a gate and not a true reflection of reduced 
receptor density (Ev and Fv). Flow cytometry Panel 6 was used for acquisition, as described in Table 3-14. 
Figure 5-23: To reduce the concentration of dead cells (high side scatter region) a ficoll procedure was 
performed at Day 34 to conditions 7 and 8. A and B show conditions 7 and 8 respectively; i and ii show 
forward scatter – side scatter profiles of cells before and after ficoll processing. In this case, the ficoll 
procedure did not select for the target cell population. 
A i B i A ii B ii 
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5.7. Early culture dynamics as an indicator of forward programming trajectory 
Monitoring early differentiation trajectory attributed (markers and / or proliferation) and 
using those attributes to predict end stage programming outcomes– or better - enhance 
process control to ensure products achieve the required specification would be a powerful 
process development tool. Understanding how control variables influence process 
parameters at different time points through the process may also lead to improved 
understanding of the mechanisms which drive growth and phenotypic changes, which also 
could enable the implementation of better processes and enhanced control. 
As noted in the technology transfer exercise (Section 5.4.4), currently the marker expression 
and transition during forward programming are not fully understood . To gain insight into 
early stage growth and phenotypic changes, high temporal resolution cell counts and 
phenotype assays were performed during the DOE experiment outlined in Table 5-3. Cell 
counts using flow cytometry, and Panel 6 as described in Table 3-14 was used for phenotypic 
analysis. Both cell counts and phenotype analysis was performed at day 2, 4 and 10. At day 2 
there were only 4 conditions (rather than 8) because TPO was supplemented from day 2 
onwards, according to the transfer protocol (see Figure 5-2 and Section 2.3.2) 
The proliferation and phenotype changes from day -1 until day 10 are shown in Figure 5-24. 
Highest proliferation was achieved between day -1 and 2 and in low density cultures (as 
shown in A). At this stage Dox concentration did not appear to affect the proliferation. This 
might be because the cell numbers were relatively low and, assuming a cell-mediated 
degradation of Dox, small cell densities may have produced slow rate of Dox degradation 
leading to similar growth responses in high Dox treated cultures (5,6) and low Dox treated 
cultures (1,2).  
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The comparatively high growth rate between Day -1 and 2, which was reduced in higher 
density cultures, likely contributed to the identification of seeding density as the variable that 
had the highest effect on the number of cumulative population doublings at D18 (Figure 5-11). 
Furthermore seeding density was also the term with the biggest standardised effect when 
using net growth rate as a measure of proliferation (Figure 5-15 C), suggesting that seeding 
density has a negative effect across the culture period.  
Growth rate from day 2 – 4 is approximately half that of day -1 – 2. Condition 3 (low density, 
low Dox, high TPO) proliferated less during this period, but recovered from Day 4 – 10. From 
Day 4 – 10 differences in proliferation due to cell density were observed; for equivalent 
TPO/Dox conditions (1 & 2, 3 & 4, 6 & 5, 7 & 8) the lower density cultures had a greater 
number of population doublings per day. This may have been caused by cell mediated 
degradation of nutrients / supplements or contact inhibition. The cultures with high Dox 
concentrations also outperformed low Dox conditions, except for 3 (low density, low Dox, 
high TPO), again supporting the hypothesis that TPO supported growth in the presence of low 
Dox. 
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Figure 5-24: Summary of cell culture until Day 10. (A) Number of population doublings per day at various 
time points show highest growth rates were achieved between Day -1 and 2, with lower density cultures 
reaching higher growth rates (data shows N=3, ±STD) (B) The proportion of CD34+ cells peaked at Day 4, at 
which point lower density cultures showed higher expression that high density cultures (conditions 1, 3, 6 
and 7). By Day 10 this trend was reversed as higher density cultures (conditions 2, 4, 5 and 8) had higher 
proportion of cells which were CD34+, suggesting that the higher density cultures are delayed in maturing 
rather than the higher densities preventing maturity. (C) The proportion of CD235a+ cells increased from 
Day 4 to 10. At Day 4 the cultures treated with the lower concentrations of Dox had a higher proportion of 
CD235a+ cells, however at Day 10 this trend switched since the cultures with the highest expression were 
low density, high Dox and high TPO treated (7) followed by low density, high Dox and low TPO (condition 
6) and low density, low Dox and high TPO. (D) A low proportion of cells are CD41a+ at Day 4. At Day 10 the 
high Dox treated cultures (conditions 5, 6, 7, 8) had a higher proportion of CD41a+ cells compared to low 
Dox cultures (conditions 1, 2, 3, 4). Again, the highest the condition with the highest proportion of CD41a+ 
cells was low density, high Dox and high TPO treated (7). Flow cytometry Panel 6 was used for acquisition, 
as described in Table 3-14. 
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The proportion of cells that were CD34+ peaked at Day 4 (Figure 5-24 B) and then decreased 
again, suggesting cells were differentiating along the haematopoietic lineage. Cultures which 
had highest expression were low seeding density, and either high Dox concentration 
(Condition 6), high TPO concentrations (3) or both (7). CD235a expression peaked at Day 10 
(Figure 5-24 C), and the highest expression was seen in low seeding density, high Dox, high 
TPO concentrations (7). It should be noted that the data is a snapshot of the cells in time as 
they are passing through lineage trajectories, so other cultures may have reached peak levels 
at different time points, which limits the conclusions which can be drawn. Greater insight 
would be gained by considering the transition rates between populations and the growth rate 
of each population in response to different media or media supplementation and the 
degradation of each media component. 
CD41a expression also increased from Day 4 to Day 10 (Figure 5-24 D). All high Dox treated 
conditions (5, 6, 7, 8) had a higher proportion of CD41a+ cells compared to the counterpart 
low Dox concentration conditions (2, 1, 3, 4). Of the high Dox concentration cultures, high 
TPO and low seeding density (7) had the highest CD41a expression, which indicates that high 
Dox concentrations promoted cell maturity. 
From the outputs measured early in the differentiation and presented above, CD41a 
expression at day 10 and CD34 expression at day 4 were prioritised for further analysis. CD41a 
expression is a key marker required for functionality of platelets (See Section 3.2.1), and 
therefore measuring expression differences between different conditions is likely to inform 
differentiation trajectory. CD34 expression was selected because this is a key haematopoietic 
progenitor marker, and therefore would possibly be useful when measuring markers early in 
the differentiation process. Measuring proliferation was not selected because cell counts can 
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be variable in early differentiation (as noted by Process Risk 8) and CD235a expression was 
not selected because of uncertainty of expression in off-target (erythrocyte lineage) as well 
as on-target (MK lineage) cells. 
5.7.1.1. DOE analysis of CD41a expression at day 10 
At day 10, all control variables were found to have a statistically significant effect on CD41a 
expression as shown in Figure 5-25 (A). Seeding density had a negative correlation with CD41a 
expression whereas Dox and TPO concentrations had a positive correlation with CD41a 
expression. The interaction plot Figure 5-25 (B) shows that the interaction between Dox and 
TPO was the only statistically significant interaction, where higher TPO concentrations 
increased only increased CD41a expression (relative to low concentrations of TPO) at high 
concentrations of Dox. The pareto chart Figure 5-25 (C) shows Dox was the variable with the 
highest impact on CD41a expression, followed by TPO and seeding density (which had similar 
standardised effects). 
Aside from Dox removal (which is not considered here, as it only occurred after day 10) 
compared to the effect of control variables at day 18 (Figure 5-20) all main effects have the 
same trend of effect (positive or negative correlation with expression) of effect on CD41a 
expression and Dox concentration still has the overall highest standardised effect. 
However, the interaction between Dox and TPO is reversed. It is hypothesised that: 
• At day 10 Dox was driving differentiation and therefore at higher concentrations of 
Dox more cells were at a differentiation stage where they are responsive to TPO. 
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• By day 18 most cells were responsive to TPO, and if Dox triggers the same biochemical 
pathways as TPO in this differentiation stage, at higher concentrations of Dox 
supplementation of extra TPO would not improve phenotype since the pathway is 
already saturated (i.e. is at the top of the sigmodal dose response curve). 
 
Seeding density had a significant (P<0.05) effect at both day 10 and day 18. As discussed in 
Section 5.6.1, it is unlikely that local cell density effects were driving this effect, rather was a 
function of the effects of bulk medium and supplement supply per unit cell density. and time 
Figure 5-25: DOE analysis of the effect of control variables on CD41a expression at day 10. (A) Main effects 
plot shows seeding density had a negative correlation with CD41a expression, whereas Dox and TPO had a 
positive correlation with CD41a expression. (B) The only statistically significant interaction was Dox*TPO 
which showed that at lower concentrations of Dox the concentration of TPO did not correlate with a change 
in CD41a expression, whereas at higher concentrations of Dox, increasing TPO concentrations correlated 
with higher CD41a expression. (C) Pareto chart showed that Dox concentration was the variable with the 
highest effect on CD41a expression. 
5-195 
 
as confirmed by the differences in achieved local density (Figure 5-17) and interactions 
between seeding density and supplements (Figure 5-20 B). As shown in Figure 5-21, when 
conditions 7 and 8 were expanded past day 18, differences in phenotype converged, as did 
net growth rate. At day -1 cells were seeded at a set number of cells per surface area and the 
bulk medium supply was the same volume (meaning different cell density conditions had both 
different cell densities per surface area and per volume of media), whereas at day 10 all 
conditions were set to the same cell density per volume (as they were forced into suspension 
– see Figure 5-14). Therefore, all conditions had the same bulk medium supply per unit 
cell.time Since in conditions 7 and 8 the phenotype and net growth rate converged by day 
27, .this indicates that the detrimental effects of medium undersupply in early stages can be 
“recovered” if the supply of bulk medium is adjusted later. This means that bulk medium 
supply is a lower priority from a control perspective as it can be corrected; however, a detailed 
study of the impact on COGs of  over- or under-supply is not covered in this work. This style 
of DOE analysis does not identify what the optimal bulk medium supply rate should be; a 
modelling approach including dynamic culture environment changes would be more suited 
to determining improved medium supply regimes [81]. 
5.7.1.2. DOE analysis of CD34 expression at day 4 
CD34 expression was monitored as a surrogate measurement for cells that were progressing 
from a pluripotent to a haematopoietic linage. Day 4 was the earliest time point where CD34 
expression was measured in addition to TPO being supplemented. The main effects plot 
Figure 5-26 (a) shows that seeding density had a negative correlation with CD34 expression 
whilst Dox had a positive correlation with CD34 expression. TPO did not have a significant 
effect. This suggests that the cells were not were not at a point in the differentiation trajectory 
where they responded to TPO. If this is the case, future studies could be targeted to finding 
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the point at which TPO supplementation is required, since COGs could be decreased by 
initiating TPO supplement at a later point in the differentiation trajectory. 
The only statistically significant effect was seeding density and Dox, where at higher seeding 
densities, higher Dox concentration promoted a higher CD34 expression, whereas at lower 
seeding densities, higher Dox concentrations did not improve CD34 expression to the same 
extent. The seeding density * Dox interaction was a significant effect on CD41a expression at 
day 18 (Figure 5-20 B) but not at day 10 (Figure 5-25 B) Therefore, the following mechanisms 
are hypothesised: 
Day 4  
• Cultures which had been seeded at a higher seeding density still had higher recorded 
cell counts compared to lower density (Figure 5-17), therefore cell seeding density 
could be used as an accurate surrogate measure for cell number present at day 4. 
• The cells did not respond to TPO (and future work may consider supplementing TPO 
at later stages of culture), Dox drove differentiation.  
• Cell mediated decay of Dox was higher at higher seeding densities, so lower 
concentrations of Dox had lower CD34 expression at higher cell seeding densities.  
Day 10 
• Cultures which had been seeded at a higher seeding density did not have higher 
recorded cell counts compared to lower density, so cell seeding density could not be 
used as an accurate surrogate measure for cell number present at day 10 (Figure 5-17). 
Therefore, it is more challenging to make accurate assumptions about cell-mediated 
decay effects based on cell numbers. This is limitation of DOE analysis with dynamic 
data sets. 
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• Therefore, the interaction between Dox and seeding density was not statistically 
significant due to changing relative cell numbers between conditions confounded cell-
mediated effects. 
• TPO concentration was a statistically significant effect since at day 10 a higher 
proportion of cells responded to TPO in addition to Dox as cultures were progressing 
towards a MK phenotype. 
Figure 5-26: DOE analysis showing the effect of control variables on CD34 expression at day 4. (A) main 
effects plots indicates that was a negative correlation with seeding density and CD34 expression, the was 
a positive correlation between Dox and CD34 expression and there was little impact of TPO on CD34 
expression. (B) The interaction between seeding density and Dox concentration was the only statistically 
significant interaction, where Dox mitigated the negative effect of higher seeding densities compared to 
lower Dox concentrations. (C) Pareto chart showed the standardised effect of seeding density and Dox 
concentrations were similar. 
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5.8. DOE model validation  
To check the validity of the DOE model effects, an experiment was conducted which 
replicated a smaller number of conditions the low TPO / low Dox, low TPO / high Dox and high 
TPO / high Dox, and concentrations, at low seeding density and retaining Dox 
supplementation throughout culture (conditions 1, 6 and 7 respectively as listed in Table 5-4). 
These conditions were selected as Dox and TPO concentrations were found to have complex 
and interacting effects on both cell growth (Figure 5-11) and phenotype (Figure 5-20). A low 
cell density was selected as it was likely that medium exhaustion effects were likely to be 
confounding cell output (as shown by the interactions between Dox / TPO concentrations and 
since a higher input cell number resulted in lower cell growth - Figure 5-11). Dox 
supplementation was continued post-day 10 since the was no benefit to its withdrawal on 
cell proliferation (Figure 5-11) and lead to a decrease in CD41a expression (Figure 5-20). A 
further change was made from the original experimental conditions where the high TPO 
supplementation was retained past day 10 at 100 ng.mL-1 (previously TPO supplementation 
had been decreased to 25 ng.mL-1 after day 10), to test the effect of continued higher 
supplementation. 
Here, the individual effects of Dox and TPO are more clearly demonstrated. Figure 5-27 (a) 
shows that both low TPO conditions had virtually identical average cell expansion rates, 
whereas the high TPO condition had an average of one extra cumulative population doubling 
levels at day 26 (although this was not a statistically significant effect). Whereas the low Dox 
conditions produced average CD41a expression of 70% compared to 97% for both high Dox 
conditions.  
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Figure 5-27: Confirmatory runs showed that (a) higher TPO supplementation increased cell expansion 
(although there was not statistically significant effect on the number of population doublings) and (b) 
increased Dox supplementation increased CD41a expression with (c) over 9x greater on-target cell yield 
was achieved from high TPO/Dox compared to low Dox/TPO supplementation. and (*) denotes statistical 
significance (P<0.05) using ANOVA. Legend key: LTLD = low TPO & low Dox, LTHD = low TPO & high Dox, 
HTHD = high TPO & high Dox. 
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Qualitatively, these results confirm the relationships established with the DOE models for 
proliferation and phenotype (Dox and TPO having positive effects on both). However, when 
using the DOE model to predict the cell expansion (shown in Table 5-6) only one of the 
confirmatory runs form the LTLD and HTHD conditions and none of the runs from LTHD 
condition achieved within the 95% confidence interval predictions. All the runs from the high 
Dox conditions achieved CD41a expression within the 95% confidence interval predictions but 
the LTLD condition underperformed in terms of phenotype. Therefore, expansion is more 
variable across experiments than within experiments, indicating that there is an unknown 
variable within the system that has not been controlled. Phenotype is more stable at high Dox 
concentrations between experiments but not at low Dox concentrations – another indication 
that high Dox concentrations should be used in future work. 
Table 5-6: DOE model predicted expansion and phenotype and confirmatory run results. Yellow highlights 
indicate runs within 95% confidence predictions. 
Condition 
Cumulative number of population 
doublings 
CD41a expression 
Predicted (95% PI) Confirmatory runs 
(1, 2, 3) 
Predicted (95% PI) Confirmatory run 
LTLD 4.92 (4.78, 5.06) 5.35, 4.86, 5.86 89.4 (82.1,96.7) 42.3, 42.1, 48 
LTHD 6.73 (6.60, 6.87) 4.45, 5.61, 5.31 93.7 (86.5, 101.5) 98.2, 95.0, 97.4 
HTHD 7.03 (6.89, 7.17) 6.52, 6.93, 6.66 94.2 (86.9, 101.5) 90.1, 90.6, 90.9 
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5.9. Proposed mechanistic model framework describing forward programming 
This work has shown that DOE can be applied to assess the general impacts of control 
variables on CQAs for FOPMKs and to narrow down routes for further investigation (for 
example, Dox supplementation should continue past day 10 of culture). However, DOE is 
limited in utility since the relationships between variables and outcomes are complex and 
non-linear and therefore applying DOE to define optimal process are challenging, since DOE 
does not directly test the nature of the underlying mechanism. 
Based on the data presented in this chapter and relevant literature [46], [55], [134], [159], 
Figure 5-28 shows a schematic diagram for a proposed mechanistic model for FOP. Here, cell 
populations are divided into discrete units which assume consistent growth and rate 
conversion behaviours within each population unit. Different variables (growth factor 
concentration, Dox concentration, medium exhaustion, positive cell released conditioning 
factors) may have different impacts on the growth and conversion rates of associated 
populations. It would be assumed that rates have a sigmodal dose response to variables [100].  
The challenge with developing models that are usable for manufacturing outcomes is to 
develop a model which has the minimum level of complexity to achieve desired 
manufacturing outputs. More complex models may more accurately describe behaviour, but 
they require much more resource to parameterise. A first iteration of this model could utilise 
a single growth rate modulated by TPO and medium exhaustion could be applied to all 
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populations with r2 and r3 modulated by a Dox and TPO relationship. To parameterise this 
model the following relationships would need to be established: 
• The maximum growth rate of populations when growth factors, Dox and medium 
exhaustion isn’t limiting. 
• Whether there is a changing trajectory of dose response to supplement 
concentrations across forward programming. 
• Whether the time-dependent decay rate of medium components, growth factors and 
Dox were significantly impacting rates. 
Figure 5-28: Proposed mechanistic model structure for FOP. The model would separate cell populations 
into discrete populations (green boxes) with associated growth rates (µx) and conversion rates (rx), utilising 
the smallest number of populations to create a model with process optimisation utility. It hypothesised 
that there is a sigmodal dose response of Dox on r2, r3 and µ2, and a sigmodal dose response of TPO on µx. 
It is also hypothesised that a cell-mediated factor (medium exhaustion through either nutrient depletion 
or metabolite excretion) would impact µx and rx. 
5-203 
 
This type of mechanistic model would be challenging to parameterise, but it would have 
advantages over established DOE methods, since the outcomes of different components 
would be traceable through the differentiation and proliferation of cultures. It would account 
for non-linear, dynamic relationships that aren’t currently described in this work and thus 
allow more precise optimisation of processes and has huge potential to reduce medium costs 
and therefore COGs for clinical cell therapies. 
5.10. Conclusions  
In the first part of this work a technology transfer exercise was completed with two runs of 
the protocol from the originating lab. During the tech transfer process, the cultures were 
analysed using the rationale outlined in Section 5.3 and process risks were identified (Section 
5.4) for input into a Risk Assessment (Section 5.5). The following factors were identified as a 
high priority for further study: Seeding density, bulk medium supply, Dox, SCF and TPO 
concentrations and Dox exposure time. Since effects of medium exhaustion could not be 
separated from seeding density effects bulk medium supply (volume per unit time) was kept 
consistent, but volume per cell was adjusted through seeding density changes. A preliminary 
study was conducted to test concentration ranges of TPO and SCF and from this TPO was 
selected for use in DOE analysis. 
A DOE was conducted with seeding density, Dox and TPO concentrations and Dox exposure 
times as control variables. Effects on proliferation and phenotype were measured for 19 days 
post seeding. Two conditions (high Dox, high TPO, continued Dox supplementation past day 
10 and both high and low densities) were continued to day 34 post Dox-exposure. DOE 
analysis was also performed on CD41a expression at day 10 and CD34 expression at day 4 to 
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identify whether culture dynamics present early in FOP were similar to dynamics observed at 
day 18. 
It was repeatedly shown that Dox (concentration and continued supplementation), TPO 
concentration and low seeding densities improved cell expansion and increased the 
proportion of phenotypically on-target cells; whereas seeding density had a negative impact 
on both proliferation and phenotype. Therefore, it is likely that both Dox and TPO are 
degraded at a rate which is cell density dependent. Although the removal of Dox from cultures 
at day 10 did not have a statistically significant impact on cell proliferation, removal had a 
negative impact on CD41a expression. Since Dox costs are insignificant compared to the rest 
of the bulk medium (<0.1% of cost per unit volume) Dox supplementation should be 
maintained throughout culture. Furthermore, the interaction between Dox and TPO (where 
a higher concentration of one overcame the negative effects of lower concentration on the 
other) could be investigated further. Since Dox costs a fraction of the cost of TPO small 
concentrations of TPO combined with higher concentrations of Dox may have the potential 
to reduce COGs for FOPMK derived platelet transfusion products. 
When cultures were continued past 18 days, over 95% CD41/2a+ cells were achieved, but 
cultures stopped proliferating at Day 26 post Dox addition despite having different recorded 
levels of cumulative population doublings. It is unclear whether changing TPO or Dox supply 
would affect the total period of proliferation and the total number of achievable on-target 
FOPMKs. 
In this system, Dox activates a genetic cassette containing GATA1, FLI1 and TLA1 – 
transcription factors that were shown to be essential in megakaryocyte differentiation and 
maturity [160], [161], hence their inclusion for forward programming [116]. The necessity of 
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TPO for megakaryocyte differentiation is widely reported [162]–[165] and its signalling 
pathway has been linked to endogenous GATA-1 expression [166]. Therefore, if there was 
Dox dose-dependent expression of the inserted transcription factors, at lower Dox 
concentrations higher TPO supplementation may stimulate the expression of endogenous 
GATA-1, which compensates for the lower expression of inserted GATA-1. Furthermore, if the 
degradation of TPO and Dox was cell-mediated, higher cell seeding densities would 
exacerbate the negative effects of low TPO / Dox concentrations, which is demonstrated in 
these data.  
5.10.1. Further work 
Further work characterising Dox inducible iPSCs should focus on determining whether the 
effect of seeding density on proliferation between Day -1 and 2 is a true effect or whether it 
was caused by an error in cell counting, and whether the TPO and Dox supply affect the overall 
proliferation capacity of the cells and the number of achievable CD41/2a+ cells. Further 
increases in TPO and Dox may produce added benefit, however this should be balanced 
against the extra cost of supplying these to the cultures and higher concentrations of Dox may 
be toxic to cells. Lower seeding densities may improve also improve quality of final product 
and lower concentrations of SCF may be tolerated. 
The Cellgro SCGM medium is a proprietary medium formulation, and so work to modify this 
medium would be limited. Therefore, changing the basal medium to a system which the 
components are known and can be changed during optimisation work should also be 
considered. Potential benefits on an IMDM base medium is shown in Figure 4-11, but this 
medium contains supplements that are not chemically defined and are derived from humans. 
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Recombinant versions of these components are now available and should be used in future 
systems since these components would be most relevant to clinical applications. 
The current differentiation process is undertaken as adherent cultures from Day -1 to Day 10 
in planar vessels (well plates or T-flasks). Suspension cultures would allow for more precise 
control of the cell culture environment, cell density, medium exhaustion and 
supplementation which, as the data presented in this chapter demonstrates, can have a 
significant impact on culture trajectory and economics. Maintaining pluripotency and 
initiating differentiation in suspension cultures of PSCs is well established [167]–[169]. 
Investigating the potential to conduct forward programming in suspension platforms is a high 
priority for future work. 
A mechanistic modelling framework is proposed in Section 5.9. Parameterising this model, in 
the current adherent or suspension format would facilitate process improvement and 
enhanced control. The work should also be repeated with clinically relevant cell lines as it is 
expected that the relationship between the variables will still be maintained (since the genetic 
engineering is the same), however it may be parameterised slightly differently.  
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6. The application of Design of 
Experiments and mechanistic 
modelling to identify and quantify iPSC 
culture phases and assess their 
potential impact on manufacturing of 
in vitro platelet transfusion units. 
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6.1. Introduction 
In a manufacturing process that produces platelets from FOPMKs, the expansion of 
genetically engineered iPSCs is an important step. The economics and risk of this process will 
impact on the supply chain of FOPMKs and therefore the end platelet product. Determining 
the process productivity and understanding the factors which limit it allow process economics 
to be determined and focus improvement strategies. Aside from the production of platelets, 
iPSCs have wide-ranging applications due to their theoretical unlimited ability to produce 
functional human tissue, either for clinical application or drug discovery purposes [170]. So 
far, iPSCs have been used in clinical trials to treat age-related macular degeneration [171], 
clinical trials for Parkinson’s disease are currently recruiting following successful primate 
disease models [172]. Other future clinical applications include hepatocyte replacement for 
liver failure and pancreatic β-cells for treatment of diabetes, for which it is estimated that 1-
10 × 109 functional cells will be required per patient [173]. 
Pluripotent stem cells are adherent cells and are most commonly cultured using static flat 
plastic systems, and protocols usually dictate that cells are passaged once a certain confluency 
is reached as determined by observation using light microscopy [174]–[177]. For re-seeding, 
rather than obtaining cell counts, “split ratios” (where a proportion of cells are added to new 
flasks, e.g. 1:3 where cells harvested from one well are split into three wells) are sometimes 
used and are decided based on the observed confluency of cultures [176]–[178].  
The passaging of adherent cells is often accompanied by a cell loss and/or lag phase of culture. 
The mechanisms underpinning lag and losses for pluripotent cells are not widely discussed in 
the literature. Instead, empirical comparisons are drawn between the length of lag phases 
and certain conditions, assuming that attachment is the primary driver of length of lag phase 
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[179], [180]. Lag phase studies in bacterial cultures are ubiquitous. Reported parameters that 
affect the length of the lag phase include absolute values of time, changes in temperature, 
pH, medium components and seeding density [181], [182]. Despite the breadth of studies, 
the lag phases of bacterial cultures are poorly understood due the impact and interactions of 
large numbers of variable. 
It is a generally accepted that pluripotent cultures must not be allowed to become over 
confluent as this can lead to growth inhibition. As noted by Stacey et al. [100], the growth 
inhibition of a culture is a function of time, cells and/or the product of cells and time. In non-
adherent culture, growth inhibition which is governed by cell density (cell number per unit 
volume) is a function of oxygen/nutrient demands of the cells and mass transfer properties 
of the system. Density limitation in adherent systems (cell number per unit volume and/or 
surface area) could be caused by contact inhibition, such as cell-cell interactions [183] (seems 
unlikely for PSCs, since cells grow in densely packed colonies), or a phenomena that behaves 
similarly to contact inhibition (for example concentration of paracrine factors over high 
density monolayer due to lack of mixing, or within multi-layered cells that grow on top of each 
other; similar factors could lead to mass transfer constraints for gasses). Growth inhibition 
governed by time can be caused by the decay of factors (either supplied through medium or 
produced by cells) and growth inhibition controlled by a function of cell × time is caused 
through medium utilisation (consumption of essential nutrients and growth factors or 
production of toxic metabolites). During passaging of pluripotent stem cells a ROCK inhibitor 
(RI, also referred to RhoK inhibitor in the literature) is also commonly included to reduce the 
occurrence of apoptosis within a population [184]. 
6-210 
 
All mechanisms of culture growth inhibitions are dynamic; thus characterisation of these 
mechanisms will benefit from a framework which accounts for the dynamic changes. 
Previously, a mechanistic modelling framework has been successfully applied to suspension 
cultures [81], but its utility for describing adherent cultures and generating manufacturing 
outputs has yet to be demonstrated. Sections 4 and 5 describe suspension cultures which are 
limited by medium exhaustion using both tradition statistical and mechanistic modelling tools. 
Due to the added complexity of potential surface area limitations with adhered iPSCs we aim 
to investigate the primary growth dynamics and inhibition of iPSC cultures over the course of 
a passage in order to define the productivity limits of this culture system. Development of a 
complete system model (for example, one that treats each cell as an individual unit) is beyond 
the scope of this work; rather its aim is to produce a reasonably simple model (in terms of 
computation power required) but is still accurate enough to characterise the system to be 
useful for manufacturing process development. 
6.1.1. Chapter Aims 
• Identify the mechanisms of iPSC growth inhibition and cell loss upon seeding in flat 
plastic culture format. 
• Identify the control variables that determine whether growth inhibition and cell loss 
upon seeding will occur. 
• Quantify the operational boundaries of a system that will not incur significant growth 
inhibition or cell losses. 
• Quantify the productivity of the system in terms of key resources given operational 
boundaries. 
• Determine the likely requirement for system productivity improvement, given cell 
demand per product, and the strategies likely to deliver this. 
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6.2. Materials and methods 
Cell line derivation and culture was performed as described in Section 2.3. Cell counting was 
performed using flow cytometry and described in Section 2.5.2. Flow cytometry sample 
preparation, equipment used, staining and acquisition is described in Sections 2.6.1-2.6.3. The 
flow cytometry assay used is described in Section 3.3.2.5, and the assays used are identified 
in relevant sections and figure legends associated with flow cytometry data. 
Design of experiments were conducted as detailed in Section 2.8.1. The number of factors, 
levels of factors, outputs and whether a centre point was included is detailed along with the 
results of the DOE outputs in relevant sections. 
6.3. Identifying the mechanisms of iPSC growth inhibition in flat plastic 
The primary task of the first section of work was to qualitatively identify whether the primary 
mechanism of growth inhibition for iPSC cultures was a function of cells (cell density), time 
(medium factor decay) or cell × time (medium exhaustion). To determine which of these 
inhibitory factors was the primary limitation in the standard protocol, an experiment was 
designed where cultures were treated with the standard medium supply regime (a daily 
complete exchange, as described in 2.3) and twice daily exchanges of the same volume 
(therefore double the medium volume was supplied per day to those conditions). The 
medium exchanges are detailed in Figure 6-1. High temporal resolution cell counts were 
obtained from sacrificial wells to monitor the proliferation of cultures. The rationale for this 
experimental design is that the absolute cell density inhibition should occur at the same point 
irrespective of the medium exchange frequency. If this terminal inhibition is comparable 
across both experiments the absolute density limitation is therefore identified with 
reasonable confidence. If, however, the terminal inhibition occurs at a higher density in the 
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high frequency medium exchange this indicates that the medium supply is limiting under 
standard operating conditions. 
The results of this experiment are shown in Figure 6-2. All conditions achieved a similar cell 
yield over 96 hours, proliferated at a similar rate and produced a good fit for an exponential 
growth curve, shown by high R2 values. However, the average number of population 
doublings per hour achieved between each cell count measurement (Figure 6-2 C) decreased 
over the course of the experiment, which indicates that the growth rate decreased with time.  
 
 
 
Figure 6-1: Schematic diagram representing experimental conditions to determine whether medium 
exhaustion was limiting cultures. All cultures were treated equally until 57 hours when a medium exchange 
was performed in for condition 2 but not in condition 1. A medium exchange was performed on all cultures 
at 66 hours. Conditions were split again at 81 hours where Conditions 1.2 and 2.2 underwent a medium 
exchange whereas conditions 1.1 and 2.1 did not. Cells were harvested at 96 hours. Medium supernatant 
was taken for nutrient and metabolite analysis and daily sacrificial wells were used for cell counts. 
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Since this reduction in growth rate was equivalent with time across all conditions, it was likely   
that the growth inhibition was linked to surface area (i.e. a local density limitation), rather 
than medium provision. It should be noted that the differences in the means of the growth 
rate were not statistically different from each other as determined using ANOVA (since P>0.05) 
but there was a difference between the growth rate means at P<0.1 level between the growth 
rate at 24 hours and condition 2.1 and 2.2 (66 – 92 hours) and condition 1 (48-66 hours) shown 
in Figure 6-2 D. Between 66 -92 hours the cultures which had received a higher supply of 
medium had a lower standard deviation, indicating that a higher supply of medium may have 
led to more consistent growth. 
There was little difference between the growth rate of cultures when twice the medium 
provision was provided daily; therefore the assumption can be made that the lowest supply 
at the point where the cell density was highest (conditions 1.1 and 2.1, Figure 6-2 and Figure 
6-3) was not limiting cultures; so the medium provision for the product of cell and time was 
sufficient at that point. 
Since the cell density at time T (𝑁𝑇2) (cells.mL
-1) is a function of the starting cell number 𝑁𝑇1, 
time (t) and growth rate (hr-1) as in Equation 6-1: 
𝑁𝑡 = 𝑓(𝑡) = 𝑁0𝑒
𝜇𝑡𝑑𝑡 6-1 
Figure 6-2: Growth rate of all conditions were similar across a single passage. (A) Cell count data across 
time showed a similar expansion rate and end cell yield for all conditions. (B) Net growth rate calculated 
by applying an exponential model to cell count data varied by <2% and models for all conditions showed 
R2 values > 99% indicating that this model was a good fit for the data. (C) Normalised number of population 
doubling between each cell count shows that mean growth rate decreased with increasing time since 
passage. However, there was no statistical significance between conditions or time periods. (D) ANOVA 
report summary from statistical software package Minitab showing that there was a statistical difference 
between the proliferation rate of all conditions at 19-44 and 66-92 hours (P = 0.084). Since P>0.05, 
significance is not noted on (C). Graphs show mean ± STD (N=3). 
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Then the product of cell density time is the integral of Equation 6-2 between time T1 and T2: 
Using Equation 6-2 to calculate the cell.time at the end of the culture period, the minimum 
medium capacity is 2.4×107 cell.hrs.mL-1. Therefore, there are huge inefficiencies of medium 
usage in the first 72 hours of culture where cell numbers are low. In flat plastic systems is 
difficult to reduce medium volumes as a minimum volume of medium is required to cover the 
surface of the vessel. It could be possible that a lower frequency exchange regime could be 
employed, however supplementation of growth factors may be required since FGF2 is known 
to be unstable in culture [185], [186]. A detailed cost model would be required to evaluate 
the economic impact of adjusting feeding regimes and supplementation of FGF2, which is 
beyond the scope of this work since medium exhaustion is not the primary system limitation. 
There was cell loss of 62% between seeding and the first 19 hours of culture compared to the 
target seeding density (Figure 6-2 A). As cell counts were not taken upon seeding and so it is 
not clear whether the loss of cells was caused as an effect of seeding or whether they were 
lost during the passaging process. For this reason, the growth rate of cells and nutrient 
consumption / metabolite production was not considered during this time period. 
6.3.1. Medium consumption 
To understand the medium utilisation, and identify potential inhibitory concentrations, 
lactate, ammonium and glucose production/consumption was monitored across the passage, 
as shown in Figure 6-3. Of these, lactate may have reached inhibitory concentrations at 92 
hours in conditions 1.1 and 2.1 based on reported literature values [151]. However, since the 
∫ 𝑁𝑡 𝑑𝑡
𝑇2
𝑇1
=
𝑁𝑇1
𝜇
(𝑒𝜇𝑇2 − 𝑒𝜇𝑇1) 
6-2 
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cell yields were very similar across all conditions (Figure 6-2 A), with different levels of lactate 
dilution, it is unlikely that the lactate concentrations were causing growth inhibition. 
Across the passage the specific production rate of lactate decreased. As shown in Figure 6-3 
(Aii), there was a statistically significant difference between the measured production rate of 
lactate across time compared to the previous period, but not between conditions within a 
time-period. The production rate of ammonium also decreased across the passage. However, 
there was not a statistically significant difference between the production rate during the first 
and second periods (19-44 hours and 44-66 hours). Although the mean ammonium 
concentrations were lower in the second period, the lower ammonium concentrations are 
towards the limits of the detection range of the analytical measurement technique, which 
leads to a larger proportion of variation compared to the mean. Ammonium and lactate 
production rates are linked to the supply of glucose and glutamate, where a higher supply 
leads to higher consumption [154], which in turn relates to a higher production rate of lactate 
and ammonium. The link between nutrient concentration and metabolite production may 
have caused the decreasing consumption rates across the passage; since more cells were 
present, more nutrients were consumed per unit time, which lowered the concentration of 
nutrients and so decreased the production rate of metabolites. The decrease in lactate and 
ammonium production also qualitatively correlate with decreased growth rate trends. 
The measured glucose concentrations and consumption rates (Figure 6-3 Ci and Cii 
respectively) were more variable across the culture period compared to the lactate and 
ammonium production rates. The changes in glucose concentrations at the start of the 
cultures were low and so were likely to be outside the precision of detection of the 
measurement instrument.  
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Figure 6-3: Consumption and production of glucose, lactate and ammonium reduced as time from passage 
increased. Changes in lactate (A), ammonium (B) and glucose (C) concentrations increased (i) and specific 
production rates decreased (ii) with increasing time since passage. Data show mean ± STD (N=3) and (*) 
denotes statistical significance (P<0.05) using ANOVA. 
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However, unlike the ammonium and lactate production rates there was a statistically 
significant difference between the consumption of glucose for conditions 1.2 and 2.1. This 
suggests that relatively high- and then low-supply of glucose compared to the baseline supply 
(and vice versa) caused larger differences in consumption rates. A lower supply of glucose has 
been linked previously to higher growth rates and lower lactate production in mammalian cell 
cultures [95], [187]. Furthermore, nutrient restriction has been shown to switch metabolic 
pathways [188] which could account for the differences in consumption rates observed here. 
 
6.4. Qualitative identification of control variables which impact growth inhibition and 
cell loss / lag phase 
In the previous section, cell surface area was the most likely primary limiting factor for system 
productivity and cell losses of 62% were observed upon passage. Therefore, understanding 
the effects of control variables on these two bottleneck areas is key to developing targeted 
strategies for improving system productivity. Furthermore, since the medium supplied at the 
beginning of the process was in excess for the first 24 hours (and probably the first 48 hours 
- as discussed previously in Section 6.3) the volume of medium used upon seeding was 
reduced by half across all conditions. It was hypothesised that the use of less medium would 
lead to reduced system costs. 
It was hypothesised that increasing cell seeding density would reduce cell losses on seeding 
due to the release of beneficial paracrine factors [189] and the use of RI would promote cell 
survival therefore decreasing cell losses [190]. To test this hypothesis, a range of seeding 
densities were tested with and without the use of RI, as shown in Table 6-1.  
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Table 6-1: Summary of conditions to test the effect of seeding density and RI on culture phases. 
Condition Target seeding density (cells.cm-2) RI present 
1 1000 Y 
2 5000 Y 
3 9000 Y 
4 1000 N 
5 5000 N 
6 9000 N 
 
Sacrificial harvests were performed to obtain cell density data in Figure 6-4 (B). The cell 
density data at 0 hours were based on cell counts taken from the vessel that contained the 
cells prior to seeding. The data at 19 hours post seeding was measured from enzymatically 
removing the cells attached to the surface and sampling the suspended cells. The medium 
supernatant was also analysed to see if viable cells were suspended and not attached, 
however only debris was observed (data not shown).  
Again, a cell loss phase was observed as all cultures observed a loss of cells from 0 - 19 hours 
which was followed by a period of growth and then inhibition at the end of the passage. In 
this case, all conditions had greater than 80% losses compared to the post-seeding count 
(Figure 6-4 C), with lower density conditions (1 and 4) having the highest losses. This was 
higher than observed previously, and it was therefore hypothesised that the low seeding 
volume contributed to the increased losses. Lag phases are commonly reported for 
pluripotent stem cell cultures and are mostly attributed to cell attachment; however, the 
mechanisms of the lag phase are largely unknown. For example, the effect of parameters on 
cell death, proliferation or attachment are often considered as a single phenomenon and 
referred to as the “lag-phase” [191]–[193]. 
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Figure 6-4 (D) shows the average population doublings per hour at different periods in the 
passage. Cultures that were treated with RI (RI+, 1,2 and 3) proliferated less from 24-48 hours 
compared to conditions without RI in the first 24 hours (RI-, 4,5 and 6). This was either caused 
by lower growth, or more cell death, leading to a lower average growth rate. It was 
hypothesised that the presence of RI would decrease cell losses since RIs are noted for aiding 
cell survival post-passage [184] and higher cell seeding densities would also decrease cell 
Figure 6-4: Cell density data for a single passage testing effects of different seeding densities and the 
presence of RI showed three culture phases; cell loss after seeding, exponential growth and growth 
inhibition. (A) Cell density data showed that cell loss occurred in the first 24 hours, followed by a period of 
exponential growth, which slowed in the latter hours for higher density cultures, indicating growth 
inhibition occurred. Graphs show mean ± STD (N=3). (B) There was >80% losses of cells 24 hours after 
seeding across all cultures and lower cell density cultures had higher proportional loss. (C) Population 
doublings per unit time show that cultures did not have a consistent growth rate across the experiment. 
Higher density cultures proliferated less at the end of the experiment, likely to be caused by density surface 
area limitations. 
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losses since it has been noted that paracrine factors enhance cell survival and inhibit ROCK 
pathways [194], so the observation that the presence of a RI for the first 24 hours 
contradicted this hypothesis. 
From 48 - 96 hours all conditions had a similar average growth rate, and from 96 – 143 hours, 
cultures with higher seeding densities proliferated less than medium densities, which in turn 
proliferated less than lower seeding densities. This indicates that cultures approached a 
surface area density limitation leading to growth inhibition. In a flat plastic system is it 
challenging to deliver higher surface area without providing extra volume (as discussed in 
Section 6.3). To overcome the issue of surface area limitations an alternative system may be 
considered for scale-up, such as a packed-bed culture platform or adaptation to suspension 
culture. 
6.5. Quantitative methods for determining effect of control variables on culture phases 
6.5.1. Cell loss upon seeding / lag phase 
Since the mechanisms which govern cell culture lag phases are complex and largely undefined, 
non-dynamic statistical modelling (DOE) was selected to quantify the effects on input 
variables on lag phase in the culture format being used (6 well plates). This type of model 
could help to form mechanistic hypothesises that could be tested in future work with dynamic 
models that may be applicable across multiple culture platforms and scales. 
6.5.2. Growth and inhibition phases 
Considering the cell lag phase separately, it was hypothesised that the growth and inhibition 
dynamics observed from 24 hours onwards can be modelled using an mechanistic ODE 
framework [100] that predicts cell density (ρ, cells.cm-2) at a given time where growth rate is 
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a function of a maximum growth rate and sensitivity to a critical cell density value determining 
growth inhibition as in Equation 6-3: 
𝑑𝜌
𝑑𝑡
=  𝑟𝑔𝜌(1 + 𝑒
𝑖𝑠(𝜌−𝑖𝑐))
−1
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Where 𝑡 is time (hrs), 𝑟𝑔 is maximum growth rate (hr
-1), 𝑖𝑠 is inhibition sensitivity (cm
2.mL-1) 
and 𝑖𝑐 is the inhibition critical value (cells.cm
-2). It is frequently noted in the literature that the 
growth of pluripotent cells is dependent on the surface area available for adherence [195], 
[196]. 
  To test this hypothesis, model formulation and parameter fitting was undertaken as 
described previously [81], [100] where least squares deviation was minimised. Modelling cell 
behaviour dynamics in this way gives enhanced insight to the process compared to statistical 
methods such as DOE which often fail to produce predictive models over longer time courses, 
Figure 6-5: Summary of culture phases and the ways in which they were modelled. 
Cell loss on seeding
Exponential growth
Growth inhibition
Empirical relationships to determine cell loss 
using statistical modelling to limit losses to an 
acceptable level. 
There is limited value in defining this phase 
with a mechanistic model at this scale. 
Dynamics of cell growth and inhibition in 
relation to cell density per unit surface area 
are non-linear.  
 
 
Mechanistic models provide deeper insight 
than empirical models and enhanced 
opportunities for optimisation. 
iPSC culture phases  
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since the behaviour is highly non-linear. The culture phases and how they were modelled are 
summarised in Figure 6-5. 
6.6. Quantifying effects of system control variables on cell losses following seeding 
6.6.1. Effect of seeding density and RI 
To quantify the effect of seeding density and RI presence on proportional cell losses, shown 
in Figure 6-4 (C), were analysed using a 2 factor, 2 level DOE design using statistical software, 
Minitab. Backwards elimination was applied (α = 0.1). Parameters are described in Table 6-2. 
Table 6-2: DOE parameters to quantify effects of seeding density and RI on cell losses. 
 
Parameter High level Low level Midpoint(s) 
Seeding density (cells.cm-2) 9000 1000 5000 
RI presence for first 24hrs Y N Y & N 
Output % cell loss after 24 hours compared to seeding 
count 
Figure 6-6: DOE analysis summary showed relationship between seeding density and cell loss upon seeding. 
DOE analysis was performed using statistical software package Minitab with stepwise backwards 
elimination (a=0.1) applied for a 2-level, 2-factor, factorial design. The R2 (adj) fit of this model was 61.3 %. 
(A) Main effects lot showed a negative correlation between seeding density and cell loss. Centre point 
position suggested that the relationship was nonlinear. (B) Pareto chart showed that seeding density was 
the only parameter with P>0.05 effect on proportional loss.  
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As shown in Figure 6-6, only seeding density had a statistically significant effect (P<0.05) 
where increased seeding densities, decreased cell losses. The model was highly non-linear as 
shown by the position of the mid-point in the main effects plot (Figure 6-6 A) and the R2 (adj) 
was 61%, meaning that nearly 40% of the variation in the proportional losses was not 
accounted for by this model, indicating high levels of noise. The non-linearity of the model 
contributed to the lack of fit also. 
As mentioned in Section 6.4, the proportional losses were higher than those observed in 
Figure 6-2. Here, a lower volume was used to seed the cultures, as it was shown in Figure 6-3 
that medium was supplied in excess. It was hypothesised that this change may have caused 
higher cell losses (due to independent effects of medium volume on initial adherence and 
survival vs subsequent growth) and therefore the effect of medium volume during seeding 
was investigated and the results are discussed below in Section 6.6.2. 
6.6.2. Effects of seeding volume, seeding density and RI treatment 
Since larger cell losses were shown in Figure 6-4 (A) compared to Figure 6-2 (A), it was 
hypothesised that the reduction in volume at seeding may have caused higher cell losses. 
Therefore, volume was tested along with seeding density and RI treatment. Furthermore, 
higher temporal resolution cell counts were taken at the beginning of the passage to further 
understand the nature of the cell losses post-seeding. A summary of the conditions used and 
the cell densities over the culture period are shown in Table 6-3. 
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Table 6-3: Summary of conditions to test the effect of seeding density, seeding volume and RI on culture 
phases. 
Condition Target seeding density (cells.cm-2) RI present Seeding volume (mL in a 12 well plate) 
1 1000 Y 0.38 
2 9000 Y 0.38 
3 1000 Y 1.14 
4 9000 Y 1.14 
5 1000 N 0.38 
6 9000 N 0.38 
7 1000 N 1.14 
8 9000 N 1.14 
9 5000 Y 0.76 
10 5000 N 0.76 
 
 
  
Figure 6-7: Cell densities across a single passage with various seeding densities, medium volume at seeding 
and treatment with RI conserved the three culture phases identified in Figure 6-5. (A) Details of different 
culture treatments. (B) Cell density data shows cell loss phase was followed by exponential growth and 
inhibition. Data shows mean (N≥2) ±STD. 
6-226 
 
Again, the three culture phases were present; cell loss, growth and growth inhibition; as 
shown in Figure 6-7. There was high variation in the high seeding density, low volume 
conditions (2 and 6) as shown by the large standard deviation error bars relative to the other 
conditions. It is unclear whether the source of the variation was a product of a variable growth 
rate or variations in detachment and processing or a combination of these effects. Despite 
the cause being unknown, the added variation from these conditions would be detrimental 
to a manufacturing process since it increases the risk of failure to meet required product 
yields. 
The proportion of cell loss compared to the cell count at seeding is shown in Figure 6-8 (a). 
There was a range of losses across the culture conditions with the impact of the variables 
were analysed using a 3 factor, 2 level DOE design using statistical software, Minitab. 
Backwards elimination was applied (α = 0.1). Parameters are described in Table 6-4. 
The pareto chart (Figure 6-8 B) DOE analysis showed that seeding volume had the greatest 
impact on proportion of cell losses followed by the target seeding density, and the RI 
treatment. The main effects plot shows that increased target seeding density decreased the 
proportion of losses, the addition of RI increased losses and increased seeding volume 
decreased cell loss. The interaction plots (Figure 6-8 C) show that at low seeding densities the 
addition of RI did not impact the proportion of losses, whereas at higher cell densities the 
inclusion of RI increased proportion losses. The interaction plots also indicate that higher 
medium volumes at seeding led to lower proportional losses at higher seeding densities. 
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Table 6-4: DOE parameters to quantify effects of seeding density, RI and seeding volume on cell losses. 
 
The impact of medium volume on cell loss was unlikely to have been caused by lower 
provision of nutrients since, as shown in Figure 6-3, these are supplied in excess during the 
first 24 hours. Since seeding losses are relevant only in the first 24 hours the volume of 
medium used after this point does not impact losses, but after this point all conditions are 
provided with the same volume of medium. 
Further, the conversion rate of suspended to attached cells was not likely to have caused the 
variation in cell losses. At 4 hours post seeding, cell counts were performed on the medium 
supernatant to check the number of cells suspended in the medium that had not attached. 
The expected number of suspended cells were calculated by subtracting the attached number 
of cells from the cell count at seeding. The number of counted cells in the medium 
supernatant at 4 hours was only 3% of the expected number (data not shown), and therefore 
it was concluded that the cell loss was caused by a physical effect due to the low medium 
volume. The mechanism underpinning this loss and whether it will affect different scales of 
culture is unknown. It is hypothesised that it is a physical effect of the meniscus, related to 
how cells interact between the surface boundary between air and medium. If this is the case, 
it will be highly dependent on culture vessel surface area, and may be irrelevant in other 
Parameter High level Low level Midpoint(s) 
Seeding density (cells.cm-2) 9000 1000 5000 
RI presence for first 24hrs Y N Y & N 
Seeding volume (mL) 1.14 0.38 0.76 
Output % cell loss after 24 hours compared to seeding 
count 
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systems, where gas-liquid surface area to volume ratio will be much lower than in flat plastic 
culture systems. 
 
Figure 6-8: Cell loss after seeding was dependant on main effects target seeding density, RI treatment and 
seeding volume. (A) Proportional loss based on seeding counts. Data shows mean (N≥2) ±STD. (B) Pareto 
chart shows all significant main effects and interactions (P<0.05, except AC, where P=0.077 and therefore 
was not statistically significant). (C) Main effects plots show increased seeding density decreased 
proportional losses, RI treatment increased proportional losses and increased medium volume at seeding 
decreased proportional losses. (D) Interaction plots show RI treatment did not impact losses at low cell 
seeding densities, but at high cell seeding densities RI treatment increased proportion cell losses and 
increased seeding medium volume further decreased losses at high cell densities. DOE analysis summary 
showed relationship between seeding density and cell loss upon seeding. DOE analysis was performed 
using statistical software package Minitab with stepwise backwards elimination (a=0.1) applied for a 2-
level, 3-factor, factorial design. The R2 (adj) fit of this model was 85.0 %. 
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The presence of high cell loss in low seeding volumes in other systems would determine the 
value of further investigating the mechanisms underpinning cell loss due to low culture 
seeding volume. Despite not understanding these mechanisms, the simplest way to reduce 
cell losses is to use a higher volume of medium during seeding in this system. For example, 
comparing conditions 1 (low seeding density, +RI, low volume) and 3 (low seeding density, 
+RI, high volume) shows a reduction in average proportional losses from 83% to 23%.  
An increase in cell seeding density was shown to decrease losses. This has been demonstrated 
by other groups [197] It is hypothesised that the mechanisms underpinning this are caused 
by the release of protective paracrine factors or cell-cell contact effects through cell adhesion 
molecules [184], [198]. Although higher seeding densities reduce cell losses, they also lead to 
cultures reaching confluency faster. This would lead to shorter passage times, meaning more 
frequent exposure of cells to dissociation reagents, which may impact cell quality (pluripotent 
phenotype or forward programming efficiency). This may be mitigated by using scalable-
suspension aggregate systems, where higher cell densities per unit volume could be achieved. 
Suspension aggregate cultures have not been applied to FOP-inducible iPSCs yet. 
The use of RI for pluripotent stem cell cultures is widely reported in the literature. The first 
reports of use was to enhance the survival of dissociated cells [184], and has been used as 
enhancing cell survival through the duration of a passage [199]. However, other reports show 
that the Rho-signal is critical to long-term survival and expansion of human embryonic stem 
cells [200]. The data presented here contradict this, since use of RI either had no effect at low 
densities; as demonstrated by comparing low density, low volume conditions 1 (+RI) and 5 (-
RI) in Figure 6-8 (A); or promoted cell loss; as demonstrated by comparing the high density, 
high volume conditions 4 (+RI) and 8 (-RI) and the mid-point conditions 9 (+RI) and 10 (-RI). As 
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explained previously, these effects are quantified as shown in the DOE analysis Figure 6-8 (C 
and D). 
6.7. Quantifying effects of control variables on growth inhibition 
6.7.1. Effect of seeding density and RI 
The fitted parameters for Equation 6-3 and the resulting model are shown in Figure 6-9. The 
data are split into +RI and -RI treatments for ease of comparison, but the same parameters 
were fitted to all conditions. There was an observable pattern in the residuals (Figure 6-9 ii) 
where the model under predicts cell counts in the latter stages of the passage for +RI cultures 
and over predicts cell count for -RI conditions. This suggests that the presence of RI during 
the first 24 hours affected either the growth rate or inhibition critical value (ic) of the culture. 
The R2 value for each condition is shown in Figure 6-9 (D) which is high for all conditions except 
condition 4 with an R2 of 73%. Further, for condition 4 the residuals show that the model 
systematically over predicted the cell count data (Figure 6-9 Bi and ii). 
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Figure 6-9: Mechanistic modelling output for fitting 24hr+ data to equation 6-3 using a least squares fit 
method. (i) shows observed cell counts and model predictions and (ii) shows residual error between 
observed cell counts and predictions for (A) +RI cultures and (B) -RI cultures. Model under predicted cell 
density in +RI conditions and over predicted cell density in -RI cultures. (C) Fitted parameters for equation 
6-3 (D) R2 values for each condition. 
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6.7.2. Effects of seeding volume, seeding density and RI treatment 
The cell growth limited by density model (described in Equation 6-3) was parameterised using 
the observed cell densities from 24 hours after seeding. The low volumes cultures were 
excluded from this model since there was large variations in the data (presumed to be caused 
by the low volume treatment since this was not observed in the high volume cultures) and, 
as described in Section 6.6.2, it is likely that this detrimental effect was specific to the culture 
vessel (a 6 well plate). Therefore, the detrimental effect of low volume is unlikely to be 
relevant in a manufacturing setting and easily overcome by adding more volume for 24 hours 
post seeding. However, this again highlights the that medium engineering in a flat plastic 
system will make a low impact on system productivity, since a minimum volume must be 
supplied to prevent cell losses on seeding. 
The fitted model and data are shown in Figure 6-9 (Ai) +RI  and (Bi) -RI. The same model was 
fitted to each data set but are split in the figure to for ease of comparison. The residual error 
between the data and the fitted model are shown in (ii). There was a pattern in the residual 
error, where the model under predicted the cell densities in the latter stages of the culture 
for the RI+ cultures (Aii), whereas the model over predicted cell densities in the RI- cultures 
(Bii). The maximum growth rate (rg) fitted in Figure 6-10 was 20% lower than in the first data 
set (shown in Figure 6-9), the inhibition critical value (ic) was 18% higher and the inhibition 
sensitivity (is) was 4 orders of magnitude higher. The average of the R2 values were also lower 
in Figure 6-10 compared to Figure 6-9.  
Since there was a systematic pattern in the residual which was split on +RI / -RI conditions a 
separate model was fitted to these conditions, shown in Figure 6-11. In the RI+ cultures 
(Figure 6-11 A) the refit removed the pattern in the residuals shown Figure 6-10 Aii. As shown  
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Figure 6-10: Mechanistic modelling output for fitting 24hr+ data to Equation 6-3 using the same parameters 
for each condition and a least squares fit method. Low volume cultures (1, 2, 5 and 6) were not included in 
model due to variation show in Figure 6-7 and large cell losses shown in Figure 6-8. (i) shows observed cell 
counts and model predictions and (ii) shows residual error between observed cell counts and predictions 
for (A) +RI cultures and (B) -RI cultures. Model under predicted cell density in +RI conditions and over 
predicted cell density in -RI cultures. (C) Fitted parameters for Equation 6-3. (D) R2 values for each 
condition. 
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Figure 6-11: Mechanistic modelling output for fitting 24hr+ data to Equation 6-3 using different parameters 
for each RI treatment and a least squares fit method.(i) shows observed cell counts and model predictions, 
(ii) shows residual error between observed cell counts and predictions and (iii) shows fitted parameters for 
Equation 6-3 for (A) +RI cultures and (B) -RI cultures. Conditions treated with RI had higher growth rates 
and inhibition critical values. (D) R2 values for each condition were improved for conditions treated with 
RI. 
6-235 
 
by Table 6-5, the maximum growth rate (rg) increased relative to the fit in Figure 6-10, but was 
15% lower than the initial data set shown in Figure 6-9; ic was identical and the inhibition 
sensitivity was decreased by 4 orders of magnitude. For the RI- conditions 9 (Figure 6-11 B), 
rg decreased, ic decreased and is increased. This suggests that removing RI decreased the 
maximum achievable growth rate of the cells, or increased cell death which was not measured 
or accounted for in this model structure. Removal of RI also lowered the inhibition critical 
value, i.e. lower maximum cell capacity per unit surface area prior to growth inhibition and 
increased the sensitivity to this maximum, so when the critical value was reached, the rate of 
change of rg was greater. RI has been previously empirically shown to “kick-start” growth of 
PSCs and increase colony sizes, and the effect of RI was reversable upon removal of RI from 
the culture [201]. However, here we see a lasting effect of RI on growth rate since it was used 
in the first 24 hours of a passage only. As discussed in Section Figure 6-4, the mechanism of 
action for RI is hypothesised to prevent apoptosis upon dissociation of PSCs [199], but in this 
work the use of RI increased losses on passage but increased growth rate from 24 hours 
onwards. Perhaps this is linked to the hypothesis presented by Ohgushi et al. [200] that Rho 
mediated signalling is required for long term survival and expansion of pluripotent stem cells 
and by providing RI in the first 24 hours only, the pathway is triggered, promoting higher 
survival and bulk growth rates.  
The parametrisation applied for the RI- conditions appeared to systematically over predicted 
cell densities in conditions 7 and 10, but underpredicted cell densities for condition 8 in the 
later stages of the passage. Condition 8 was a high seeding density, high volume, no RI 
condition. It is unclear why this condition was an outlier. One reason may be related to the 
low cell loss upon passage – perhaps the cells that are lost are the slower growing less 
“healthy” cells which leads to a lower growth rate. This selection pressure could also explain 
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why there was a higher maximum achievable growth rate demonstrated in the initial data 
(see Figure 6-9 and Table 6-5) since greater than 80% of cells were lost in the first 24 hours.  
Table 6-5: Comparison of the parameters fitted to equation 6-1 across all model fitted data sets. 
 Figure 6-9 Figure 6-10 Figure 6-11 A (+RI) Figure 6-11 B (-RI) 
rg 0.047 0.0375 0.040 0.355 
ic 2.45×105 3.60×105 3.60×105 3.05×105 
is 2.45×10-5 0.19 2.00×10-5 0.17 
 
6.8. Cell quality: qualitative effect of control variables on cell phenotype 
The median fluorescence intensity for three common pluripotency markers at Day 3 and Day 
6, during the passage from the experiment shown in Figure 6-4 , are shown in Figure 6-12. 
Lower density cultures had higher expression (higher MFI) for TRA-1-81 and NANOG than the 
higher density cultures and higher expression at Day 3 than Day 6. This suggests that there is 
an effect of density or of growth inhibition on expression of some pluripotent markers. The 
expression of Oct 3/4 increased in some conditions with time. However, the expression data 
were obtained from a pooled sample of three biological replicates so the variation within a 
condition is not known, so the magnitude of change of effect against background variation is 
unknown. This data was collected as first screen to check changes in common pluripotent 
marker expression. Further work should encompass a detailed literature search for 
pluripotent markers, since recent studies have focused on the use of flow cytometry to 
identify different pluripotent “states” i.e. naive vs. primed [202], [203] and include the use of 
differentiation markers (such as SSEA-2) to track early stages of loss of pluripotency. 
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6.9. iPSC demand for in-vitro derived platelet transfusion product 
The aim of this work is to understand the impact of iPSC culture dynamics as part of a 
production process for platelet transfusion units. Figure 6-13 shows the required input iPSCs 
to produce enough platelets for one transfusion unit (3×1011 platelets per transfusion unit), 
is determined by the expansion during forward programming post-Dox addition and the 
number of platelets produced per mature megakaryocyte. As the population doublings in 
Figure 6-12: iPSC phenotype changes over a passage. MFI values show a decrease in TRA-1-81 (A) and 
NANOG expression (B). Oct 3/4 expression increased for conditions 1-4 but decreased for conditions 5 and 
6. Data shows flow cytometry data acquisition results from three pooled cultures. 
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forward programming decrease, the requirement of input iPSCs increases exponentially. 
Based on the data shown in Section 5, the achievable number of population doublings during 
forward programming was approximately 13, shown on Figure 6-13 as a green solid line. 
However, this expansion may be changed by altering the concentration of Dox, TPO and / or 
other factors such as bulk medium supply. The number of platelets produced in vitro is also 
variable, with studies reporting between 3-20 platelets.MK-1 [204], [205]. Ultimately, the 
relative cost of each process - iPSC culture vs. forward programming expansion vs. platelet 
generation –  will determine the expansion / production in each phase to produce the 
adequate number and quality of platelets for clinical transfusion units.  
  
Figure 6-13: The required number of input iPSCs to produce a platelet transfusion unit is dependent on the 
expansion of cells post Dox-induction to maturity and the number of platelets that can be harvested and 
stored from each FOPMK. Based on data discussed in Section 5, approximately 13 population doublings can 
be achieved post Dox induction (shown here in green). In vivo, mature MKs produce around 1000 platelets 
per cell, whereas in vitro methods have produced between 5 platelets per MK, which could result in much 
lower productivity once losses from processing are considered. 
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6.10. Conclusions and future work 
This chapter applies a combination of statistical and mechanistic modelling tools to 
understand culture dynamics within an iPSC passage. Three culture phases are identified: cell 
lag / loss phase, exponential growth and growth inhibition caused by surface area limitations. 
In mammalian cell culture and microbiology, the lag phase is complex and with ill-defined 
mechanisms and therefore a traditional statistical modelling tool (DOE) was selected to 
empirically define relationships between variables and cell losses. The DOE linked decreased 
cell losses in the first 24 hours with increased cell seeding density, not using RI in the first 24 
hours and increasing the volume of medium used for the first 24 hours. 
From 24 hours of culture onwards, the cell growth and inhibition was modelled using a 
mechanistic model that related culture growth to the availability of surface area. Cultures that 
were treated with RI in the first 24 hours achieved higher maximum growth rates compared 
to those that were not exposed to RI and had a higher critical sensitivity values.  
It is hypothesised that the differences in maximum growth rates between conditions was 
caused by the selection of faster growing or advanatged cells surviving upon passage through 
loss of “fragile” cells. This hypothesis could be tested further through multiple passages, and 
clone colonies. There are examples in the literature where extended passaging increased 
differentiation capacity [206] and reduces the genetic abnormalities in iPSCs [207]. It is 
possible that the selection events observed in this data set could contribute to these 
phenomena, and further investigation would  be needed to confirm this. 
This work was conducted on FOP Dox-inducible iPSCs. To gain insight into the broader 
applicability of this work, it would be useful to see how the relationships defined here are 
conserved across other iPSCs. Regardless of parameterisation, the model frameworks and 
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approaches to model development, both for DOE and mechanistic modelling, are applicable 
to any adherent cell line. 
The effect of variables on pluripotency was measured using flow cytometry markers. Both 
TRA-1-81 and NANOG appeared to decrease across a passage, whereas Oct 3/4 increased. 
Unlike haematopoietic cells which are highly characterised by cell surface markers, 
pluripotency markers are not well established, and measuring the “quality” of pluripotent 
stem cells is debated [208]. Gene expression monitoring methods have been developed [209] 
but flow cytometry had advantages over PCR methods, as it is rapid and allows for individual 
cell analysis. Future work focusing on the culture dynamics of pluripotent stem cells should 
consider developing a wider marker panel compatible with flow cytometry for the rapid 
measurement of the effect of pluripotency. 
The outcomes of the modelling approaches (both DOE and mechanistic models) must be 
validated to confirm outcomes mentioned here. The effect of passage time with respect to 
growth rate trajectory (i.e the difference in performance in onward passage when cells are 
passaged at varying levels of growth inhibition) would be an important extension of this work 
to inform a longer scale expansion that would likely be required for clinically relevant 
manufacturing processes. 
Finally, pluripotent cell passaging has been demonstrated in scalable, suspension aggregate 
cultures [167]–[169]. In this case, surface area limitations may not be relevant. However, as 
shown in Section 4 and relevant literature [81], [100], the mechanistic modelling approach 
used here can be readily applied to medium exhaustion dynamics. The need to drive towards 
this type of expansion will depend on the process economics required for expansion for each 
phase of platelet generation (iPSC expansion, forward programming or platelet biogenesis). 
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7. Conclusions 
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7.1. Introduction 
Since the first scoping of this project in 2015 the cell therapy industry has matured 
significantly with the first regulatory approvals of CAR-T therapies in 2017. This work shows 
that in order to accelerate process development of complex cell therapy products, modelling 
approaches can be applied to define system productivity, thereby allowing targeted medium 
supply to ensure product quality and increase efficiency of input consumables. Here FOPMKs 
were used as a case study. 
7.2. Identification and measuring CQAs  
Quality by Design is an established methodology applied to the manufacture of small 
molecule pharmaceuticals which first identifies a product QTPP. In Section 3, standards used 
for clinical platelet transfusion units were used as the basis of the QTPP for a platelet product 
derived from forward programmed megakaryocytes. From the QTPP, CQAs were selected to 
be used to ensure quality in process development that were biologically relevant and 
measurable using currently available process analytical technologies. Markers were selected 
that represented different stages in maturity of cells (from pluripotent to mature MKs). Flow 
cytometry was the selected process analytical technology for marker measurement and 
robust assays were developed to measure selected markers. Cell counting assays were also 
developed as the number of cells present in culture is fundamental to build models based on 
the utilisation of culture medium by cells. 
There is growing interest in standardisation in the cell therapy community [210]–[212]. Here, 
the first QTPP has been developed for a in vitro platelet derived product and a novel assay 
was developed to track the differentiation state of FOPMKs from pluripotent to mature MKs . 
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This flow cytometry assay has the ability to be standardised across multiple sites with the use 
of Application Settings.  
7.3. Identifying the productivity limits of 1st generation FOPMKS 
The first generation of FOPMKs displayed similar characteristics to a cell line, as cell expansion 
took place over 90 days and was relatively phenotypically stable. By conducting high-temporal 
resolution growth curves in Section 4, it was found that the system productivity of the first 
generation FOPMKs was 1.48 ± 0.28 × 106 viable cells.ml-1. The system productivity was a 
function of the product of cells present and time, which was linked to conversion of viable to 
non-viable cells. This medium exhaustion dynamic was quantified using a novel mechanistic 
modelling approach, which showed that growth inhibition in addition to cell death dynamics 
were present in cell culture systems.  
There was a discrepancy between culture behaviour of short-term (days) and long term 
(weeks) cultures, where short-term cultures had higher maximum growth rate and lower 
creation rate of toxin (surrogate for medium exhaustion). It was hypothesised that this 
discrepancy was caused by different exhaustion kinetics being present over the long-term 
cultures (for example, medium component decay present through partial medium exchanges) 
and the short-term cultures being exposed to higher concentration of medium exhaustion 
since no medium exchange were performed, therefore creating a more “toxic” environment 
to cells than present in the long term environment. 
The root cause of the medium exhaustion was not identified, since part way through this 
process the forward programming technology moved on and so further work on this system 
was no longer considered high value. However, it was unlikely to be glucose, lactate nor 
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ammonium as, compared to other systems described in the literature, the concentrations of 
these components were unlikely to be causing the cell death seen in this system. 
Unlike other approaches which build models of cultures based on responses to specific factors 
[76], [79], [80], [95], [213], the model framework used here characterises cultures based on 
broad limitations – either a product of time, cell density or the product or cells and time. The 
model is a flexible framework that has a low barrier to entry for users who have little 
knowledge of ODEs. 
7.4. Application of QbD to 2nd generation FOPMKs 
The 2nd generation FOPMK process had different challenges associated with expansion, since 
the inducible nature of the cell line shifted cell expansion to a phase where cells were 
phenotypically maturing and cell growth ceased after approximately 30 day post-Dox 
induction, as shown in Section 5. Through a Technology Transfer exercise, it was found that 
the end stage number and quality (where quality was defined as phenotypic marker 
expression CQAs identified in Section 3) were dependent on input variables. Using DOE as a 
statistical modelling tool (as typical in QbD approaches), there was positive correlation 
between higher cell yields and CD41a expression and  main effects TPO and Dox 
concentrations and a negative correlation for cell seeding density and the removal of Dox 
from culture. There were also multiple statistically significant variable interactions, for 
example at higher concentrations of Dox lower concentrations of TPO were required to 
produce the same effect on cell number and yield – suggesting that the same biochemical 
pathways may be triggered in response to both Dox and TPO. Dox costs are insignificant 
compared to TPO, therefore, investigating further the response of cells to Dox with lower TPO 
concentrations may lead to significant cost savings. 
7-245 
 
Statistical models should be driven by a mechanistic hypothesis, but they are empirical 
models which treat the system as a “black-box”. This can lead to little process insight. 
However, DOE is an efficient methodology which can help to form mechanistic hypothesis 
which could help to narrow down parameters for investigation using mechanistic modelling 
which is more resource intensive. Future investigations leading from this work should focus 
on enhanced productivity and control of FOPMK cultures by developing dynamics models of 
the effects of Dox and TPO concentrations on cell expansion and phenotype. 
7.5. Application of DOE and mechanistic modelling to iPSC culture 
Adherent culture of iPSCs would be the first phase of production for a platelet transfusion 
product derived from the 2nd generation FOPMK process, therefore the productivity limits of 
iPSC culture was investigated. iPSC culture was shown to have three distinct culture phases; 
lag/loss followed by exponential growth and eventual growth inhibition. Using an DOE 
approach, the lag phase was shown to be a function of seeding volume, RI treatment and cell 
seeding density. It was hypothesised that there was an interaction between the meniscus of 
the culture vessel and the cells which increased losses in the first 24 hours of culture. Since it 
was likely that the mechanisms of this loss would dependent on the culture vessel (a 6 well-
plate is not a scalable platform for production) and losses may be easily overcome by using a 
higher culture volume, this was not investigated further. Mechanistic models were developed 
to quantify the growth and growth inhibition phases of iPSC cell growth and growth inhibition, 
which shown to be a function of cell density and the presence of RI (which facilitated higher 
cell densities to be achieved). 
Since this work has identified a cell density limitation, future work should focus on identifying 
medium productivity limits, either in suspension iPSC cultures or prior to cultures reaching 
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their cell density limit. Since this system already utilises fully defined medium, component 
screening should be undertaken and, through understanding the medium exhaustion 
dynamics, a targeted medium supplement developed. 
Finally, the required number of input iPSCs to create one platelet transfusion unit was shown 
to be driven by the expansion of FOPMK expansion post-Dox addition and the number of 
platelets produced per FOPMK. Based on the current protocol, and assuming 5 platelets were 
generated per FOPMK, approximately 7 × 106 iPSCs would be required per platelet transfusion 
unit – the equivalent to 20 cm2 of confluent cells. 
7.6. Future work 
7.6.1. Improving system productivity of FOPMKs 
The root cause of the medium productivity limit for the first generation FOPMK process was 
not established in this work, although it was unlikely to be due to “standard” bioprocess limits, 
such as glucose, lactate or ammonium. Future work should focus on a medium which is not a 
black box system and contains recombinant components only. From this, medium can be 
“reverse engineered” to determine what is limiting the culture system. Furthermore, scalable 
expansion systems should be employed, such as suspension culture of iPSCs rather than 
adherent cultures.  
7.6.2. Application of modelling tools to cell therapy processes 
This work has shown that dynamic, mechanistic models can deliver powerful insights into cell 
therapy expansion processes. However, the processes are complex and dynamic models can 
be resource intensive to build and validate. In order to characterise processes and obtain 
meaningful manufacturing insight, “simple” dynamic models were built here using a 
maximum of 7 parameters, but higher numbers of parameters may would be required to 
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characterise a system that was phenotypically unstable, as in the 2nd generation FOPMK 
expansion process. 
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